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SUMMARY 
A large proportion of the human genome, over 60% by estimation, is derived from 
transposable element (TE) sequences. Majority of these TE sequences in the human 
genome are retrotransposons – a type of TEs that replicates and inserts in the host genome 
via reverse transcription of RNA intermediates [1, 2]. TEs are known to contribute to the 
regulation of the human genome. Despite the fact that the majority of known TE-derived 
regulatory sequences correspond to relatively ancient insertions, which are fixed across 
human populations, there are several active families of retrotransposons, including the Alu 
[3, 4], LINE-1 (L1) [5, 6], and SVA [7, 8] retrotransposons that are capable of mobilizing 
via reverse transcription of RNA intermediates . Germline transposition of these elements 
generates polymorphisms between individuals, and somatic transposition generates 
cellular heterogeneity.  
Given the disruptive potential of TE insertions, along with the regulatory potential 
of TE-derived sequences, one may expect a complex interplay between TE insertion 
polymorphisms and inter-individual differences in the expression of human genes, as well 
as TE activities and the host regulatory mechanisms. In the past, the host genome regulation 
on TE activities, as well as the impact of TE on host gene expressions, have been studied 
mostly in cell lines and model organisms. Due to the nature of the experimental approach, 
previous studies only evaluated a limited number genes that regulates TE activities. For the 
TE sequences that may potentially regulates host gene expression, majority of the previous 
studies have been focusing on fixed TE elements, i.e. elements that are no longer capable 
of transposition, and evaluated their impact on the human genome. Other studies that have 
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focused on polymorphic TE insertions were limited the investigation within model 
organisms or human cell lines.  
Recently, with the growing number of whole genome sequences of healthy human 
individuals available at the population scale, it is now possible for the first time to 
systematically screen for modifiers of TE activities, as well as, evaluate the impact of TE 
on host genome regulation at the genome-wide scale. My dissertation is focusing on the 
role of polymorphic TEs in the regulation of the genes and how the human genome 
regulates TE activities. Specifically, I used the genome-wide association approach to 
evaluate how the host genome regulates TE activities, and the extent to which recent TE 
activity could lead to regulatory polymorphisms among populations.  
Research Advance 1: Genome-wide association screens were performed in search 
for modifiers of human L1 activities. With integrated genotype profiles and gene 
expression profiles of matched individuals, the association analysis was performed to relate 
the SNP genotype profiles and gene, L1 transcript abundance levels. Full-length, intact L1 
expression levels were quantified with covariates adjusted to control for confounding 
variables. The expression quantitative trait loci (eQTL) analysis was applied for the 
discovery of individual single nucleotide polymorphisms (SNPs) that are jointly associated 
with both L1 and gene expression.  Putative L1 modifier genes were identified including 
35% of 34 known L1 modifier genes, 24% putative transcription factor genes and 30% 
chromatin modifier genes.  
Research Advance 2: Genome-wide association screens were performed to 
evaluate the impact of polyTE on human genome regulation. The locus-specific polyTE 
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insertion genotypes were related to B cell gene expression levels among 445 individuals 
from 5 human populations.  My results showed that numerous human polyTE insertion 
sites correspond to both cis and trans expression quantitative trait loci (eQTL) with genes 
that are directly related to cell type-specific function in the immune system. A polyTE 
insertion loci was found to be associated with the expression level of a cell type specific 
transcription factor PAX5 and its downstream target genes. The genome-wide significant 
associations indicate that human TE genetic variation can have important phenotypic 
consequences. Our results also suggested that TE-eQTL may be involved in transcriptional 
network rewiring and population-specific gene regulation.   
Research Advance 3: Integrated genome-wide associations and other evidences 
was performed to evaluate the impact of polyTE on human disease and health outcomes.  
TE insertion polymorphisms were related to common health and disease phenotypes that 
have been previously interrogated through genome-wide association studies (GWAS) 
based on the linkage disequilibrium (LD) structure of the population. eQTL analysis was 
performed on the GWAS SNP-linked and enhancer co-localized polyTEs to identify 
polyTE insertions that are linked to gene expression changes in B-cells. Two polyTE loci 
that are co-located with cell type-specific enhancers were linked to common diseases 
phenotypes. Taken together, my results showed that polyTE could impact human health 
and disease phenotypes by causing changes in gene expression.   
Research Advance 4: A comprehensive survey of recent research progress on 
evaluation of the impact of polyTE on human genome regulation. Genome-enabled 
approaches, including developed bioinformatics tools and high-throughput experimental 
approaches, for characterizing TE insertion variants were developed in recent years. 
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Several studies have applied these approaches to characterize polyTE insertion profiles at 
population level. The eQTL approaches, along analyses of linkage disequilibrium 
structures in the population have uncovered the connection between TE insertion 
polymorphisms with previously characterized genome-wide association study (GWAS) 
trait variants of common complex diseases. In summary, these genome-enabled population 
scale analysis approach shows great potential for evaluating the contribution of recent and 






CHAPTER 1. INTRODUCTION 
1.1 Transposable elements (TEs) – definitions and concepts 
Transposable elements (TEs) are DNA sequences that capable of moving themselves 
to a new location in the host genome. There are two distinct mechanisms through which 
TEs can transpose [9]. One is the so called “copy-and-paste” mechanism, where the TE 
sequences in the host genome were first transcribed into RNA and then reverse transcribed 
to DNA and insert back to a new genomic location in the host genome. This type of TEs 
are called retrotransposons. Another way through which the TE sequences jumps in the 
host genome is the “cut-and-paste” mechanism. The type of TEs are transposes through 
this mechanism is called DNA transposons.  
 
1.1.1 Retrotransposons 
In order to facilitate their transposition in the host genome, some retrotransposons 
encode their own proteins that helps them transpose. This type of retrotransposons are 
known as the autonomous retrotransposons. Both the long terminal repeat (LTR) 
retrotransposons and the non-LTR encodes their own proteins, and the latter ones encode 
proteins with a poly A tail [10-12]. The retrotransposons that does not encode their own 
proteins are called non-autonomous retrotransposons. Not surprisingly, these non-
autonomous retrotransposons that do not encode any proteins lack the molecular machinery 
that are required for transposition. In fact, the non-autonomous retrotransposons are found 
to rely on the reverse transcriptase and endonuclease that encoded by autonomous elements 
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to transpose [13, 14]. A successful transpositional event of retrotransposons will create at 
least one new copy of themselves in the host genome. Therefore, transposable element 
activities can be measured by their copy numbers in the host genomes. In addition to the 
direct observation of the copy numbers of retrotransposon in the host genome, the 
abundance of gene transcripts and protein products that encoded by the autonomous 
retrotransposons become a key measurement of the activities of TE activities. 
 
1.1.2 TE compositions in the host genomes 
TEs were initially discovered in maize by Barbara McClintock in the late 1940s [15]. 
As more genomes have been studied, TEs sequences were found to have broad existence 
in the genomes of almost all living organisms. Different host genomes usually have quite 
distinct profiles of TEs - both in terms of the types of TEs that exist in the host genome and 
the proportion that the host genome is comprised of TE sequences. In fact, in the maize 
genome where TEs were initially discovered, TEs comprised about 60% of its genome, 
whereas the proportion of TE sequences in other species, such as the yeast genome can be 
as low as 3% [16].  
The human genome project was the first systematic characterization of transposable 
elements throughout the entire human genome [1]. By estimation, there are more than 50% 
of the human genome sequence that is derived from TE insertions, containing both 
retrotransposons and DNA transposons [1, 2]. Retrotransposons, specifically the long 
interspersed elements (LINEs), short interspersed elements (SINEs) and long terminal 
repeat (LTR) retrotransposons, are the major types of TEs in the human genome. LINEs 
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are the largest class of TEs in the human genome measured by bases, taking up over 20% 
of the genome. SINE is the largest class of TEs in the human genome measured by copy 
number, with over 1.5 million copies in the human genome. LINEs and SINEs takes up a 
total of 34% of the human genome. The remaining TEs in the human genome are ~0.5 
million LTR, including endogenous retroviruses (ERVs) and ~0.3 million DNA 
transposons. Among all the LINEs, the LINE-1 (L1) is the most abundant class in the 
human genome, with over half million copies and 462.1 megabases (Mb) in total lengths 
[1]. Among all the SINEs in the human genome, Alu is youngest and the the largest 
subclass of SINEs [3, 4].  
 
1.2 Functional Roles of TEs 
Followed by the initial discovery of TEs, the “selfish DNA” hypothesis seemed to 
hold when little was known about any function that these widely spread repetitive 
sequences encodes and how they could be involved in various of basic biological processes 
that are necessary for the survival of their host. As genome parasites, it seems plausible 
that the only purpose of TEs in the host genome is simply to propagate themselves and 
colonize the host genome. However, accumulating evidences have been found to show that 
TE sequences have been widely recruited and integrated in the host genome regulatory 
machinery, providing functional regulatory elements [17]. In fact, TEs provide an abundant 
source of regulatory sequences in the host genomes [17, 18]. 
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1.2.1 TE-derived cis-regulatory elements 
TEs were originally studied for their impact on the expression of host gene due to 
the destructive effects that the new TE insertions have on the host genes or regulatory 
elements. Nevertheless, TEs actually provide an abundant source of cis-regulatory 
elements for the host genomes [17], including promoters [19-21], enhancers [22-26]. It has 
been shown that TE sequences were present in ~25% of experimentally validated human 
promoter [20]. Over 50 thousand ERV-derived sequences were found to initiate 
transcription in the human genome[19]. These observation is coherent with our knowledge 
about TEs from an evolutionary perspective. In order to survive and proliferate in the host 
genome, TEs carry cis regulatory sequences that mimic the host promoters. In addition to 
promoter sequences, TE can also function as enhancers and alternatively spliced exons and 
regulate host gene expression levels [22-27].  
 
1.2.2 Trans-regulatory activities of TEs 
In addition to its cis-regulatory activities, TEs were also found to contribute a number 
of trans-regulatory elements such as transcription terminators [28], small RNAs [29-31],  
chromatin boundary elements [32] and involved in regulatory networks [33]. There are 55 
experimentally validated human microRNA (miRNA) genes were found to be derived from 
TEs. These TE-derived sequences could impact thousands of human genes that are 
regulated by these miRNAs [30]. A subclass of SINEs, the mammalian-wide interspersed 
repeats (MIRs) in the human genome were found to provide insulators that could organize 
the chromatin in different regulatory domains through enhancer-blocking and separate 
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active and repressive chromatin domains through chromatin barrier activity [32]. A set of 
closely related ERV sequences were found to have significant impact on human tumor 
suppressor gene p53 regulatory network by providing a near-perfect binding site for its 
target genes [33]. Therefore, TE-derived sequences can have a directly impact on host gene 
expression through regulating chromatin states, as well as have an indirect impact on host 
gene expressions via regulatory network rewiring. 
 
1.3 Human genome regulation of TE activities 
Human TE activities were initially discovered by their mutagenic effects. The 
repetitive sequences in TEs may introduce genome instabilities such as alterations and 
inversions in the host genome. TE insertions may also occur in genes or regulatory regions 
such that they disrupt function encoded by the gene and lead to deleterious effects to the 
host. In fact, there are many diseases that are found to be directly caused by TE insertions. 
For example, there are 96 genetic diseases that have been demonstrated to be caused by 
retrotransposon insertions, including cystic fibrosis (Alu), hemophilia A (L1) and X-linked 
dystonia-parkinsonism (SVA) [34, 35].  In addition, somatic mutations caused by human 
TE activity have been linked to a number of different kinds of cancer [36, 37]. Therefore, 
it is not surprising that the host genomes have evolved to have different suppression 
mechanisms to suppress TE activities. Specifically, for retrotransposons the host 
suppressions target both the transcriptional processes and post-transcriptional processes. 
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1.3.1 Transcriptional suppression of TE activities 
Transcriptional suppression of TE activities mainly relies on the epigenetic silencing 
of TE sequences through different chromatin modifications, including DNA methylation, 
histone modification and chromatin remodeling [38]. TE activations have been observed 
in mice with deficiencies in their DNA methyltransferases (DNMTs) [39]. The cytosine 
methyltransferases are enzymes that transfer methyl groups to cytosine nucleotides of 
genomic DNA and maintain the methylation. Loss of function in these enzymes will cause 
the loss of methylation at the CpG island of TE promoter regions and thus lead to the 
derepression of TEs. In humans, hypomethylation of L1 DNA has been shown to be 
associated with elevated L1 transcriptional activities [40-42]. Histone modifications have 
also been shown to silence TEs in mice and preimplantation embryos [43]. Moreover, loss 
of function in genes involve in repressive histone modifications also lead to activation of 
TEs. Mutations in a methyltransferase gene for histone H3 lysine 9 (H3K9) methylation in 
mice result in the overexpression of TEs [44]. In humans, analysis on global histone 
modifications have found that H3K9 is enriched at human retrotransposons, suggesting the 
repression role of histone methylation in TE repression [44-46]. Proteins that involve in 
alteration of chromatin structures, such as condensation and packing, could also be critical 
for TE silencing [47]. For example, condensin II subunit, which participates in maintaining 
the structures of chromosomes, has been shown to repress retrotransposition in Drosophila. 
Nevertheless, epigenetic silencing is not the only mechanism through which the host cells 
suppress retrotranspositions. Other mechanisms at the post-transcription level act as a 
suppression to TE activities. 
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1.3.2 Post-transcriptional suppression of TE activities 
In addition to transcriptional suppressions, there are also different mechanisms that 
suppresses TE activities at the post-transcriptional level. The RNAi pathway also plays an 
important role in the post-transcriptional silencing of TEs [48]. In the RNAi pathway, the 
dicer proteins cleave the dsRNAs of the TE transcripts and yield small interfering RNAs 
(siRNAs) [48]. The siRNAs and the RNA-degrading complexes forms the siRNA-guided 
transcript-cleavage complex RISC and the degrade TE transcripts that are complementary 
to the guide siRNA.  It has been shown that many human siRNAs were generated from 
TEs and antisense transcripts-mediated RNAi regulate retrotranspositional activities [49]. 
In addition to RNAi, other mechanisms has also been shown to suppress retrotransposition 
It has been shown that in human cells, ribonucleoprotein (hnRNPL) interact with L1 RNA 
and down-regulates L1 retrotransposition [50]. The melatonin receptor 1 (MT1) was found 
to inhibit retrotranspositional activities of L1 through downregulation of the transcripts 
[51].  For L1s, the ORF1 protein (ORF1p) and ORF2 protein (ORF2p) binds the L1 
mRNAs and forms a ribonucleoprotein (RNP). Therefore, addition to degrading RNA 
transcripts of L1s, some host mechanisms also targets the RNP formation and delivery to 
genomic DNA processes in order to inhibit retrotransopositions [52]. The innate immune 
system has also been found to play a role in post-transcriptional TE suppression. The 
autophagy signaling pathway has been shown to prevent new TE insertions by degrading 
RNA intermediate of TEs [53]. 
In summary, existing evidences show that the host genome regulates TE activities 
through a variety of mechanisms. Different mechanisms interact or interfere with each 
other and other host regulatory machineries in a complex way. Several genes were 
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demonstrated to be essential for the suppressing or silencing of TE activities in mammalian 
cells [22, 23]. However, genome-wide screens for such suppressor genes were only 
performed in a few organisms such as S. cerevisiae [6] and C. elegans [7]. Moreover, most 
of the current human-specific analysis on TE suppressors were performed under disease 
conditions such as cancers, which may not represent the full picture of the TE regulations 
by human genomes. Therefore, the question of how TE activities are regulated in human 
cells has yet to be systematically addressed at the genome-wide scale. 
 
1.4 Active TEs in the human genome 
While most of the TE sequences in the human genome are remnants of ancient 
insertional events. In other words, a large proportion of the TE sequences in the human 
genome are no longer capable of transposition. There are three families of retrotransposons 
that are currently active in the human genome: Alu [3, 4], L1 [5, 6] and SVA [7, 8]. Recent 
studies have also found a small number of human endogenous retrovirus K (HERV-K) 
elements are also active in the human genome [54].  
A full-length L1 is ~6 kilobases (kb) in length and encodes its own RNA polymerase 
II promoter, and two proteins – the ORF1 and ORF2 proteins [55, 56]. The ORF1 proteins 
have the RNA-binding function and the ORF2 proteins can function as both the 
endonuclease and reverse-transcriptase [56]. These molecular functions collectively 
facilitate the transpositions, and thus make L1 the dominant autonomous retrotransposons 
in the human genome. In addition to its own transposition, the machinery that encoded by 
L1s also promotes the reverse transcriptional activities in the human genome, including the 
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transposition of other non-autonomous retrotransposons such as the Alu elements. While 
most of the L1 sequences accumulates mutations over time and gradually lost their 
mobility, there are ~145 full-length, intact L1s in the human genome [5, 57]. These L1s 
have their have their intact ORF1 and ORF2 sequences that encodes a functional protein 
and thus they have their full capacity to transpose. As a result, for these full-length, intact 
L1 elements, it is possible to measure their transcription levels with a relatively high 
confidence via either a targeted assay approach or whole transcriptome approach.  
As a class of non-autonomous retrotransposons, SINEs do not encode any protein. 
Of the ~1.5 million copies of SINEs in the human genome, ~1.1 million copies of them are 
Alu, which is the most abundant [1]. Among all the SINEs in the human genome, Alu is 
youngest and the only active element. An Alu element is usually ~300 base pairs (bp) long 
and harbors their own RNA polymerase III promoter sequence [58]. Since Alu sequences 
do not carry any RNA polymerase III termination signal, therefore, once Alu sequences get 
transcribed, the transcription will carry through until a termination signal was reached [59]. 
As a result, most observed Alu transcriptions via the whole transcriptome approach would 
be read-through transcripts. 
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Figure 1 Schematic showing the structure of different TEs in the human genome 
The SINE-VNTR-Alus (SVAs) are hominoid specific retrotransposons that are 
currently active in the human genome. SVA, as its name SINE-VNTR-Alu indicates, is a 
chimeric retrotransposon that is comprised of SINE, VNTR and Alu sequences. SVAs 
usually have a full length of ~2 kb long [7, 8]. Like Alu elements, they are also non-
autonomous retrotransposons and therefore, its transposition is also likely to rely on the L1 
machinery. Unlike Alu sequences that carries an internal RNA polymerase III promoter, 
SVAs do not encode any internal promoter sequence. It has been shown that SVAs can be 
by RNA polymerase II and it is likely to rely on the promoter sequences from its flanking 
regions [7, 8]. In other words, the observed transcription of SVA sequences is likely to be 




1.5 Human TE Polymorphisms and Genome Regulation 
The retrotransposition rate (RR) of active human TEs have been estimated be about 
one insertion every 10 to 100 births [60]. When members of the active TE families jump 
in the somatic cells, they generate cellular heterogeneity. Similarly, when they jump in 
germline cells, they create inter-individual differences at the TE insertional sites. These 
sites segregate human individuals within and between populations through TE insertional 
polymorphisms.  
The initial studies on TE polymorphisms were started in the 1990s where a small 
number of sites in the human genome with very recent insertions were studied. The Alu 
elements, namely Ya5/8 and Yb8 Alu elements were found to be present in some human 
populations while absent in others [3, 61, 62]. Four Alu insertion polymorphisms were 
identified for the first time in 16 populations worldwide [62]. Subsequent study 
characterized 8 polymorphic Alu insertions in 1,500 individuals from 34 populations 
worldwide [63]. In the past decade, new experimental and computational approaches have 
been developed to systematically characterize structural variations, including TE 
polymorphisms in the entire human genome [64]. The 1000 genomes project (1KGP) has 
applied multiple approaches to characterize TE polymorphisms in 2,504 individuals from 
26 populations worldwide [65]. Given the disruptive nature of TE insertions, along with 
the demonstrated impact of TE-derived sequences to on the regulation of the human 
genome, TE insertion polymorphisms opened a new opportunity for us to systematically 
study the impact of TEs on inter-individual differences in the regulation of gene expression. 
For example, some human TE polymorphisms may lead to differences in gene expression 
patterns between individuals. Therefore, inter-individual differences in regulatory 
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variations generated by these recent TE insertions may have important implications for 






CHAPTER 2. GENOME-WIDE SCREEN FOR MODIFIERS OF 
HUMAN LINE-1 EXPRESSION 
2.1 Abstract 
LINE-1 (L1) is an active family of transposable elements (TEs), which exerts a major 
impact on the structural integrity of the human genome.  L1 transpositional activity is 
highly disruptive, and L1-mediated insertions have been linked to more than one hundred 
human diseases.  Accordingly, human cells employ a wide variety of mechanisms to 
mitigate the impact of L1 activity by suppressing their expression.  Here, we report the 
development of a novel genome-wide screen for genetic modifiers of human L1 expression.  
Our approach relies on expression quantitative trait loci (eQTL) analysis for the discovery 
of individual genetic variations, i.e. single nucleotide polymorphisms (SNPs), which are 
jointly associated with both L1 and gene expression.  We applied this approach to known 
modifiers of L1 expression (n=34), as a positive control, along with sets of transcription 
factor (n=1,244) and chromatin associated (n=450) protein encoding genes.  The joint L1-
gene eQTL association analysis was able to recover 35% of 34 known L1 modifier genes, 
including the DNA methyltransferase gene DNMT3A and the RNA helicase gene MOV10.  
We also discovered 24% putative transcription regulator genes and 30% chromatin 
modifier genes, which that can be considered as putative L1 modifiers based on the results 
of our screen.  Notable transcription regulator genes uncovered by our screen include the 
TAF13 gene, which encodes part of the transcription factor IID complex, and the TCF19 
cell-type specific transcription factor gene.  With respect to putative chromatin modifiers 
of L1, a number of histone deacetylase genes, including HDAC1, HDAC3, and HDAC5, as 
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well as the histone H3 lysine demethylase gene KDM5A, were detected via the joint L1-
gene eQTL analysis.  The list of putative L1 modifiers detected by our genome-wide screen 
can be considered as a set of working hypotheses regarding human regulation of L1 
activity; definitive proof for the role of these genes in the regulation of L1 expression will 
require further experimental interrogation.  Nevertheless, our results underscore the 
potential utility of genome-scale approaches to the analysis of host-TE interactions, 
particularly in terms of the ability to substantially narrow down the search space for 
candidate genes of interest. 
 
2.2 Introduction 
Transposable element (TE) derived sequences make up more than half of the human 
genome, and members of a single TE family alone, LINE-1 (L1), comprise 17% of the 
genome sequence [1].  L1s are retrotransposons, which transpose via the reverse 
transcription of an RNA intermediate.  Full-length L1 elements are ~6 kilobases (kb) in 
length and encode an RNA polymerase II promoter along with the ORF1 and ORF2 
proteins that catalyze reverse transcription [55, 56].  L1s are the only family of autonomous 
TEs that remain active in the human genome [5], and the L1 transcriptional machinery is 
also responsible to catalyzing the transposition of the non-autonomous Alu and SVA TE 
families [58, 66].  Accordingly, L1 activity has a major impact on the structure of the 
human genome. 
Ongoing L1 activity poses a direct threat to human genome stability.  In fact, L1 
transpositional activity was discovered by virtue of a Hemophilia A causing insertion in 
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the Coagulation Factor VIII gene (F8) [6].  To date, 124 independent TE insertions 
resulting from L1 activity, including L1-mediated Alu and SVA insertions, have been 
linked to human disease [67].  For example, germline L1 insertions are causal mutations 
for chronic granulomatous disease, Duchenne muscular dystrophy, and Hemophilia B [68-
70].  Somatic L1 insertions have been implicated in a variety of cancer types [71], including 
colorectal cancer [72], head and neck cancers [73, 74], and lung carcinomas [75].  L1s can 
also disrupt genome stability by facilitating non-homologous recombination and 
chromosome breakage [66, 76]. 
Host genomes’ TE regulatory machinery are a crucial component of genome 
stability.  Human cells employ a wide variety of mechanisms to mitigate the impact of L1 
insertions by tightly regulating their activity.  As transcription is rate-limiting step for the 
activity of retrotransposons, such as L1, host genomes keep these elements in check by 
regulating their expression at the pre- and post-transcriptional levels [76-78].  Different 
cell types can employ distinct cellular machineries to suppress L1 activities.    
In germline cells, the PIWI-interacting RNA (piRNA) pathway inhibits L1 activity 
via DNA methylation genomic L1 genomic sequences and RNA degradation of L1 
transcripts.  This pathway involves the methylation regulator DMNT3L and the piRNA 
bidnding protein PIWIL4 [79, 80].  Recent evidence has shown that piRNA pathway may 
be active in tissues other than the germline [81, 82].  In embryonic stem cells (ESCs), three 
DNA methyltransferases genes, DNMT1, DNMT3A and DNMT3B coordinately maintain 
the repressive L1 methylation [83].  The Sirtuin 6 (SIRT6) protein has been shown to 
repress L1s in mice embryonic fibroblast cells by packaging the L1 sequences into 
heterochromatin in collaboration with the tripartite motif containing 28 (TRIM28) gene 
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(also known as KAP1) [84].  In neural stem cells, the transcription factor Sox2 (SOX2) and 
the histone deacetylase 1 protein (HDAC1) form a complex on the L1 5’ promoter region 
to represses element transcription [85, 86]. 
Post-transcriptional suppression mechanisms usually target L1 mRNA or the 
formation and transportation of the L1 ribonucleoprotein (RNP) complexes.  For example, 
dicer proteins of the RNA interference (RNAi) pathway cleave dsRNAs from L1 
transcripts to yield small interfering RNAs (siRNAs). The siRNA-guided RNA-induced 
silencing complex (RISC) then identifies and the degrades L1 transcripts complementary 
to guide siRNA sequences [48].  The ribonucleoprotein hnRNPL has been shown to 
interact with L1 mRNA directly and inhibits retrotransposition by decreasing steady-state 
levels of L1 transcripts [50].  The Mov10 RNA helicase (MOV10), which is a component 
of the RNA-induced silencing complex (RISC), physically associates with the L1 RNP and 
represses L1 retrotransposition by promoting stress granule formation [52, 87, 88].  The 
endonucleases TREX1 and ERCC1 inhibit L1 retrotransposition post-transcriptionally by 
cleaving the reverse-transcribed L1 cDNA molecules [89, 90]. 
The experimental approaches used to characterize the modifiers of L1 expression 
described above traditionally rely on candidate gene approaches, which require a priori 
knowledge regarding host L1 activity related pathways and their constituent genes 
(proteins).  Candidate L1 modifier genes are experimentally manipulated, e.g. via knock-
out or over-expression techniques, and the impact on L1 activity is then observed.  For 
example, the role of the piRNA pathway in L1 repression was investigated by insertional 
mutation of the PIWIL4 gene followed by the use of in situ hybridization to compare L1 
transcript levels in wild-type versus mutant cells [80].  Similarly, for studies of the SIRT6 
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L1 suppressor gene, an L1 green fluorescent protein (L1-EGFP) [91] reporter system was 
used to measure de novo retrotransposition events in wild type versus SIRT6 knockout 
cells [84].  While approaches of this kind have been extremely valuable in characterizing 
the host L1 regulatory machinery, they are typically limited to a relatively small set of 
candidate genes (proteins). 
For this study, we developed and applied a genome-wide screen for putative genetic 
modifiers of L1 activity.  Our genome-wide screen uses the expression quantitative trait 
loci (eQTL) approach to look for genetic variants, i.e. single nucleotide polymorphisms 
(SNPs), which are associated with both L1 and gene expression levels (Figure 1).  We 
considered SNPs that are jointly associated with L1 and gene expression to be putative 
genetic modifiers of L1 expression, with the paired genes implicated as members of L1 
regulatory pathways.  This approach can be considered to be largely hypothesis free, and 
therefore less biased, compared to more traditional candidate gene approaches, and it is 
also distinguished by its genome-wide scale, with respect to the ability to screen thousands 
of genes at a time. 
We applied our eQTL approach to known L1 modifier genes, as a positive control, 
along with potential L1 modifier genes encoding transcription factors and chromatin 
associated proteins.  In addition to recovering known L1 modifier genes, such as DNMT3A 
and MOV10, our screen also identified a number of novel L1 transcriptional regulator genes 
(TAF13 and TCF19) as well as chromatin associated proteins implicated in L1 regulation 
(HDAC5 and KDM5A).     
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2.3 Materials and Methods 
2.3.1 Genome-wide SNP genotypes 
Genome-wide SNP genotype calls for 358 individuals from four European 
populations were accessed from the phase 3 variant release of the 1000 Genomes Project 
(1KGP) [92], corresponding to the human genome reference sequence build 
GRCh37/hg19.  The four populations are CEU: Utah Residents (CEPH) with Northern and 
Western Ancestry, FIN: Finnish in Finland, GBR: British in England and Scotland and 
TSI: Toscani in Italy.  As previously described for the 1KGP [92], whole genome 
sequencing (DNA-seq) was performed for lymphoblastoid cell lines, i.e. Epstein–Barr 
virus (EBV) transformed B-lymphocytes (B cells), from these individuals and used to call 
genetic variants.  The SNP genotype data were accessed from the 1000 Genomes Project 
ftp server maintained at the NCBI: 
http://ftp-trace.ncbi.nlm.nih.gov/1000genomes/ftp/release/20130502/. 
 
2.3.2 Gene expression quantification and normalization 
Matched gene expression data for the same 358 individuals were taken from 
Genetic European Variation in Health and Disease (GEUVADIS) project [93].  Gene 
expression levels were measured for the same lymphoblastoid cell lines that were used for 
DNA-seq analysis in the 1KGP.  PEER normalization was applied on the gene expression 
levels, with parameters optimized for cis eQTL discovery, as previously described [94].  
The PEER normalization controls for multiple, potentially confounding sample covariates 
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in a similar way as described for the L1 expression analysis below.  Normalized RNA-seq 





2.3.3 L1 expression quantification and normalization 
Matched RNA-seq data from the GEUVEDIS project were also used to quantify 
the expression levels of full-length, intact and potentially active L1 elements genome-wide.  
The locations of 145 full-length, intact human L1s were obtained from L1Base version 2 
(http://l1base.charite.de/) [95].  RNA-seq reads mapped to the human genome reference 
sequence build GRCh37/hg19 were access from the GEUVADIS project ftp server 
maintained at EBI: 
ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/GEUV/E-GEUV-
6/processed/ 
The program TEtranscripts was used to quantify the expression levels for each of 
the 145 individual, full-length L1 elements.  The TEtranscripts program works by re-
mapping RNA-seq reads genome-wide, allowing for ambiguous or multi-mapped reads, 
and generating read counts for both genes and TEs [96].  The program subsequently uses 
an EM algorithm to optimally map ambiguous reads to a unique genomic location, taking 
into account the entire space of reads mapped genome-wide.  The resulting uniquely 
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mapped reads were used to generation L1-specific read counts, which were log transformed 
and quantile normalized to a standard normal distribution using the edgeR package [97].  
A series of additional normalization steps were used to control for sample covariates, as 
described below, in order to allow for accurate downstream eQTL analysis. 
 
2.3.4 Controlling sample covariates for L1 expression levels 
We controlled for the effects of potential confounding variables in the eQTL 
analysis by regressing sample covariates out of the expression dataset, following 
previously suggested analysis standards [93, 98].  The specific sample covariates controlled 
for are (1) gender, (2) sequencing batch, (3) population group, (4) gene expression 
heterogeneity, and (5) population structure.  All covariates were combined in a single 
covariates matrix 𝐶𝐶 with sub-matrices representing each of the five covariates.  (1) Gender: 
a binary vector of gender labels for each individual sample.  (2) Sequencing batch: a vector 
with sample labels for the sequencing labs where the RNA-seq experiments were 
conducted.  (3) Population group: a matrix of sample indicator variables for each of the 
four populations – CEU, FIN, GBR, and TSI.  (4) Gene expression heterogeneity: to control 
for variance due to unknown experimental factors or confounding factors in the expression 
dataset, we used the top 10 principal components (PCs), corresponding to the top 10 
eigenvectors, of the covariance matrix of quantile normalized expression levels as sample 
covariates.  (5) Population structure: in addition to the population group sample labels, we 
also used the top 2 PCs from the SNP genotype matrix of the individuals to control for any 
additional population structure.  The genotype matrix was built using biallelic SNPs with 
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minor allele frequency (MAF) > 10%.  The program PLINK was then used to perform LD-
pruning with a window size of 50 SNPs, a step size of 5 SNPs and a pairwise correlation 
cutoff of 0.5 [99].  The final genotype matrix contains genotypes for pruned SNPs across 
all individuals, where for each SNP location, 0, 1, and 2 correspond to reference 
homozygous, heterozygous, and alternative homozygous.  
Using the combined covariates matrix 𝐶𝐶, made up of the five submatrices described 
above, we computed the hat matrix 𝐻𝐻 as: 
𝐻𝐻 = 𝐶𝐶(𝐶𝐶𝑇𝑇𝐶𝐶)−1𝐶𝐶𝑇𝑇 
We then applied the hat 𝐻𝐻  matrix to residualize the gene expression levels.  The 
residualized gene expression matrix was computed as: 
𝑌𝑌 = (1 − 𝐻𝐻)𝑌𝑌′ 
where 𝑌𝑌′ is the matrix of quantile normalized expression levels and 𝑌𝑌 is the matrix of 
residuals.  Finally, L1 expression levels were extracted from the residualized expression 
matrix for downstream analysis. 
 
2.3.5 eQTL association analysis 
We performed two kinds of eQTL association analyses using the program Matrix 
eQTL [100]: (1) association of SNP genotypes with L1 expression levels, and (2) 
association of SNP genotypes with gene expression levels.  For the L1 eQTL associations, 
SNP genotypes with MAF > 5% were regressed against residualized L1 expression levels 
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using the additive linear analysis option of Matrix eQTL with no covariates.  Sample 
covariates were not included since they were explicitly controlled for as described above.  
The false discovery rate (FDR) was used to control for multiple statistical tests, with an 
FDR cutoff of 0.05, corresponding to P<1.37 x 10-7, used to define statistically significant 
associations.  As an eQTL association control, we permuted the unlinked SNP genotypes, 
by randomly assigning them to individual genomes, and then ran the same eQTL 
association with permuted SNP genotypes analysis against residualized L1 expression 
levels.  The resulting random eQTL association P-values were used as a null distribution 
against which the observed eQTL association P-values were compared. 
For the gene eQTL associations, SNP genotypes with MAF > 5% were regressed 
against PEER normalized gene expression levels using the additive linear analysis option 
of Matrix eQTL with gender and population sample covariates included.  The gene eQTL 
associations were limited to cis SNPs, which were defined as falling within 1Mb upstream 
or downstream of annotated gene model boundaries (transcription start and stop sites).  An 
FDR cutoff of 0.05, corresponding to P < 9.54 x 10-4, was used to define statistically 
significant associations.  The same random SNP permutation procedure as described above 
was used to generate a null P-value distribution for comparison with the observed eQTL 
association P-values.    
 
2.3.6 Genetic modifiers of L1 expression 
To search for potential genetic modifiers of L1 expression, individual SNPs that are 
jointly associated with both L1 and gene expression were identified.  Fisher’s combined 
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probability test was used to combine P-values for matched SNP-L1 and SNP-gene eQTL 
associations.  The χ2 distribution, with 4 degrees of freedom (2 x 2 P-values combined), 
was used to measure the significance of the combined P-values.  An FDR cutoff of 10-4, 
corresponding to P < 3.21 x 10-5, was applied to filter out jointly significant gene-L1 pairs.  
We focused on eQTL associated with three classes of genes, encoding for: known L1 
suppressors, transcription factors, and chromatin associated proteins.  A collection of 34 
previously characterized L1 suppressor genes were curated from the literature.  Human 
gene ontology (GO) annotations provided NCBI 
(ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz) were parsed in order to identify 1,244 
transcription factor genes and 450 chromatin association protein encoding genes.    
 
2.4 Results and Discussion 
2.4.1 Genome-wide screening with shared eQTL associations 
We used joint eQTL association analysis of L1 and gene expression levels in order 
to conduct a genome-wide screen for genetic modifiers of L1 expression (Figure 1).  
Genome-wide SNP variant calls for 358 individuals from 4 European populations – CEU, 
FIN, GBR, and TSI – were taken from the phase 3 release of the 1KGP, and matched gene 
expression levels for the same individuals were taken from the GEUVEDIS RNA-seq 
project.  Gene expression levels were characterized for the same lymphoblastoid cell lines 
that were used for DNA-seq analysis in the 1KGP project.  Gene expression levels were 
normalized using the PEER method in order to optimize downstream eQTL association 
analyses.  We re-analyzed the GEUVEDIS RNA-seq read data in order to measure gene 
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expression levels at 145 full-length, potentially active L1 loci.  L1 expression analysis was 
performed in such a way as to find the best locations for multi-mapping sequence tags and 
to control for potentially confounding sample covariates, such as population structure and 
sequencing batch (Supplementary Figure S1).  The details of our L1 and gene expression 
analyses are provided in the Materials and Methods. 
 
Figure 2 Genome-wide approach to screen for genetic modifiers of L1 expression 
SNP genotype and transcriptome profiling of 358 European individuals were combined for 
expression quantitative trait loci (eQTL) analysis.  SNP genotypes were regressed against 
L1 and gene expression levels to search for shared eQTL associations.  An example of a 
shared eQTL association that represents a L1 suppressor is shown, where the SNP 
genotypes associated with decreased L1 expression are simultaneously associated with 
increased expression of the putative L1 modifier gene.   
 
Individual SNP genotypes were regressed against both L1 and gene expression 
levels to search for shared associations (Figure 1).  SNPs that are jointly associated with 
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both L1 and gene expression are considered to be putative genetic modifiers of L1 
expression.  We did this for known L1 modifier genes, as a proof of principle (i.e. a positive 
control), along with candidate L1 modifier genes encoding transcription factors and 
chromatin associated proteins.  Results of our genome-wide eQTL analysis are shown 
separately for L1 expression (Figure 3A) and for gene expression (Figure 3B).  The 
observed eQTL associations for both L1 and gene expression are compared to a null 
distribution of eQTL associations generated via random permutation of SNP genotypes.  
The Q-Q plots for L1 and gene expression show substantially more significant associations 
than expected by chance, as indicated by the deviation of the observed values from both 
the diagonal line and the randomly permuted SNP genotype association values.  Manhattan 
plots also show a striking difference between the genome-wide distributions of the 
observed versus permuted eQTL associations.  The L1 eQTL association Manhattan plot 
shows distinct peaks on chromosome 6, 12, and 16.  There are far more significant 
association peaks observed for gene expression, likely owing to the fact that we analyzed 
far more gene (22,128) than L1 (145) loci.  
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Figure 3 Results of the eQTL association analyses for L1 and gene expression  
Quantile-quantile (Q-Q) plots (left) and Manhattan plots (right) are shown for the L1 (A - 
orange) and gene (B - blue) results.  The Q-Q plots show the observed eQTL association 
log transformed P-values (L1-orange and gene-blue dots) compared to randomly permuted 
association P-values (gray dots) and the expected P-value distribution under the null 
hypothesis of no association (gray lines).  The upper panels of the Manhattan plots show 
the observed eQTL association log transformed P-values and the lower panels show 
randomly permuted association P-values.  
 
L1 and gene eQTL association P-values were combined to screen for shared SNP 
eQTL, i.e. putative L1 genetic modifiers.  Fisher’s combined probability test was used to 
combine L1 and gene association P-values, yielding χ2 values for shared associations 
(Figure 4).  The combined P-value χ2 distributions show 2,346 statistically significant 
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shared L1-gene eQTL associations (χ2>25.9, df=4, FDR q<10-4) across all three classes of 
genes that we evaluated.  This includes numerous shared associations with known L1 
modifier genes as should be expected if our genome-wide screen is adequately powered to 
detect L1-gene regulatory interactions.  We also found many shared associations with 
genes that encode transcription factor and chromatin associated proteins; these shared 
associations point to potentially novel genetic modifiers of L1 expression.  Comparison of 
the three gene categories does not show any substantial difference in the strength of shared 
associations.  The top shared associations observed for each of these three categories of 
genes are shown in Table 1, and examples for each of the three categories are described in 
the following sections of the manuscript.   
 
Figure 4 Results of the joint L1-gene eQTL association analysis 
SNP rs11126321 genotypes Joint L1-gene eQTL results are shown for SNPs associated 
with known L1 suppressors (red), transcription factor (purple), and chromatin associated 
(green) genes.  Cumulative distributions are shown for Fisher’s combined probability test  
𝜒𝜒42 values for all three gene sets.  The left panel shows the entire distribution, and the 
middle panel shows only statistically significant values (FDR < 10-4).  The right panel 




2.4.2 Known modifiers of L1 expression 
The potential utility of our eQTL genome-wide screen for L1 genetic modifiers can 
be illustrated by the results seen for known modifiers of L1 expression, including both 
transcriptional and post-transcriptional modifiers.  For example, the alternate allele (A) of 
the SNP rs11126321 was found to be jointly associated with increased L1 expression and 
decreased expression of the DNA Methyltransferase 3 Alpha gene (DNMT3A) (Figure 5A).  
DNMT3A encodes a de novo DNA methyltransferase that is known to repress L1 
expression via the methylation of CpG islands proximal to element promoters [83].  
Accordingly, the expression levels of DNMT3A and L1 are expected to be inversely 
correlated as can be seen here.  
In a similar example, we found shared, and inverse, eQTL L1-gene associations for 
the SNP rs6537785.  The alternate allele of this SNP (T) is associated with increased L1 
expression and decreased expression of the Mov10 RISC Complex RNA Helicase 
(MOV10) (Figure 5B).  MOV10 has been implicated in post-transcriptional regulation of 
L1 elements by virtue of its role as an inhibitor of L1 mRNA transport between the nucleus 
and the cytoplasm, a critical, rate-limiting step it the retrotransposition cycle [52].  MOV10 
achieves this by promoting the degradation of L1 mRNA in the cytoplasm via the formation 
of cytoplasmic stress granules, thereby limiting their ability to return to the nucleus where 
reverse transcription takes place. 
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Figure 5 Known L1 suppressor genes implicated by the joint eQTL association 
analysis 
 (A) L1 and gene eQTL associations for a known L1 transcriptional suppressor.  SNP 
rs11126321 genotypes are jointly associated with increased L1 expression and decreased 
expression of DNMT3A (left).  A schematic for the role of DNMT3A in L1 suppression 
(right).  (B) L1 and gene eQTL associations for a known post-transcriptional suppressor 
of L1.  SNP rs6537785 genotypes are jointly associated with increased L1 expression and 
decreased expression of MOV10 (left).  A schematic for the role of MOV10 in L1 post-
transcriptional suppression (right).   
 
An interesting counter example of shared L1-gene associations for known L1 
modifiers was seen for the Nuclear RNA Export Factor 1 gene (NXF1).  In this case, the 
SNP rs111438108 shows the same pattern of association for L1 and gene expression, 
whereby the alternate allele (T) is associated with decreased expression of both (Figure 6).  
NXF1 also plays an important role in the transport of L1 mRNAs from the nucleus to the 
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cytoplasm by forming part of the nuclear pore through which the mRNAs pass to the 
cytoplasm [101].  Presumably, increased expression of the gene would facilitate greater 
transport of L1 mRNAs and accordingly higher apparent L1 expression. 
 
Figure 6 Known L1 retrotransposition promoting genes implicated by the joint 
eQTL association analysis.   
L1 and gene eQTL associations for a known post-transcriptional modifier of L1.  SNP 
rs111438108 genotypes are jointly associated with decreased L1 expression and decreased 
expression of NXF1 (left).  A schematic for the role of NXF1 is enhancing L1 expression 
(right).      
 
2.4.3 Novel transcription factor L1 modifiers 
We were most interested in the discovery of novel potential modifiers of L1 
expression via our shared eQTL approach.  We found a number of transcription factors, 
which to our knowledge were not previously implicated in L1 regulation, that are 
associated with SNPs which are also eQTL for L1 expression (Table 1).  For transcription 
factors, we focused on shared eQTL that showed the same direction of association, 
reasoning that their increased expression may lead in turn to upregulation of L1 elements.  
An example of this pattern can be seen for the SNP rs28515780, for which the alternate 
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allele (A) is associated with increased gene expression of the TATA-Box Binding Protein 
Associated Factor 13 gene (TAF13) along with increased expression of four L1 loci (Figure 
7A).  TAF13 encodes the 18 KDa subunit of the basal transcription initiation factor protein 
TFIID, which is expected to be crucial for the expression of L1 elements by the RNA 
polymerase II machinery. 
Table 1 Top modifiers genes identified via joint eQTL analysis 
Gene 












rs2887269 HNRNPL L1-136 34.41 6.14E-07 4.60E-06 
rs11126321 DNMT3A L1-136 31.57 2.34E-06 1.42E-05 
ss1388073530 AICDA L1-49 29.35 6.64E-06 3.22E-05 
rs7529736 AGO1 L1-56 29.19 7.15E-06 3.41E-05 







rs4668938 DDX1 L1-78 103.62 1.66E-21 9.27E-20 
rs28366287 CSNK2B L1-28 98.19 2.39E-20 1.19E-18 
rs540748076 BRD2 L1-28 54.88 3.45E-11 5.88E-10 
rs10902548 MEF2A L1-106 53.18 7.82E-11 1.27E-09 
rs13202640 GMNN L1-120 48.61 7.05E-10 9.78E-09 
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Gene 















rs386525443 TCF19 L1-103 72.19 7.84E-15 2.04E-13 
rs113823631 RXRB L1-57 64.07 4.05E-13 8.76E-12 
rs386525443 POU5F1 L1-103 61.28 1.56E-12 3.18E-11 
rs841657 ARNTL2 L1-94 56.91 1.29E-11 2.34E-10 
rs7258563 ZNF790 L1-129 51.12 2.11E-10 3.19E-09 
 
A similar example of this kind can be seen for genes that encode a pair of 
transcription factors – Transcription Factor 19 (TCF19) and POU Class 5 Homeobox 1 
(POU5F1) – both of which show increased expression associated with the alternate allele 
(T) of the SNP rs386525443 (Figure 7B).  The same allele of rs386525443 is also 
associated with increased expression of four L1 elements.  These two transcription genes 
are located in close proximity on the short arm of chromosome 6, within the major 
histocompatibility locus (MHC).  There is evidence suggesting that these two genes 
function together, and they are both important in embryonic development and stem cell 
pluripotency.  It may be the case that they are connected to developmentally regulated 




Figure 7 Putative L1 modifier transcription factors uncovered by the joint eQTL 
association analysis 
 (A) Shared gene and L1 eQTL associations for the putative L1 transcription factor TAF13.  
SNP rs28515780 genotypes are jointly associated with increased expression of TAF13 
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(upper – blue) and four L1 loci (lower – orange).  A schematic for the role of TAF13 in 
regulating L1 transcription is shown.  (B) Shared gene and L1 eQTL associations for the 
putative transcription factors TCF19 and POU5F1.  SNP rs386525443 genotypes are 
associated with increased expression of both TCF19 and POU5F1 (upper – blue), along 
with increased expression of four L1 loci (lower – orange).  A schematic showing the 
shared genomic location of TCF19 and POU5F1. 
 
2.4.4 Novel chromatin L1 modifiers    
We searched for novel chromatin modifiers of L1 expression, with an emphasis on 
shared L1-gene eQTL that showed the opposite direction of association.  The rationale 
behind this approach is based on the fact that chromatin compaction plays an important 
role in the suppression of L1 activity [102] and can be considered to serve as the ‘ground 
state’ through which L1 elements are held silent across the genome.  Accordingly, 
decreased expression of chromatin modifiers is expected to lead to increased expression of 
L1 elements.  We found three histone deacetylase encoding genes – HDAC1, HDAC3, and 
HDAC5 – each of which has a shared and inverse eQTL association with L1 expression 
(Figure 8 A-C).  Activity of these histone deacetylases leads to decreased acetylation, 
decrease chromatin compaction and increased expression of L1s, consistent with the 
inverse directions of the shared associations observed here.  We found a similar inverse 
shared eQTL association for the Lysine Demethylase 5A encoding gene (KDM5A), which 
demethylates lysine 4 of the histone H3 (Figure 8D).  Histone methylation is also a 
repressive chromatin mark, so decreased expression of this gene is expected to be 
associated with increased L1 expression as we observe here (Figure 8E).  
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Figure 8 Putative chromatin L1 modifiers uncovered by the joint eQTL association 
analysis 
Shared gene and L1 eQTL associations are shown for three histone deacetylase genes: 
HDAC5 (A), HDAC3 (B), and HDAC1 (C) along with the histone demethylation gene 
KDM5A (D).  In each case, there is a single SNP with genotypes that are simultaneously 
associated with increased L1 expression and decreased expression.  (E) A schematic 








Our genome-wide approach to the discovery of genetic modifiers of L1 expression 
yielded a number of promising results, including confirmation of previously characterized 
L1 modifiers (i.e. positive controls) as well as potentially novel L1 modifiers that act at the 
level of transcription initiation or chromatin modification.  These results attest to the power 
of genome-scale eQTL studies to decipher the regulatory architecture governing the 
expression of human TEs.  Given TEs’ known roles in mutation and genome dynamics, a 
deeper understanding of genetic modifiers of L1 expression has important implications for 
studies of mutagenesis and genome stability. 
The current study is limited by its focus on a single tissue type – the lymphoblastoid 
cell lines that were used for both the 1KGP DNA-seq and GEUVEDIS RNA-seq studies.  
This limitation is based on the fact that eQTL association studies of the kind employed here 
require the characterization of genome-wide sets of genotype calls and gene expression 
levels from hundreds of matched human samples.  Until recently, this has only been 
available for the single tissue type analyzed here.  However, the recently completed GTEx 
project provides matched genotype and expression data for scores of human samples.  
Exploration of this rich data set, together with consideration of the known tissue-specific 
expression profiles of L1 elements, should yield additional resolution for the discovery of 
novel L1 modifiers.  In particular, paired discovery and validation analyses could be used 
to provide an additional line of support for putative L1 modifiers. 
Another note of caution is that the identities of the novel L1 genetic modifiers 
discovered here should be treated with caution given the bioinformatics techniques 
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employed for their discovery.  Indeed, these putative L1 modifiers can be best considered 
as predictions, or hypotheses, that will need to be validated by careful experimental efforts.  
Nevertheless, the genome-wide screen approach that we took here should prove to be 
useful in guiding future experiments.  In particular, we hope that evaluation of our lists of 
putative L1 modifiers by L1 experts, and experimentalists with deep knowledge of L1 
regulation, will prove to be useful in substantially narrowing the space of possible studies 







CHAPTER 3. HUMAN POPULATION-SPECIFIC GENE 
EXPRESSION AND TRANSCRIPTIONAL NETWORK 
MODIFICATION WITH POLYMORPHIC TRANSPOSABLE 
ELEMENTS  
3.1 Abstract 
Transposable element (TE) derived sequences are known to contribute to the 
regulation of the human genome.  The majority of known TE-derived regulatory sequences 
correspond to relatively ancient insertions, which are fixed across human populations.  The 
extent to which human genetic variation caused by recent TE activity leads to regulatory 
polymorphisms among populations has yet to be thoroughly explored.  In this study, we 
searched for associations between polymorphic TE (polyTE) loci and human gene 
expression levels using an expression quantitative trait loci (eQTL) approach.  We 
compared locus-specific polyTE insertion genotypes to B cell gene expression levels 
among 445 individuals from 5 human populations.  Numerous human polyTE loci 
correspond to both cis and trans eQTL, and their regulatory effects are directly related to 
cell type-specific function in the immune system.  PolyTE loci are associated with 
differences in expression between European and African population groups, and a single 
polyTE loci is indirectly associated with the expression of numerous genes via the 
regulation of the B cell-specific transcription factor PAX5.  The polyTE-gene expression 
associations we found indicate that human TE genetic variation can have important 
phenotypic consequences.  Our results reveal that TE-eQTL are involved in population-
specific gene regulation as well as transcriptional network modification.   
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3.2 Introduction 
Transposable elements (TEs) are mobile DNA sequences that create copies of 
themselves when they move among chromosomal locations.  TE activity has had a major 
impact on the evolution and structure of the human genome; millions of TE sequence 
copies have accumulated over the last ~100my.  The initial sequencing and subsequent 
analysis of the human genome revealed that >50% of the genome sequence is derived from 
past TE sequence insertions [1, 2]. 
TEs can also shape the function of the human genome, particularly with respect to 
the regulation of gene expression[17].  Human TE-derived sequences have been shown to 
provide a wide variety of gene regulatory sequences including promoters [19-21], 
enhancers [22-26], transcription terminators [28] and several classes of small RNAs [29-
31].  Human TEs also influence various aspects of chromatin structure throughout the 
genome [1, 32, 103-106].   
The vast majority of human TE sequences are remnants of ancient transposition 
events that occurred many millions of years ago [1].  Accordingly, studies that have 
uncovered the regulatory properties of TE-derived sequences have dealt with fixed TE 
insertions that are present at the same locations in the genome sequences of all human 
individuals.  Such fixed TE-derived regulatory sequences are not expected to provide for 
gene regulatory variation based on insertional polymorphisms between individuals. 
It has only recently become possible to systematically evaluate the effects of TE 
genetic variation within and between human populations, i.e. TE polymorphisms.  Human 
TE polymorphisms are primarily generated via the activity of three families of 
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retrotransposons: Alu [3, 4], L1 [5, 6] and SVAs [7, 8].  Transposition events by members 
of these polymorphic TE (polyTE) families yield numerous differences in the 
presence/absence of insertions at specific loci among individual human genome sequences.  
The recent phase 3 variant release of the 1000 Genomes Project included a catalog of 
presence/absence genotypes for >16,000 polyTE loci among 2,504 individuals from 26 
human populations [65, 99].  This genome-wide collection of polyTE genotypes provides 
an opportunity to explore the phenotypic consequences of TE activity at the level of human 
populations.   
Considering the known regulatory properties of human TEs, together with the fact 
that TE insertional activity is known to be highly disruptive [34, 35], we hypothesized that 
polyTE activity can lead to gene expression differences between human individuals.  We 
used an integrated analysis of polyTE genotypes and genome-wide expression profiles, for 
the same set of 1000 Genome Project samples, in order to test this hypothesis (Figure 9).  
Gene expression levels were regressed against polyTE genotypes to search for polyTE-
gene expression associations.  This approach revealed numerous human polyTE loci that 
correspond to expression quantitative trait loci (eQTL).  The TE-eQTL uncovered here are 
involved in the establishment of population-specific expression profiles as well as 





3.3 Materials and Methods 
3.3.1 Polymoprhic transposable element (polyTE) analysis 
Genotype calls for three families of human polyTEs – Alu, L1 and SVA – in 445 
individuals from 5 populations were taken from the phase 3 variant release of the 1000 
Genomes Project[99].  The phase 3 variant release corresponds to the human genome 
reference sequence build GRCh37/hg19.  The 5 human populations are CEU: Utah 
Residents (CEPH) with Northern and Western Ancestry, FIN: Finnish in Finland, GBR: 
British in England and Scotland and TSI: Toscani in Italy from Europe along with YRI: 
Yoruba in Ibadan, Nigeria from Africa (Figure 9).  These populations were chosen because 
they have matching RNA-seq data for the same individuals (see RNA-seq analysis section).  
PolyTE genotypes were characterized by the 1000 Genomes Project Structural Variation 
Group using the program MELT as previously described [65].  The polyTE genotype data 
were accessed from the 1000 Genomes Project ftp server maintained at the NCBI: 
http://ftp-trace.ncbi.nlm.nih.gov/1000genomes/ftp/release/20130502/.   
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Figure 9 Scheme for the polymorphic transposable element (polyTE) expression 
quantitative trait loci (eQTL) analysis conducted 
Data were taken from 87 African and 358 European individuals from the 1000 Genomes 
Project.  Genome (DNA-seq) and transcriptome (RNA-seq) data were used to characterize 
polyTE genotypes and gene expression levels for all individuals in the study.  Individual 
gene expression levels were regressed against polyTE insertion genotypes in an effort to 
reveal associations between polyTE loci and human gene expression, i.e. TE-eQTL. 
 
For any given polyTE insertion site, there are three possible presence/absence 
genotype values for an individual genome: 0-no polyTE insertion (homozygote absent), 1-
a single polyTE insertion (heterozygote), and 2-two polyTE insertions (homozygote 
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present).  PolyTE genotypes were used for eQTL analysis as described below.  PolyTE 




∑ |𝑔𝑔𝑥𝑥𝑥𝑥 −  𝑔𝑔𝑥𝑥𝑥𝑥|𝑛𝑛𝑥𝑥=1 , where 𝑔𝑔𝑥𝑥𝑥𝑥   and 𝑔𝑔𝑥𝑥𝑥𝑥  are the polyTE genotype value for 
individual 𝑥𝑥 and individual 𝑦𝑦 at insertion site 𝑖𝑖, for a total of 𝑛𝑛 sites.  The resulting pairwise 
polyTE genotype distance matrix was subject to dimension reduction using 
multidimensional scaling (MDS)[107], using the cmdscale function from the R statistical 
package version 3.2.2[108], in order to visualize the genetic relationships between 




Figure 10 Distribution of polyTEs among the African and European population 
groups analyzed 
Data are broken down into Alu, L1 and SVA polyTE families.  (A) PolyTE insertion allele 
frequency distributions for African and European populations are shown along with the 
numbers of shared and population-specific polyTE loci.  (B) The numbers of African and 
Europen polyTE insertions with allele frequencies >5%.  (C) Genetic relationships among 
the individuals analyzed here based on their polyTE genotypes.  Individual’s population 






3.3.2 RNA sequencing (RNA-seq) analysis 
RNA-seq expression data, for the same 445 individuals from 5 human populations 
with polyTE genotypes characterized as described in the previous section, were taken from 
the GUEVADIS RNA sequencing project for 1000 Genomes samples[109].  These RNA-
seq data characterize genome-wide expression levels from the same lymphoblastoid cell 
lines, i.e. Epstein–Barr virus (EBV) transformed B-lymphocytes, used for DNA-seq 
analysis in the 1000 Genomes project.  RNA isolation, library preparation, sequencing and 
read-to-genome mapping was performed as previously described [109].  As with the 
polyTE data, the RNA-seq read mapping corresponds to the human genome build 
GRCh37/hg19.  Mapped reads were used to quantify gene expression levels for ENSEMBL 
gene models[110] and normalization of gene expression levels was done using a 
combination of a modified RPKM approach followed by the probabilistic estimation of 
expression residuals (PEER) method[111] as previously described[112].  The PEER 
normalized RNA-seq gene expression levels were accessed from the GUEVADIS project 
ftp server maintained at EBI: 
ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/GEUV/E-GEUV-
1/analysis_results/. 
Genome-wide expression profiles were used to compute pairwise phenotypic 
distances between individuals as: 𝑑𝑑𝑥𝑥𝑥𝑥𝑒𝑒 = �∑ (𝑒𝑒𝑥𝑥𝑥𝑥 −  𝑒𝑒𝑥𝑥𝑥𝑥)2𝑛𝑛𝑥𝑥=1   where 𝑒𝑒𝑥𝑥𝑥𝑥  and 𝑒𝑒𝑥𝑥𝑥𝑥  are the 
normalized gene expression level for individual 𝑥𝑥 and individual 𝑦𝑦 at gene 𝑖𝑖, for a total of 
𝑛𝑛  genes.  The resulting pairwise expression distance matrix was subject to dimension 
reduction using multidimensional scaling (MDS)[107], using the cmdscale function from 
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the R statistical package version 3.2.2[108], in order to visualize the relationships between 
individuals based on their genome-wide expression profiles (Figure 11A).  Differential 
gene expression between African and European populations was evaluated using a paired 
ttest implemented with the genefilter package from Bioconductor[113] (Figure 11B). 
 
Figure 11 Gene expression profiles within and between populations analyzed 
(A) Individuals from different populations are related based on their genome-wide 
expression profiles.  Individual’s population origins are color coded as shown in the key.  
(B) Heatmap showing genes that have expression profiles that are significantly different 
between the African and European population groups.  Gene expression levels are color 
coded as shown in the key. 
 
3.3.3 Expression quantitative trait loci (eQTL) analysis 
PolyTE genotypes from the individuals analyzed here were related to their gene 
expression levels to identify eQTLs that correspond to polyTE insertion sites (TE-eQTLs) 
using the program Matrix eQTL[114] (Figure 9).  Only polyTE insertion sites with >5% 
TE-present allele frequency were used for this purpose (Figure 10A and B).  Matrix eQTL 
was run using the additive linear (least squares model) option with covariates for gender 
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and population.  This was done for all possible pairs of polyTE insertion sites and genes.  
Cis versus trans eQTLs were defined later as polyTE insertion sites that fall inside (cis) or 
outside (trans) 1Mb from gene boundaries.  P-values were calculated for all pairs of 
polyTE-gene expression comparisons, and FDR q-values were then calculated to correct 
for multiple statistical tests.  The genome-wide significant polyTE-gene expression eQTL 
association threshold was set at FDR q<0.05 (P<4.7e-7).   
A series of three additional control analyses were implemented in an effort to 
control for potentially confounding effects regulatory SNPs in particular, on the TE-eQTL 
associations that passed the genome-wide significance threshold (Figure 27).  [Control 1] 
TE-eQTL versus SNP-eQTL comparisons: For all of the genes found to be associated with 
TE-eQTLs, we searched the results of the GEUVADIS RNA-seq project [109] to identify 
the number of SNPs that were previously implicated as eQTLs for the same genes (Figure 
27A).  [Control 2] Conditional association analysis: For the genes that were found to be 
associated with both TE-eQTLs and SNP-eQTLs, we performed conditional association 
analysis whereby multiple regression of expression against genotype is done using both TE 
and SNP genotype information used as explanatory variables in the same multiple 
regression model (Figure 27B).  The conditional association analysis was performed using 
the same multiple regression approach as implemented in the GCTA program[115].  
[Control 3] Regional association scans: Regional eQTL association scans were done by 
defining linked 1Mb regions that are centered on individual polyTE loci, and then all SNP 
and polyTE genotypes from the linked regions were further evaluated for association with 
gene expression using the same approach used for TE-eQTLs (Figure 27A).  Results of the 
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regional eQTL association scans were visualized using the regional association plot R 
script from the Broad Institute of MIT and Harvard [116]. 
 
3.3.4 Functional enrichment analysis 
Genes that correspond to best TE-eQTLs were used for gene set enrichment 
analysis using the KEGG, BIOCARTA and REACTOME data sets from the Molecular 
Signatures Database webserver (version 5.1)[117] in order to identify functionally enriched 
gene categories.  A FDR q-value threshold of 0.05 was used for this purpose. 
 
3.3.5 Transcription factor (TF) target identification 
TF (PAX5) target genes were taken from annotations of experimentally 
characterized TF binding sites from the 2015.1 version of GENOME TRAXTM 
(www.biobase-international.com/genome-trax) from BIOBASE corporation[118].  TF-
target gene interactions were visualized using the program Circos (version 0.69)[119]. 
 
3.4 Results 
3.4.1 The landscape of human TE polymorphisms 
Computational analysis of next-generation (re)sequencing data can be used to 
identify the locations of polyTE insertions genome-wide[120].  Recent applications of this 
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approach to human genome sequences from the 1000 Genomes Project has resulted in a 
deep characterization of human genetic variation resulting from TE activity[65, 99].  We 
analyzed polyTE loci from the genome sequences of 445 individuals sampled from 5 
human populations (4 European and 1 African) characterized as part of this project.  There 
are a total of 10,106 polyTE insertions observed for these 445 individual genome 
sequences: 8,274 for Alu, 1,307 for L1 and 525 for SVA (Figure 10A).  Most of the polyTE 
insertions that we observe (9,799) can be considered to be cis to human genes as they either 
fall within gene boundaries or within 1Mb upstream or downstream of genes.  Furthermore, 
consistent with previous results, the majority of polyTE loci for these 5 populations show 
low frequencies of TE insertions (i.e., low minor allele frequencies), suggesting that TE 
insertions are highly disruptive and subject to strong purifying selection[65, 121].  
Nevertheless, there are 2,617 polyTE loci that show >5% TE insertion frequency for these 
populations (Figure 10B); these common polyTE loci were used for the subsequent eQTL 
analysis.  The vast majority of these are Alu polyTE loci with an order of magnitude fewer 
L1 and fewest SVA loci.   
Despite the similar shapes of the TE insertion allele frequency distributions, many 
of the loci are specific to individual populations or continental population groups.  Indeed, 
genetic distances between individuals calculated based on their polyTE genotypes clearly 
separates European from African populations (Figure 10C).  Population-specific polyTE 
loci with higher insertion frequencies can be considered to be more likely to exert broad 
regulatory effects across individuals and populations.  Accordingly, we focused our 
subsequent analysis on these (relatively) high frequency polyTE loci, and searched for 
possible population-specific regulatory effects of such loci. 
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3.4.2 TE expression quantitative trait loci (TE-eQTL) 
We analyzed genome-wide expression profiles for these same individuals in an 
effort to evaluate the relationship between TE genetic variation and human gene regulation.  
Genome-wide expression profiles were compared to compute a pairwise phenotypic 
(regulatory) distance matrix for the individuals analyzed here.  Unlike what is seen for the 
polyTE genetic distances, genome-wide expression profiles do not separate individual 
humans among different population groups (Figure 11A).  In other words, gene expression 
variation does not segregate globally in the same way that TE genetic variation does.  
Nevertheless, there are several hundred genes that do show statistically different levels of 
expression between the African and European populations analyzed here (Figure 11B). 
We evaluated the relationship between TE genetic variation and human gene 
regulation by searching for expression quantitative trait loci (eQTL) that correspond to 
polyTE insertion sites.  To do this, gene-specific expression levels were regressed against 
presence/absence genotypes – 0, 1 or 2 TE insertions – for individual polyTE loci (Figure 
9).  We used an additive linear model as described in the Methods section to search for 
statistically significant associations between the polyTE genotypes at any given locus and 
expression levels for individual genes.  This was done separately for African and European 
population groups as well as for all individuals considered together.  The total number of 
statistically significant (FDR q-value<0.05, P<4.7e-7) polyTE-gene expression 
associations (TE-eQTLs) for the different population cohorts, and different polyTE 
families, are shown in Figure 12A.  Alu polyTE loci provide the greatest number of TE-
eQTL by far, consistent with their substantially higher numbers in the genome.  A quantile-
quantile (Q-Q) plot for these data confirms a strong overall signal of statistically significant 
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associations (Figure 12B), which are shown along individual chromosomes, and broken 
down by polyTE family, in the Manhattan plot in Figure 12C.  A complete list of the TE-
eQTL discovered here is provided as Table 3.  
 
Figure 12 Polymorphic transposable element expression quantitative trait loci (TE-
eQTL) detected  
(A) Numbers of statistically significant TE-eQTL are shown for different population group 
cohorts and different polyTE families.  The numbers of individuals (n) are shown for each 
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population cohort at the top of the table, and the total number of genes involved in TE-
eQTL associations are shown at the bottom of the table.   (B) Quantile-quantile (Q-Q) plot 
showing observed versus expected distributions of polyTE loci-gene expression association 
P-values (negative log transformed).  (C) Manhattan plot showing the genomic distribution 
of polyTE-gene expression association values.  The dashed yellow line indicates the FDR 
q-value cutoff of 0.05, which corresponds to a P-value of 4.7e-7.  P-values are color coded 
according to polyTE families as shown in the key. 
 
The set of genes that are associated with TE-eQTL is enriched for a number of 
immune-related functions including IgA production, antigen processing/presentation and 
several signalling pathways that lead to immune cell differentiation and activation (Figure 
13 and Table 4).  This result is consistent with the fact that the expression data were taken 
from lymphoblastoid cell lines (i.e., transformed B-lymphocytes) and points to cell type-
specific functional relevance of polyTE mediated gene regulation. 
We performed a series of additional analyses in an effort to control for the potential 
effects of other genomic variations, regulatory SNPs in particular, on the TE-eQTL 
associations uncovered by our initial screen (see Materials and Methods; Figure 27).  First, 
we assessed the extent of overlap between the genes that we observe to be associated with 
TE-eQTL here and genes previously found to be associated with SNPs using the same 
sequence and expression data.  The overlap between the TE-eQTL genes identified here 
and the previously identified SNP-eQTL genes is extremely low (n=71 or ~1%), consistent 
with the fact that we are primarily identifying novel regulatory associations (Figure 28).  
Second, for those genes that were found to be associated with both TE-eQTL and SNP-
eQTL, we performed conditional association analyses that combine both TE and SNP 
genotypes.  The majority of the TE-eQTL from the initial screen remain significant after 
conditioning on the SNP genotypes (Table 5).  Third, regional association scans were used 
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to evaluate the regulatory effects of all genomic variants linked to the TE-eQTL discovered 
here (Table 6).  Examples of this analysis can be seen in the following section on 
population-specific TE-eQTLs.   
 
Figure 13 Functional enrichment of polyTE loci associated genes   
Enriched, immune-related gene sets are shown along with the FDR q-values indicating the 
significance of the enrichments. 
 
3.4.3 Population-specific TE-eQTL 
A number of factors suggested the possibility that TE-eQTL may exert population-
specific effects on human gene regulation.  The polyTE landscapes of human populations 
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are very distinct, with polyTE genetic variation clearly delineating African from European 
populations.  While gene expression does not show the same overall pattern of population 
divergence, there are hundreds of genes that do show population-specific expression.  
Finally, the numbers of TE-eQTL vary substantially for the African, European and merged 
population cohorts. 
To evaluate the population-specific effects of TE-eQTL, we searched for gene-by-
population interactions whereby specific polyTE loci are only associated with gene 
expression in the European or African populations (but not both).  There are a total of 589 
TE-eQTL that show such gene-by-population interactions: 407 for African and 182 for 
Europe (Figure 29).  These apparent population-specific effects of TE-eQTL can be 
attributed to cases where the polyTE genotypes are differentially distributed across 
population groups (Figure 14A and B) or where polyTE genotypes are shared across 
populations but their effects on gene expression are limited to one population group (Figure 
14C). 
The polyTE locus Alu-5788 is strongly associated with REL expression levels when 
both population groups are considered together (Figure 14A).  However, polyTE insertions 
at this locus are almost entirely African-specific and are associated with higher expression 
of the gene.  Thus, consideration of the European population group alone would not turn 
up any association between this polyTE locus and the REL gene.  REL encodes the c-Rel 
protein, which is part of the NF-κB family of transcription factors[122].  REL is considered 
to be a proto-oncogene that influences the survival and proliferation of B-lymphocytes.  
The gene’s function has clinical significance with somatic mutations that are associated 
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with B-cell lymphomas[123] and SNPs that are associated with ulcerative colitis and 
rheumatoid arthritis[124, 125]. 
A similar kind of a population-specific TE-eQTL is seen for the Alu-10841 locus, 
which is associated with PSD4 expression levels (Figure 14B).  In this case, the presence 
of Alu insertions at the locus is associated with a reduction in gene expression levels.  Alu 
insertions at this locus are far more common in European populations, and African 
individuals that lack the insertions tend to show higher expression levels for the gene.  
PSD4 encodes a guanine nucleotide exchange factor that works with the ARF6, 
ARL14/ARF7 protein complex to control the movement of MHC class II containing 
vesicles along the actin cytoskeleton. 
Gene-by-population interactions can also be seen for polyTE loci that are found in 
both the African and European population groups.  While insertions at the Alu-1870 locus 
are commonly found in both population groups, polyTE insertion genotypes are only 
associated with decreased PRDM2 expression in the African population (Figure 14C).  The 
population-specific effects of Alu insertions at this locus could be attributable to the distinct 
genetic background of each population, via interactions with population-enriched variants 
for instance.  On the other hand, insertions at the Alu-8559 locus are similarly found in 
both African and European populations, but both populations show polyTE insertion 
associations with decreased expression levels of the HSD17B12 gene (Figure 14D).  
Interestingly, this particular example was detected with the FDR q-value cutoff employed 
here (0.05) for the both the European and merged population cohorts but not for the African 
population alone (P=8.7e-5 and FDR q-value=3.9e-1).  This may be attributable to the 
relatively low number of human samples analyzed for the single African population and 
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suggests the possibility that some bona fide African-specific associations may have been 
overlooked in this study.   
 
Figure 14 Examples of population-specific TE-eQTL detected 
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Population-specific TE-eQTL where polyTE insertions are found primarily in only one 
population group are shown for the (A) REL and (B) PSD4 genes.  Box-plots show the 
distributions of individual gene expression levels for each of the three possible polyTE 
insertion genotypes.  Regional association plots show all associations with the gene 
expression centered on the polyTE locus.  Association P-values are shown as indicated on 
the left y-axis along with the local recombination rate shown on the right y-axis.  (C) A 
population-specific TE-eQTL is shown for PRDM2 gene where the associated polyTE 
locus has insertions found in both population groups but an association with gene 
expression is only seen in the African population.  (D) A counter example of a polyTE locus 
with insertions shared among both population groups and similar associations with 
HSD17B12 are seen for both groups. 
 
3.4.4 Transcriptional network TE-eQTLs 
We found a number of cases where polyTE loci corresponded to TE-eQTL for more 
than one human gene (Figure 12A and Table 3).  This suggested the possibility that 
individual polyTE loci may participate in coordinated gene regulatory networks.  One 
possible mechanism by which this may occur is through indirect polyTE-expression 
associations that are mediated by transcription factors (TFs), which regulate the expression 
of multiple genes.  In other words, if a polyTE loci affects the expression of a TF, it may 
also appear to affect the regulation of one or more gene targets of that TF (Figure 15A).  
The Alu-7481 locus exemplifies this phenomenon.  Alu insertions at this locus are 
associated with increased expression of PAX5 (Figure 15B), which encodes a transcription 
factor crucial to the specific identity and function on B cells.  In particular, PAX5 
expression is critical for differentiation of lymphoid progenitor cells into B cells (Figure 
15C).  It achieves this by simultaneously activating B lineage-specific genes and repressing 
genes active in distinct lineages[126].  There are 274 known Pax5 target genes that show 
the identical Alu-7481 insertion genotype expression pattern as seen for their cognate TF 
(Figure 15D and Table 7).  While the majority of these do not reach the FDR q-value cutoff 
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used here, there are three immune related target genes – PIK3AP1, REL and ZSCAN23 – 
that all remain statistically significant after controlling for multiple tests (Figure 15E).  
These data suggest that polyTE insertions are also involved in establishing cell type-
specific regulatory networks with phenotypically important consequences. 
 
Figure 15 TE-eQTL and a PAX5 transcriptional regulatory network   
(A) Scheme for how a single polyTE loci can provide trans eQTL for multiple genes by 
modifying the expression of a transcription factor encoding gene (PAX5) and its 
downstream target genes.  (B) The Alu-7481 PAX5 TE-eQTL.  PAX5 expression levels are 
shown for individuals with different Alu-7481 insertion genotypes (0, 1 or 2 insertions); 
the association P-value is shown.  (C) The role of PAX5 in B-cell development.  (D) 
Average expression level of 274 PAX5 target genes for individuals with different Alu-7481 
insertion genotypes.  Normalized (z-score transformed) gene expression levels are color-
coded as shown in the key.  Target genes that correspond to the most significant Alu-7481 
TE-eQTL (FDR q-value<0.05, P<4.7e-7) are indicated.  (E) Circos plot showing the 
chromosomal locations of the Alu-7481 TE-eQTL, PAX5 and the downstream target genes.  
TE-gene associations are shown in red, and PAX5-target gene interactions are shown in 
blue.  The association P-values are shown on the inner circle as indicated in the key. 
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3.5 Discussion 
Numerous previous studies have uncovered gene regulatory contributions of human 
TE sequences[17, 19-26, 28-32, 104-106].  However, these studies have dealt with TE 
sequences derived from relatively ancient insertion events, which now are fixed in human 
populations.  In other words, these TE-derived sequences exist at the same genomic 
locations in all human genomes, and thus may not contribute substantially to regulatory 
variation between individuals.  Here, we present a systematic analysis of the regulatory 
contributions of polyTE loci that were generated by recent transpositional activity and 
thereby differ between individuals.  The TE-eQTL that we discovered underscore the 
extent to which TE-generated human genetic variation can affect regulatory differences 
within and between populations.   
Our results indicate that polyTE loci provide greater numbers of trans compared to 
cis eQTL (Figure 12A).  This may be considered somewhat surprising given the fact that 
most human eQTL studies focus on cis eQTL[109, 127].  However, studies on eQTL are 
often limited to cis associations owing the large number of possible SNP-by-gene 
comparisons that whole genome (i.e., both cis and trans) analyses entail.  Thus, it is not 
entirely clear whether cis eQTL are actually expected to be more common that trans eQTL.  
The relatively low number of polyTE loci studied here (~16,000), combined with the 
introduction of a more computationally efficient eQTL detection algorithm[114], allowed 
us to evaluate all possible cis and trans TE-eQTL.  There are several possible mechanisms 
by which polyTE loci could serve as trans eQTL.  For example, they may exert trans eQTL 
effects indirectly by regulating transcription factors, which in turn regulate numerous target 
genes, as we have shown for PAX5 (Figure 15).  In addition, TEs have been shown to 
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influence three-dimensional genome architecture, via the formation of chromosome loops 
or association with the nuclear scaffold/matrix for instance[20].  It is tempting to speculate 
that TEs can exert trans eQTL effects via similar mechanisms that bring distal, homologous 
TE sequences into close proximity. 
It is worth noting that human TE activity has often been associated with disease[34, 
35].  Indeed, transpositional activity of human TEs was confirmed via the discovery of de 
novo insertions with obvious effects on health[6].  However, the samples analyzed here 
correspond to (presumably) healthy individuals from the 1000 Genomes Project and are 
thereby taken to represent the normal scope of human genetic variation.  The fact that many 
of the polyTE loci analyzed here have accumulated to relatively high insertion allele 
frequencies (Figure 10) is consistent with the notion that they are not deleterious.  Thus, 
the phenotypic impact of human TE activity is not limited to deleterious effects; it also 
includes the generation of regulatory differences that fall within the scope of naturally 
occuring human variation.  These kinds of functionally relevant but subtle TE-genetic 
variations, which necessarily avoid elimination by purifying selection, may provide an 






CHAPTER 4. HUMAN RETROTRANSPOSON INSERTION 
POLYMORPHISMS ARE ASSOCIATED WITH HEALTH AND 
DISEASE VIA GENE REGULATORY PHENOTYPES  
4.1 Abstract 
 The human genome hosts several active families of transposable elements (TEs), 
including the Alu, LINE-1, and SVA retrotransposons that are mobilized via reverse 
transcription of RNA intermediates.  We evaluated how insertion polymorphisms 
generated by human retrotransposon activity may be related to common health and disease 
phenotypes that have been previously interrogated through genome-wide association 
studies (GWAS).  To address this question, we performed a genome-wide screen for 
retrotransposon polymorphism disease associations that are linked to TE induced gene 
regulatory changes.  Our screen first identified polymorphic retrotransposon insertions 
found in linkage disequilibrium (LD) with single nucleotide polymorphisms (SNPs) that 
were previously implicated in common complex diseases by GWAS.  We further narrowed 
this set of candidate disease associated retrotransposon polymorphisms by identifying 
insertions that are located within tissue-specific enhancer elements.  We then performed 
expression quantitative trait loci (eQTL) analysis on the remaining set of candidates in 
order to identify polymorphic retrotransposon insertions that are linked to gene expression 
changes in B-cells of the human immune system.  This progressive and stringent screen 
yielded a list of six retrotransposon insertions as the strongest candidates for TE 
polymorphisms that lead to disease via enhancer-mediated changes in gene regulation.  For 
example, we found an SVA insertion within a cell-type specific enhancer located in the 
second intron of the B4GALT1 gene.  B4GALT1 encodes a glycosyltransferase that 
functions in the glycosylation of the Immunoglobulin G (IgG) antibody in such a way as 
 62 
to convert its activity from pro- to anti-inflammatory.  The disruption of the B4GALT1 
enhancer by the SVA insertion is associated with down-regulation of the gene in B-cells, 
which would serve to keep the IgG molecule in a pro-inflammatory state.  Consistent with 
this idea, the B4GALT1 enhancer SVA insertion is linked to a genomic region implicated 
by GWAS in both inflammatory conditions and autoimmune diseases such as systemic 
lupus erythematosus and Crohn’s disease.  We explore this example and the other cases 
uncovered by our genome-wide screen in an effort to illuminate how retrotransposon 
insertion polymorphisms can impact human health and disease by causing changes in gene 
expression.     
 
4.2 Introduction 
 At least one half of the human genome sequence is derived from the replication and 
insertion of retrotransposons – RNA agents that transpose among chromosomal locations 
via the reverse transcription of RNA intermediates [1, 2].  The vast majority of 
retrotransposon-related sequences in the human genome are derived from ancient insertion 
events and are no longer capable of transposition.  Nevertheless, there are several families 
of human retrotransposons that remain active.  The most abundant active families of human 
retrotransposons are the Alu [3, 4], LINE-1 (L1) [5, 6], and SVA [7, 8] retrotransposons; 
recent evidence indicates that a smaller number of HERV-K endogenous retroviruses also 
remain capable of transposition [54]. 
 Sequences from active retrotransposon families generate insertional 
polymorphisms within and between human populations by means of germline transposition 
events.  In this way, ongoing retrotranspositional activity of these RNA agents serves as an 
important source of human genetic variation.  Retrotransposons are further distinguished 
by the fact that they are known to impact the regulation of human genes in a number of 
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different ways [17, 18, 128].  Nevertheless, the joint phenotypic implications of 
retrotransposon generated human genetic variation, coupled with their capacity for genome 
regulation, have yet to be fully explored.  We previously studied the implications of 
somatic retrotransposition for the etiology of cancer vis a vis retrotransposon induced 
regulatory changes in tumor suppressor genes [129].  For the current study, we were 
curious to understand how insertion polymorphisms generated by human retrotransposon 
activity may be related to commonly expressed health and disease phenotypes.  
 In one sense, a link between retrotransposon activity and disease is already well 
established.  Active human retrotransposons were originally discovered due to the 
deleterious effects of element insertions [6].  There are 124 genetic diseases that have been 
demonstrated to be caused by retrotransposon insertions, including cystic fibrosis (Alu), 
hemophilia A (L1) and X-linked dystonia-parkinsonism (SVA) [34, 67].  However, these 
cases represent so-called Mendelian diseases caused by very deleterious mutations that are 
expressed with high penetrance.  Disease causing mutations of this kind are extremely rare 
and do not segregate among populations as common genetic polymorphisms.  Complex 
multi-factorial diseases, on the other hand, are associated with more common genetic 
variants that exert their effects in a probabilistic as opposed to a deterministic manner.  The 
contribution of common retrotransposon polymorphisms to complex health and disease 
related phenotypes has yet to be systematically explored.   
 Given the known connection between retrotransposon activity and genetic disease, 
we hypothesized that retrotransposon insertion polymorphisms may also contribute to 
inter-individual phenotypic differences that are associated with common diseases that have 
complex, multi-factorial genetic etiology.  Since we previously showed that 
retrotransposon insertions contribute to inter-individual and population-specific 
differences in human gene regulation [130], we also hypothesized that the impact of 
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retrotransposon insertion polymorphisms on human health could be mediated by gene 
regulatory effects.  
Previously, it has only been possible to investigate the impact of retrotransposon 
polymorphisms on disease phenotypes for a limited number of individuals owing to the 
number of genomes that were available [131].  For the current study, we leveraged the 
accumulation of whole genome sequence and expression datasets, along with data on single 
nucleotide polymorphism (SNP) disease-associations, in order to perform a population 
level genome-wide screen for retrotransposon polymorphisms that are linked to complex 
health- and disease-related phenotypes. 
 
4.3 Materials and Methods 
4.3.1 Polymorphic transposable element (polyTE) and SNP genotypes 
 Human polymorphic TE (polyTE) insertion presence/absence genotypes for whole 
genome sequences of 445 individuals from five human populations were accessed from the 
phase 3 variant release of the 1000 Genomes Project (1KGP) [99].  Whole genome SNP 
genotypes were taken for the same set of individuals.  The phase 3 variant release 
corresponds to the human genome reference sequence build GRCh37/hg19, and the 5 
human populations are YRI: Yoruba in Ibadan, Nigeria from Africa, CEU: Utah Residents 
(CEPH) with Northern and Western European Ancestry, FIN: Finnish in Finland, GBR: 
British in England and Scotland and TSI: Toscani in Italia from Europe.  We chose these 
genome sequence datasets because they have matching RNA-seq data for the same 
individuals (see eQTL analysis section).  The YRI population was taken to represent the 
African continental population group (AFR), and the 4 populations from Europe (CEU, 
FIN, GBR and TSI) were grouped together as the European (EUR) continental population 
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group for downstream analysis (Figure 16).  PolyTE insertion genotypes were 
characterized by the 1KGP Structural Variation Group using the program MELT as 
previously described [65].  Previously, we performed an independent validation the 
performance of this program for human polyTE insertion variant calling from whole 
genome sequences [64].  The polyTE genotype data were downloaded via the 1000 
Genomes Project ftp hosted by the NCBI: http://ftp-
trace.ncbi.nlm.nih.gov/1000genomes/ftp/release/20130502/.  For a given polyTE insertion 
site in the genome, there are three possible presence/absence genotype values for an 
individual genome: 0-no polyTE insertion (homozygote absent), 1-a single polyTE 
insertion (heterozygote), and 2-two polyTE insertions (homozygote present).  PolyTE 
genotypes were used for eQTL analysis as described in section 2.5.  For each of the two 
continental population groups, only polyTE insertions and SNPs with greater than 5% 
minor allele frequencies (MAF) were used for the downstream analysis to ensure both the 
confidence of genotype calls and the reliability of the association analyses.  Minor alleles 
for TEs are assumed to be the insertion present allele, since the ancestral state for any 
polyTE insertion site corresponds to the absence of an insertion [121].  
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Figure 16 Integrative data analysis used to screen for polyTE disease-associations. 
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Matched DNA-seq and RNA-seq samples were analyzed for 445 individuals, 87 Africans 
(AFR - blue) and 358 Europeans (EUR - orange).  Genome-wide genotypes were 
characterized for polyTE insertions (presence/absence) and SNPs, and the linkage 
disequilibrium (LD) structure for polyTE insertions and SNP alleles was characterized for 
all samples.  The NHGRI-EBI GWAS database was mined to extract SNP disease-
associations and related information on diseases, phenotypes, genes and SNP genomic 
locations.  A series of filters was applied to screen for a set of high-confidence polyTE 
disease-associations.  PolyTEs were evaluated for: (1) minor allele frequency (MAF), (2) 
linkage to disease-associated SNPS (i.e., GWAS hits), (3) overlap with tissue-specific 
enhancers, (4) associations with gene expression, and (5) functional relevance for blood- 
and immune system-related diseases. 
 
4.3.2 PolyTE-SNP linkage analysis 
 The GCTA program (version 1.25.0) was used to estimate the linkage 
disequilibrium (LD) structure for polyTEs and SNPs in genomic regions centered at each 
polyTE insertion site.  For each polyTE insertion site, pairwise correlations (r) between the 
target polyTE insertion alleles and all SNP alleles in the same LD block were computed 
across all individual genome samples.  A correlation (r) significance P-value threshold of 
0.05 was used to identify all SNPs considered to be in LD with each polyTE insertion.  
Pairwise distances between polyTE insertion sites and linked SNPs were calculated as the 
number of base pairs between each polyTE insertion site and all linked SNP locations. 
 
4.3.3 Genome wide association studies (GWAS) for disease 
 Associations between human genetic variants (SNPs) and health- or disease-related 
phenotypes were explored using the NHGRI-EBI GWAS database [132].  GWAS database 
SNPs with genome-wide association values of P<10-5 were taken for analysis, and the 
genomic location, specific health- or disease-related phenotype, identity of the risk allele 
and original reporting publications were recorded for each associated SNP.  The GWAS 
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SNPs were screened for LD with polyTE insertions as described in section 4.3.2 to yield a 
set of candidate disease-linked polyTE insertions for further analysis.  
 
4.3.4 Evaluating polyTE regulatory potential  
 The regulatory potential for polyTE insertions was evaluated by considering their 
co-location with known enhancer sequences.  Active enhancers for 127 cell-types and 
tissues were characterized by the Roadmap Epigenomics Project using the ChromHMM 
program [133, 134].  ChromHMM integrates multiple genome-wide chromatin datasets 
(i.e., epigenomes), such as ChIP-seq of various histone modifications, using a multivariate 
Hidden Markov Model to identify the locations of tissue-specific enhancers based on their 
characteristic chromatin states.  The data files with genomic locations for enhancers across 
all 127 epigenomes were accessed through the project website at 
http://mitra.stanford.edu/kundaje/leepc12/web_portal/chr_state_learning.html.  The 
genomic locations of polyTE insertions that are in LD with disease-associated SNPs were 
compared with the genomic locations for enhancers from the 127 epigenomes, and polyTE 
insertions found to be located within active enhancer elements were considered to have 
regulatory potential.  A subset of 27 epigenomes characterized for cells and tissues related 
to blood and the immune system – such as T cells, B cells and hematopoietic stem cells – 
were selected for downstream eQTL analysis (see section 4.3.5).    
 The overall relative regulatory potential of polyTE insertions in a given epigenome 






where 𝑡𝑡𝑥𝑥 is the proportion of polyTEs that are co-located with an enhancer element in a 
given epigenome 𝑖𝑖, and 𝑠𝑠𝑥𝑥 is the proportion of SNPs from polyTE LD blocks that overlap 
with an enhancer element in the same epigenome 𝑖𝑖. 
 Physical associations between TE-enhancer insertions and nearby gene promoter 
regions were evaluated with chromatin-chromatin interaction map data, based on several 
different data sources, including 4C, 5C, ChIA-PET and Hi-C, using the Chromatin 
Chromatin Space Interaction (CCSI) database at http://songyanglab.sysu.edu.cn/ccsi/ 
[135].   
 
4.3.5 Expression quantitative trait locus (eQTL) analysis 
 Associations between polyTE insertion genotypes and tissue-specific gene 
expression levels were characterized using eQTL analysis (Figure 16).  PolyTE insertion 
presence/absence genotypes were characterized as described in section 2.1.  RNA-seq gene 
expression data for the same 445 individual genome samples used for polyTE genotype 
characterization were taken from the GEUVADIS RNA sequencing project.  Genome-wide 
expression levels were measured for the same lymphoblastoid cell lines, i.e. Epstein–Barr 
virus (EBV) transformed B-lymphocytes (B cells), as used for DNA-seq analysis in the 
1KGP.  RNA isolation, library preparation, sequencing and read-to-genome mapping were 
performed as previously described [109].  As with the polyTE genotype data, the RNA-seq 
reads were mapped to the human genome build GRCh37/hg19.  The process of gene 
expression normalization and quantification based on these RNA-seq data has been 
extensively validated as part of the GEUVEDIS project [112].  The GEUVADIS RNA-seq 
data were used to compute gene expression levels for ENSEMBL gene models as 
previously described [110].  Normalization of gene expression levels was done using a 
combination of a modified reads per kilobase per million mapped reads (RPKM) approach 
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followed by the probabilistic estimation of expression residuals (PEER) method as 
previously described [111].  This procedure has been shown to eliminate batch effects 
among different RNA-seq samples and to reduce the overall variance across samples, 
thereby ensuring the most accurate and comparable gene expression level inferences 
among samples.  The normalized gene expression levels were accessed from the 
GUEVADIS project ftp server hosted at the EBI: 
ftp://ftp.ebi.ac.uk/pub/databases/microarray/data/experiment/GEUV/E-GEUV-
1/analysis_results/. 
 PolyTE insertions that are (1) linked to at least one disease-associated SNP, and (2) 
located within a blood- or immune system-related enhancer were taken as a candidate set 
for eQTL analysis with the lymphoblastoid cell line RNA-seq data.  PolyTE insertion 
presence/absence genotypes were regressed against gene expression levels to identify 
eQTLs (TE-eQTLs) using the program Matrix eQTL [114].  Matrix eQTL was run using 
the additive linear (least squares model) option with gender and population used as 
covariates.  This was done for all possible pairs of polyTE insertion sites from the candidate 
set and all genes.  Cis versus trans TE-eQTLs were defined later as polyTE insertion sites 
that fall inside (cis) or outside (trans) 1 megabase from gene boundaries.  P-values were 
calculated for all TE-eQTL associations, and FDR q-values were then calculated to correct 
for multiple statistical tests.  The genome-wide significant TE-eQTL association threshold 
was set at FDR q<0.05, corresponding to P=4.7 x 10-7 (AFR) and P=2.6 x 10-7 (EUR).   
 
4.3.6 Interrogation of disease-associated gene function and association consistency 
 The potential functional impacts of disease-associated TE-eQTL were evaluated 
via comparison of annotated gene functions and reported GWAS phenotypes for polyTE-
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linked SNPs.  Gene functions were taken from the NCBI Entrez gene summaries, and 
GWAS phenotypes were taken from the original literature where the associations were 
reported.  Genes that were found to be functionally related to GWAS reported health- or 
disease-related phenotypes were further checked for the direction of association.  If the 
GWAS SNP-gene pair shows the same direction of association as the polyTE-gene pair, 
then the pair was included in the final set of significant gene-polyTEs association pairs 
(Table 2).  For each gene in the final set, its tissue-specific expression levels across 18 
tissues, including 4 blood- and immune-related tissues, were taken from the Illumina 
BodyMap and GTEx projects [110, 136, 137]. 
 
4.4 Results 
 We used a genome-scale data analysis approach to explore the potential impact of 
human genetic variation generated by the activity of TEs on health and disease (Figure 16).  
This approach entailed an integrative analysis of (1) TE insertion polymorphisms, (2) 
single nucleotide polymorphisms (SNPs), (3) SNP-disease associations, (4) tissue-specific 
enhancers, (5) expression quantitative trait loci (eQTL), and (6) gene function/expression 
profiles.  The rationale behind this approach was to employ a series of successive genome-
wide filters, which would converge on a set of high-confidence TE insertion 
polymorphisms that are most likely to impact health- or disease-related phenotypes.  Our 
analysis started with 5,845 polyTE insertions, with minor allele frequencies (MAF)>0.05 
for two continental population groups (European and African), and converged on a final 
set of seven high-confidence TE disease-association candidates (Figure 17).  The final set 
of seven health/disease-implicated TE insertion polymorphisms that we found are 
distinguished by their linkage to disease-associated SNPs as well as their regulatory and 
 72 
functional properties.  We describe the results and implications for each step in our TE 
disease-association screen in the sections below.   
 
Figure 17 Results of the genome-wide screen for polyTE disease-associations 
As illustrated in Figure 16, a series of filters was applied to screen for a final set of high-
confidence polyTE disease-associations.  The number of polyTE insertions that remain 
after the application of each successive filter is shown for the African (AFR – blue) and 
European (EUR – orange) population groups.   
 
4.4.1 Linkage disequilibrium for polyTEs and disease-associated SNPs 
 The genomic locations of polyTE insertions were characterized for 445 individuals 
from one African (AFR) and four European (EUR) populations as described in section 2.1 
of the Materials and Methods. This was done for the most common families of active 
human TEs: Alu, L1 and SVA.  For each polyTE insertion location, individual genotypes 
were characterized as homozygous absent (0), heterozygous (1), or homozygous present 
 73 
(2). The distributions of polyTE insertion genotypes among individuals from each 
population were used to screen for polyTEs that are found at relatively high MAF>0.05.  
The linkage disequilibrium (LD) structure of the resulting common polyTE insertions, with 
adjacent common SNPs (also at MAF>0.05), was then defined using correlation analysis 
across individual genome samples (Materials and Methods section 4.3.2).  In addition, the 
genomic locations of common polyTE insertion variants and their linked SNPs were 
compared to the locations of disease-associated SNPs reported in the NHGRI-EBI GWAS 
database (Materials and Methods section 4.3.3).  Linkage correlation coefficients between 
all polyTE insertions analysed here and GWAS SNPs are shown in Table 8 and Table 9. 
 Distributions of LD correlations between polyTEs and adjacent SNPs were 
compared separately for non-disease-associated versus disease-associated SNPs.  For all 
three families of active human TEs, in both the AFR and EUR population groups, polyTEs 
are found in significantly higher LD with disease-associated SNPs compared to non-
disease-associated SNPs (Figure 18A).  In addition, polyTE variants are located closer to 
disease-associated SNPs than non-disease-associated SNPs for the EUR population group 
(Figure 18B).  A similar enrichment was not seen for the AFR population group, which 
may be attributed to the lower number of samples available for analysis for this group 
(AFR=87 vs. EUR=358).  Indeed, when a larger number of AFR samples, which do not 
have matched RNA-seq data, were used for the same linkage analysis, the results were 
qualitatively identical to those seen for the EUR samples analysed here.  Taken together, 
these results indicate that polyTEs are more likely to be tightly linked to disease-associated 
SNPs compared to adjacent linked SNPs from the same LD blocks, suggesting a possible 
role in disease etiology for some TE variants.  This is notable in light of the facts that (1) 
the TE genotypes were not considered in the initial association studies, and (2) TE 
insertions entail substantially larger-scale genetic variants than SNPs.  Thus, polyTEs 
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found on the same haplotypes as disease-associated SNPs may be expected to have an even 
greater impact on health- and disease-outcomes in some cases.  
 
Figure 18 Linkage between polyTE insertions and SNP disease-associations from 
GWAS.   
(A) Distributions of the allele correlation coefficients (r) are shown for (1) polyTE 
insertions and non-GWAS SNPs, and (2) polyTE insertions and GWAS SNPs.  Higher 
correlation coefficients indicate tighter linkage.  The significance of the differences for the 
non-GWAS SNP versus the GWAS SNP correlation coefficient distributions are indicated 
(Kolmogorov-Smirnov test; *** = P<2.4 x 10-5).  (B) Density distributions of the distance 
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between polyTE insertions and SNPs to the nearest GWAS disease-associated SNP.  
Correlation coefficient (A) and density (B) distributions are shown separately for the Alu 
(red), L1 (blue) and SVA (green) TE families in the African (AFR – blue) and European 
(EUR – orange) population groups. 
 
4.4.2 Co-location of disease-linked polyTEs with tissue-specific enhancers 
 Given the fact that TEs are known to participate in human gene regulation via a 
wide variety of mechanisms [17, 18, 128], we hypothesized that polyTEs may impact 
disease by virtue of gene regulatory effects.  The regulatory potential of polyTEs linked to 
disease-associated SNPs was first evaluated by searching for insertions that are co-located 
with tissue-specific enhancers.  The locations of enhancers were characterized for 127 cell- 
and tissue-types based on their chromatin signatures as described in section 2.4 of the 
Materials and Methods.  An example of an enhancer co-located with a disease-linked 
polyTE is shown for an Alu element that is inserted 5’ to the Immunoglobulin Heavy 
Variable 2-26 (IGHV2-26) encoding gene (Figure 19A).  We found a total 607 disease-
linked polyTEs co-located with enhancers in the AFR population group and 437 in EUR 
group; 391 (AFR) and 336 (EUR) of those enhancers correspond to blood- or immune-
related tissues (Figure 17).  Details on the co-localization of polyTE insertions and the 
enhancers characterized for each epigenome are shown in online Supplementary Data 
Table S2. 
 We estimated the overall regulatory potential for disease-linked polyTEs in all cell- 
and tissue-types by computing the relative ratio of enhancer co-located insertions as 
described in section 2.4 of the Materials and Methods.  The results of this analysis are 
considered separately for the blood- and immune-related tissues (Figure 19B) and all other 
tissues from which enhancers were characterized.  Enhancer co-located disease-linked 
polyTEs from blood/immune cell-types show higher overall regulatory potential than ones 
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that are co-located with enhancers characterized for the other tissue-types (Figure 12C and 
4D).  These results suggest that the set of disease-linked polyTEs studied here may have a 
disproportionate impact on immune-related diseases, and we focused our subsequent 
efforts on this subset of health conditions.  
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Figure 19 Regulatory potential of disease-linked polyTE insertions. 
PolyTE insertions linked to disease-associated SNPs were evaluated for their co-location 
with tissue-specific enhancers.  (A) UCSC Genome Browser screen capture showing an 
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example of a polyTE insertion – Alu-10537 – that overlaps with a number of tissue specific 
enhancers.  The genomic location of the Alu insertion on chromosome 14, downstream of 
the IGHV2-26 gene (blue gene model), is indicated with a red arrow.  The genomic 
locations of co-located enhancers, characterized based on chromatin signatures from a 
variety of tissue-specific epigenomes, are indicated with yellow bars.  (B) Heatmap 
showing the relative regulatory potential (Materials and Methods section 2.4) of polyTE 
insertions for a variety of tissue-specific epigenomes.  Blood- and immune-related tissues 
are shown separately from examples of the other tissue types analyzed here.  (C) 
Developmental lineage of immune-related cells for which enhancer genomic locations 
were characterized.  (D) The mean relative regulatory potential for disease-linked polyTE 
insertions is shown for blood- and immune-related tissues compared to all other tissue-
types analyzed here.  Values for the African (AFR – blue) and European (EUR – orange) 
population groups are shown separately. 
 
4.4.3 Expression associations for disease-linked and enhancer co-located polyTEs 
 We further evaluated the regulatory potential of the polyTEs that were found to be 
both disease-linked and co-located with blood- and immune-related enhancers using an 
expression quantitative trait loci (eQTL) approach (see Materials and Methods section 2.5).  
Genotypes for this subset of polyTEs from the 445 genome samples analyzed here were 
regressed against gene expression levels characterized from lymphoblastoid cell lines for 
the same individuals.  Quantile-quantile (Q-Q) plots comparing the observed versus 
expected P-values for the e-QTL analysis in the AFR and EUR population groups are 
shown in Figure 20A, revealing a number of statistically significant associations that are 
likely to be true-positives.  There are 83 (AFR) and 42 (EUR) genome-wide significant 
TE-eQTL (Table 10 and Table 11), and they are enriched in genomic regions that encode 
immune-related genes (Figure 20B).  We narrowed this list further by selecting the 
strongest TE-eQTL association for each individual polyTE, resulting in a final list of 37 
(AFR) and 24 (EUR) immune-related TE-eQTL (Figure 17).   
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Figure 20 Expression quantitative trait (eQTL) analysis for disease-linked polyTEs. 
eQTL analysis was performed by regressing lymphoblastoid gene expression levels against 
polyTE insertion genotypes for the for the African (AFR – blue) and European (EUR – 
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orange) individuals analyzed here.  (A) Quantile-quantile (Q-Q) plots relating the 
observed (y-axis) to the expected (x-axis) TE-eQTL log transformed P-values.  (B) 
Manhattan plots showing the genomic distributions of TE-eQTL log transformed P-values.  
The dashed line corresponds to a false discovery rate (FDR) threshold of q<0.05, 
corresponding to P=4.7 x 10-7 (AFR) and P=2.6 x 10-7 (EUR). 
 
 The results of the TE-eQTL analysis further underscore the regulatory potential of 
the disease-linked polyTEs characterized here and also allowed us to narrow down the list 
of candidate insertions.  Starting with the list of TE-eQTL, we searched for ‘consistent’ 
examples where the disease-linked polyTE is associated with the expression of a gene that 
is functionally related to the annotated disease phenotype.  This allowed us to converge on 
a final set of seven high-confidence disease-associated TE insertion polymorphisms 
(Figure 17 and Table 2).  Four of these disease-associated polyTEs are illustrated in Figure 
21, and we provide additional information on two examples in the following section (3.4).  
The four examples shown in Figure 21 all correspond to polyTEs that are linked to disease-
associated SNPs and co-located with enhancers characterized from blood- or immune 
system-related tissues; in addition, the genes that these polyTE insertions regulate are all 
known to function in the immune system.   




 Six of the seven disease-associated polyTE insertions are considered to be 
population-specific, based on significant eQTL results in only one population, whereas a 
single case is shared between both the AFR and EUR population groups (Figure 21C).  
However, two of the six cases considered to be population-specific using the eQTL 
criterion do show consistent trends across populations but failed to reach genome-wide 
significance when controls for multiple statistical tests were implemented (Figure 21D and 
Figure 22B).   
 
Figure 21 Gene expression profiles and eQTL results for disease-associated polyTE 
insertions. 
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Bar-charts of tissue-specific expression levels and box-pots of eQTL analyses are shown 
for four examples of TE-eQTLs corresponding to disease-linked and enhancer co-located 
polyTE insertions that regulate immune-related genes: (A) Alu-2829 and LILRA1, (B) Alu-
5072 and HLA-DRB5, (C) Alu-5075 and HLA-DQB1-AS1, and (D) SVA-282 and HLA-
DPB2.  Bar-charts show tissue-specific expression levels as normalized RPKM values 
(green).  The inset eQTL box-plots show individual sample gene expression levels (y-axis) 
regressed against polyTE insertion presence/absence genotypes (x-axis): 0-homozygous 
absent, 1-heterozygous, 2-homozygous present.  Each dot represents a single individual 
from the African (AFR – blue) and/or European (EUR – orange) population groups. 
  
4.4.4 Effects of polyTE insertions on immune- and blood-related conditions 
 Here, we described two specific examples of the effects that polyTE insertions can 
exert on immune- and blood-related disease phenotypes.  Figure 22A shows the SVA-401 
insertion that is co-located with a cell-type specific enhancer found in the second intron of 
the Beta-1,4-Galactosyltransferase 1 (B4GALT1) encoding gene, which is normally 
expressed at high levels in immune-related tissues.  Chromatin interaction maps 
characterized for several different cell types – CD34, GM12878 and Mcf7 – show that this 
B4GALT1 intronic enhancer physically associates with the gene’s promoter region.  The 
disruption of the B4GALT1 enhancer by the SVA insertion is associated with down-
regulation of the gene in B-cells, for both AFR and EUR population groups (Figure 22B).  
B4GALT1 encodes a glycosyltransferase that functions in the glycosylation of the 
Immunoglobulin G (IgG) antibody in such a way as to convert its activity from pro- to anti-
inflammatory (Figure 22C) [138-140].  Down-regulation of this gene in individuals with 
the enhancer SVA insertion should thereby serve to keep the IgG molecule in a pro-
inflammatory state.  Consistent with this idea, the B4GALT1 enhancer SVA insertion is 
linked to a genomic region implicated by GWAS in both inflammatory conditions and 
autoimmune diseases such as systemic lupus erythematosus and Crohn’s disease [140]. 
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 Another example of an SVA insertion into an enhancer element is shown for the 
adjacently located Signal Transducing Adaptor Molecule (STAM) and Transmembrane 
Protein 236 (TMEM236) encoding genes.  The SVA-438 insertion is co-located with an 
enhancer in the first intron of the STAM gene (Figure 22D), but its presence is associated 
with changes in expression of the nearby TMEM236 gene (Figure 22E).  TMEM236 is 
located ~100kbp downstream of the SVA-438 insertion and is most highly expressed in 
pancreatic islet α-cells (Figure 22F) [141, 142].  Islet α-cells function to secrete glucagon, 
a peptide hormone that elevates glucose levels in the blood [143].  The SVA-438 insertion 
is associated with increased expression of TMEM236, which would be expected to lead to 
increased blood glucose levels.  This expectation is consistent with the fact that the SVA-
438 insertion is also linked to the risk allele (T) of the SNP rs6602203, which is associated 
with a reduced metabolic clearance rate of insulin (MCRI), an endophenotype that is 
associated with the risk of type 2 diabetes [144].  In other words, up-regulation of 
TMEM236 by the SVA-438 insertion may be mechanistically linked to insulin resistance 
by virtue of increasing blood sugar and decreasing insulin clearance. 
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Figure 22 PolyTE insertions associated with immune- and blood-related conditions.   
(A) UCSC Genome Browser screen capture showing the location of the SVA-401 insertion 
(red arrow) on chromosome 19 within the second exon of the B4GALT1 gene.  The inset 
shows the genomic locations of co-located enhancers, characterized based on chromatin 
signatures from a variety of tissue-specific epigenomes locations, as yellow bars.  The bar-
chart shows B4GALT1 tissue-specific expression levels as normalized RPKM values 
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(green).  (B) eQTL box-plots show individual sample gene expression levels (y-axis) 
regressed against SVA-401 insertion presence/absence genotypes (x-axis): 0-homozygous 
absent, 1-heterozygous, 2-homozygous present.  Each dot represents a single individual 
from the African (AFR – blue) or European (EUR – orange) population groups.  (C) 
B4GALT1 catalysed glycosylation of the Immunoglobulin G (IgG) antibody, resulting in 
conversion from pro- to anti-inflammatory activity.  (D) UCSC Genome Browser screen 
capture showing the location of the SVA-438 insertion (red arrow) on chromosome 10 
within the first exon of the STAM gene, upstream of the regulated TMEM236 gene.  The 
inset shows the genomic locations of co-located enhancers (yellow bars).  (E) Bar-chart of 
TMEM236 tissue-specific expression levels and box-pot of the SVA-438 TMEM236 eQTL 
analyses.  (F) Functional role and cell-type specific expression profile for TMEM236. 
 
4.5 Discussion 
 The results reported here underscore the influence that retrotransposon insertion 
polymorphisms can exert on human health- and disease-related phenotypes.  The 
integrative data analysis approach that we took for this study also revealed how polyTE 
disease-associations are mediated by the gene regulatory properties of retrotransposon 
insertions.  We adopted a conservative approach to screen for the potential regulatory 
effects of retrotransposon insertions by choosing candidate elements as those that were 
inserted into regions previously defined as tissue-specific enhancers in blood/immune 
cells.  Retrotransposons that insert into enhancer sequences could entail loss-of-function 
mutants by virtue of disrupting enhancer sequences, or they could serve as gain-of-function 
mutants by altering enhancer activity.  Our results can be considered to show instances of 
both loss- and gain-of-function enhancer mutations with respect to the decrease or increase, 
respectively, of gene expression levels that are associated with element insertion genotypes 
(Figure 21 and 22).  Nevertheless, it is worth noting that our conservative approach could 
be prone to false negatives as it would not uncover novel enhancer activity provided by 
element insertions at new locations in the genome.    
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 The TE regulatory findings that we report here are consistent with previous studies 
showing that TE-derived sequences have contributed a wide variety of gene regulatory 
elements to the human genome [17, 18, 128], including promoters [19-21], enhancers [22-
26], transcription terminators [28] and several classes of small RNAs [29-31].  Human TEs 
can also influence gene regulation by modulating various aspects of chromatin structure 
throughout the genome [1, 32, 103-106]. 
 It is important to note that the research efforts which have uncovered the regulatory 
properties of human TEs, including a number of our own studies, have dealt exclusively 
with sequences derived from relatively ancient insertion events. These ancient TE 
insertions are present at the same (fixed) locations in the genome sequences of all human 
individuals.  In other words, previously described TE-derived regulatory sequences are 
uniformly present among individual human genomes and thereby do not represent a source 
of structural genetic variation.  Such fixed TE-derived regulatory sequences may not be 
expected to provide for gene regulatory variation among individuals or for that matter to 
contribute to inter-individual differences related to health and disease. 
 Nevertheless, we recently showed that TE insertion polymorphisms also exert 
regulatory effects on the human genome [130].  Specifically, polyTE insertions were 
shown to contribute to both inter-individual and population-specific differences in gene 
expression and to facilitate the re-wiring of transcriptional networks.  The results reported 
here extend those findings up the hierarchy of human biological organization by revealing 
potential mechanistic links between polyTE-induced gene regulatory changes and the 




CHAPTER 5. TRANSPOSABLE ELEMENT ACTIVITY, 
GENOME REGULATION AND HUMAN HEALTH  
5.1 Abstract 
 A recent convergence of novel genome analysis technologies is enabling population 
genomic studies of human transposable elements (TEs).  Population surveys of human 
genome sequences have uncovered thousands of individual TE insertions that segregate as 
common genetic variants, i.e. TE polymorphisms.  These recent TE insertions provide an 
important source of naturally occurring human genetic variation.  Investigators are 
beginning to leverage population genomic data sets to execute genome-scale association 
studies for assessing the phenotypic impact of human TE polymorphisms.  For example, 
the expression quantitative trait loci (eQTL) analytical paradigm has recently been used to 
uncover hundreds of associations between human TE insertion variants and gene 
expression levels.  These include population-specific gene regulatory effects as well as 
coordinated changes to gene regulatory networks.  In addition, analyses of linkage 
disequilibrium patterns with previously characterized genome-wide association study 
(GWAS) trait variants have uncovered TE insertion polymorphisms that are likely causal 
variants for a variety of common complex diseases.  Gene regulatory mechanisms that 
underlie specific disease phenotypes have been proposed for a number of these trait 
associated TE polymorphisms.  These new population genomic approaches hold great 
promise for understanding how ongoing TE activity contributes to functionally relevant 





Transposable elements (TEs) are distinguished by their ability to move, i.e. 
transpose, among genomic locations, often making copies of themselves as they go.  TEs 
can replicate to extremely high copy numbers over time; at least 50% of the human genome 
sequence is thought to be derived from TE insertions [1, 2].  The abundance of TE 
sequences, along with their ability to colonize a seemingly endless variety of host genomes, 
begs an explanation for their evolutionary success.  The selfish DNA theory holds that TEs 
are genomic parasites, which play no functional role for their hosts and exist simply by 
virtue of their ability to out-replicate the genomes in which they reside [145, 146].  The 
selfish DNA theory is still widely considered to represent the null hypothesis that best 
explains the presence of TEs from an evolutionary standpoint.  Nevertheless, numerous 
studies have revealed instances of exaptation [147], also referred to as molecular 
domestication [148], whereby formerly selfish TE sequences have been co-opted to 
provide some functional utility for their host genomes.  The most widely observed route of 
molecular domestication entails the conversion of TE sequences into host genome 
regulatory elements [17, 18, 128]. 
TE-derived sequences provide a wide variety of regulatory elements to the human 
genome, including promoters [19-21], enhancers [22-26], transcription terminators [28] 
and several classes of small RNAs [29-31].  Human TE-derived sequences can also exert 
higher order influences on gene regulation by shaping chromatin structure across the 
genome [32, 103-106].  It is important to note that, until this time, nearly all studies on 
human TE regulatory elements have focused on TE-derived sequences that are remnants 
of relatively ancient insertion events and no longer capable of transposition.  In other 
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words, known human TE regulatory sequences largely correspond to so-called ‘fixed’ TE 
insertions, which are found at the same genomic insertion site locations within the genomes 
of all human individuals.  This distinction is critical, since fixed TE insertions are not 
expected to contribute to regulatory variation among individual humans.  In other words, 
fixed TE regulatory elements, while functionally important, do not provide a source of 
human population genetic variation. 
Over the last several years, a convergence of genome-enabled technologies has 
begun to power studies that are focused squarely on structural variations generated by the 
ongoing activity of human TEs.   There are several families of human TEs that retain the 
ability to transpose, primarily Alu [3, 4], L1 [5, 6], and SVA [7, 8].  Smaller numbers of 
HERV-K endogenous retroviruses also remain active in the human genome [54].  When 
members of these TE families transpose within the human genome, they generate inter-
individual variations that segregate within and between populations in the form of TE 
insertion site polymorphisms.  Given the known regulatory properties of human TEs, it is 
not unreasonable to expect that segregating TE polymorphisms could have significant 
regulatory consequences.  In particular, some human TE polymorphisms may lead to 
differences in gene expression patterns between individuals.  Furthermore, human 
regulatory variation generated by recent TE activity may have important implications for 
health and disease.  This mini-review is focused on recent studies that are beginning to 
shed light on the ways in which ongoing TE activity can impact human health via changes 
in genome regulation.  These studies are distinguished by their population level approach 
to the study of TE generated human variation (Figure 23). 
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Figure 23 The population genomic approach for the study of TE phenotypic effects.   
Individuals sampled from human populations are characterized using genome (DNA-seq) 
and transcriptome (RNA-seq) profiling techniques.  Genome-wide TE insertion genotypes 
are compared to tissue-specific gene expression levels to uncover TE variants implicated 
in gene regulation.  The linkage disequilibrium patterns (LD) among TE polymorphisms 
and SNPs are evaluated to identify TE insertions linked to genome-wide association study 
(GWAS) loci.  Interrogation of functional information is used to hone in on likely TE causal 
variants. 
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5.3 Genome-enabled approaches for characterizing TE insertion variants 
Two distinct classes of genome-enabled approaches for the characterization of TE 
insertion variants have emerged over the last several years [131]: (1) bioinformatics 
methods that rely on the analysis of whole genome sequence data to find TE insertions that 
differ from a reference sequence (Figure 24A), and (2) high-throughput experimental 
methods that leverage next-generation sequencing to pinpoint the locations of novel TE 
insertions (Figure 24B). 
 
Figure 24 Genome-enabled approaches for the discovery and characterization of TE 
insertion variants. 
(A) Bioinformatics methods rely on the computational analysis of whole genome sequence 
read data to characterize genome-wide patterns of TE insertion alleles and genotypes.  (B) 
High-throughput experimental methods use enrichment of genomic fragments that contain 




Computational approaches for the discovery of TE insertion variants rely on one of 
two methods: (1) discordant read-pair mapping for short read sequencing technology, or 
(2) split read mapping for long read technology [120].  Our own group recently performed 
a benchmarking study on 21 bioinformatics tools designed for detecting human TE 
insertion variants from whole genome sequence data [64].  After an initial screen of tools 
that were found to be unreliable, or no longer maintained, our study focused on seven 
programs: ITIS [149], MELT [150], Mobster [151], RetroSeq [152], Tangram [153], 
TEMP [154], and T-lex2 [155].  We found MELT to have superior performance for human 
TE variant detection from whole genome sequence data, but also show how a combined 
approach using two or more methods, including Mobster and RetroSeq, could yield 
superior performance.  Since the publication of our paper, two new computational tools for 
TE insertion discovery have been published.  The program STEAK [156] claims superior 
performance compared to existing short read methods, whereas LoRTE [157] is designed 
for PacBio® long read sequence technology.  
At this time, given the predominance of Illumina® short read sequencing 
technology, discordant read-pair mapping approaches are most widely used.  However, 
these methods are still far from perfect and there is substantial room for additional 
development in the field.  As long read sequencing technology becomes more widespread, 
split read approaches should become more popular. Perhaps more importantly, we expect 
that split read approaches will be inherently more accurate and reliable than discordant read 
pair mapping, since long reads that span entire TE insertions should be mapped with much 
less ambiguity than shorter reads.   
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High-throughput experimental techniques for TE variant detection also share 
several basic features: (1) DNA fragmentation, (2) TE enrichment, and (3) TE calling.  The 
methods are distinguished by the approaches used for each step of the process.  DNA 
fragmentation can be achieved via enzymatic digestion or by mechanical shearing.  TE 
enrichment can be performed using PCR, with active TE-specific primers, or with 
hybridization to active TE-specific probes.  Finally, TE calling is done using next-
generation sequencing, for more recent methods, or with tiling arrays for the older methods.  
The most widely used experimental methods for TE variant detection include ME-Scan 
[158], L1-Seq [159], RC-seq [160], and Transposon-Seq [75].  One area of ongoing 
improvement for these methods entails the refinement of algorithms used to map enriched 
TE fragments to genome reference sequences.  For example, the TIPseqHunter algorithm 
was recently developed to refine and improve human TE variant calls made by the existing 
TIP-seq experimental method [161].   
Genome-scale experimental approaches of this kind have been most widely applied 
to the study of somatic TE variants that characterize cancer tissues.  This is one of the most 
promising areas of recent human TE research, and it has been extensively reviewed 
elsewhere [162].  This mini-review is focused instead on germline mutations that yield 
inter-individual differences in TE insertion patterns and manifest themselves as human 





5.4 TE polymorphisms and human genome regulation 
 Our own group recently published a population-level view of the regulatory 
consequences of recent human TE activity [163].  To do so, we adopted the expression 
quantitative trait loci (eQTL) analytical paradigm for human TE polymorphisms.  eQTL 
are genomic variants associated with changes in gene expression levels [164].  The eQTL 
approach requires multiple individual samples that have been deeply characterized at both 
the genomic (DNA-seq) and transcriptomic (RNA-seq) levels.  Gene expression levels for 
individual samples are regressed against locus-specific genotypes for matched individuals 
to uncover eQTL associations.  This approach was developed for single nucleotide 
polymorphism (SNP) genotypes, whereas in our case, we used locus-specific TE insertion 
state genotypes.  TE insertion genotypes at any locus can be encoded as 0 (homozygous - 
insertion absent), 1 (heterozygous - one insertion present), or 2 (homozygous - two 
insertions present).  Differences in gene expression levels across these distinct TE insertion 
states are indicative of TE polymorphism-to-gene expression associations (Figure 23). 
 This approach was powered by the 1000 Genomes Project (1KGP), phase 3 of 
which entailed the genome-wide characterization of TE insertion genotypes for 2,504 
individuals across 26 human populations [92, 99].  B-lymphocyte gene expression data for 
445 of the same 1KGP individuals, representing one African population and four European 
populations, were taken from the Genetic European Variation in Health and Disease 
(GEUVEDIS) RNA-seq project [93].  Merging data from both projects allowed us to 
directly compare TE insertion site genotypes to gene expression levels from the same 
individuals.  Furthermore, comparison of results for African and European populations 
allowed us to uncover population-specific regulatory effects of human TE polymorphisms.  
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 Regression of gene expression against TE insertion site genotypes revealed 
hundreds of eQTL associations, and TE-eQTL were found both within and between the 
African and European populations.  A number of TE polymorphisms were shown to be 
associated with expression differences between population groups.  One advantage of using 
TE insertion site genotypes for eQTL analysis is that the relatively low number of common 
TE genotypes across the genome (~16,000) allows for both cis and trans eQTL analysis.  
This is because the number of possible eQTL associations is the product of the number of 
genes and the number of variants being compared; accordingly, the analysis of millions of 
SNPs times thousands of genes presents a combinatorically daunting bioinformatics 
analysis challenge.  For this reason, most SNP eQTL studies focus exclusively on cis SNPs 
that are found within or in close proximity to individual genes.  Since our study was not 
limited in this way, we were able to discover many trans effects of TE polymorphisms on 
human gene regulation.  In fact, we were surprised to find that trans regulatory effects for 
TE polymorphisms were even more common than cis effects. 
 For one particular example, the B cell specific transcription factor PAX5, we 
uncovered a potential mechanism that could explain the numerous trans TE-eQTL that we 
observed (Figure 25).  This example also underscores how individual TE loci can 
participate in the rewiring of entire regulatory networks.  The PAX5 gene has a cis Alu 
eQTL that is associated with increased expression in B lymphocytes.  This same Alu 
insertion is associated with increased expression of numerous PAX5 target genes, 
presumably by virtue of a transitive effect whereby increased PAX5 expression in turn 
increases the expression of downstream targets in its regulatory network.  
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Figure 25 The impact of TE polymorphisms on gene regulatory networks 
The eQTL approach is used to discover associations between TE insertion variants and 
tissue-specific gene expression levels (i.e. TE-eQTLs).  A TE insertion variant found in cis 
to a transcription factor (TF) can lead to coordinated changes across a gene regulatory 
network via transitive effects on downstream targets of the TF.  An example is shown, 
similar to what has been observed for the TF gene PAX5, where TE associated increase in 
the expression of a TF leads in turn to increased expression of the TF target genes.  This 
will reveal itself as multiple trans TE-eQTL associations for the same TE insertion variant. 
 
 To our knowledge, this is the first and only study of its kind in humans.  However, 
analogous genome-scale approaches have been used to discover TE associations with gene 
expression in the model organisms Arabidopsis [165] and maize [166].   
 
5.5 TE polymorphisms and complex common disease 
 Two recent studies have taken a similar population-level view of the phenotypic 
effects of human TE polymorphisms [167, 168].  For each of these studies, associations 
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between TE insertion site genotypes and complex common diseases were explored.  Both 
studies relied on the analysis of linkage disequilibrium (LD) patterns to discover TE 
polymorphisms linked to SNPs that were previously associated with health or disease 
related phenotypes via genome-wide association studies (GWAS).  An implicit rationale 
for genome-scale surveys of this kind is the notion that TE insertions are expected to be 
more disruptive than SNP variations given the larger scale genomic changes that they 
entail.  Interestingly, both studies report that TE polymorphisms are enriched at GWAS 
loci, highlighting their potential impact.  The first study of this kind, from the group of 
Kathleen Burns, found 44 Alu insertions in tight LD with previously discovered GWAS 
trait associated SNPs [167].  The authors pointed out that this represents a >20-fold increase 
over the number of polymorphic Alu insertions that were previously known to be 
associated with human phenotypes, thereby underscoring the power of population genomic 
approaches for studies on the phenotypic impact of TE polymorphisms.  Furthermore, the 
implicated Alu polymorphisms were found to be associated with a very broad range of 
health and disease related phenotypes.   
 Our own study on the impact of TE polymorphisms on complex common disease 
was designed to explore the connection between TE-mediated genome regulation and 
disease related phenotypic effects [168].  To achieve this aim, we used a progressive set of 
genome-wide bioinformatics screens that searched for polymorphic TE insertions that are: 
(1) found in LD with known GWAS SNPs, (2) located within tissue-specific enhancers, 
and (3) associated with tissue-specific gene expression levels.  We further narrowed our 
search for candidate TE polymorphisms to those associated with genes with blood or 
immune related functions, consistent with the fact that the gene expression data we 
analyzed is from B lymphocytes.  This progressive and stringent genomic screen uncovered 
six TE polymorphisms that are likely to be associated with disease phenotypes by virtue of 
their gene regulatory effects.  These included both Alu elements, as previously reported, as 
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well as SVA elements.  For example, we discovered an SVA insertion in the cell-type 
specific enhancer of the B4GALT1 gene (Figure 26).  B4GALT1 acts to convert the 
Immunoglobulin G (IgG) antibody from a pro-inflammatory to an anti-inflammatory form.  
The SVA insertion is associated with both down-regulation of the B4GALT1 gene, thereby 
potentially leading to increased inflammation, and linked to a genomic region implicated 
by GWAS in both inflammatory conditions and autoimmune disease. 
 
Figure 26 TE insertion variants impact on human disease via gene regulatory 
changes   
TE insertion variants are found in tight linkage disequilibrium (LD) with previously 
characterized genome-wide association study (GWAS) SNP risk alleles.  The linked TE 
insertion variant is associated with reduced gene expression, which is in turn associated 
with elevated disease risk.  The scheme shown here corresponds to a TE insertion variant 
associated with reduced expression of the B4GALT1 gene, which leads to increased 






 The population genomics view of TEs exemplified by the recent studies reviewed 
here has the potential to expand our understanding of the phenotypic impact of human TEs.  
While ongoing human TE activity has widely been considered to be deleterious, the 
presence of TE insertion variants that segregate as common polymorphisms among human 
populations indicates that many novel TE insertions must have escaped the action of 
purifying selection.  Accordingly, polymorphic human TE insertion variants comprise an 
important source of naturally occurring genetic variation with subtle effects on genome 
regulation and human health.  Functionally relevant TE polymorphisms of this kind are 
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Figure 27 RNA-seq normalization and covariate adjustments 
(A) Comparison of four RNA-seq normalization approaches that were evaluated here: 
unsupervised SVAseq, PCA, unsupervised RUVseq and empirical RUVseq.  The matrix 
shows the results of pairwise comparisons between the latent factors influencing gene 
expression estimated by each method.  For each cell in the pairwise comparison matrix, 
the shape and the color represent the magnitude of the correlation coefficient (r) observed 
between methods, based on the estimated latent factors.  Rounder shapes and lighter colors 
show lower correlations; more narrow and brighter colors show higher correlations.  (B) 
Comparison of the first two PCAs of the L1 expression matrices shown before and after 
adjustment for co-variates.  L1 expression PCA values are color coded by population 






APPENDIX B.  




Figure 28 Scheme of the three analyses used to control for the potential effects of 
regulatory SNPs on the TE-eQTL associations observed here.   
(A) TE-eQTL versus SNP-eQTL comparisons.  (B) Conditional association analysis.  (C) 
Regional association scans.   
 
 
Figure 29 TE-eQTL versus SNP-eQTL comparisons. 
Venn diagrams showing the numbers of genes found to be associated with TE-eQTL and/or 
SNP-eQTL for (A) African (blue) or (B) European (orange) populations.  The numbers of 
genes associated with both TE-eQTL and SNP-eQTL for each population group are shown 




Figure 30 Population-specific TE-eQTL associations. 
Venn diagram showing the number of polyTEs with associations that are found in Africa 
(blue), Europe (orange) or both (intersection).   
 
Table 3 Best TE eQTLs identified in the analysis 
Chr Pos TE Gene t Statistic P-value FDR TE subfamily eQTL type 
chr17 44153977 SVA_umary_SVA_706 RP11-259G18.3 22.63 7.83E-76 4.54E-68 SVA trans 
chr17 43670097 SVA_umary_SVA_705 RP11-259G18.3 14.37 1.11E-38 1.61E-31 SVA trans 
chr6 133160120 ALU_umary_ALU_5602 RPS12 -13.91 1.04E-36 1.21E-29 ALU cis 
chr17 43660599 SVA_umary_SVA_704 RP11-259G18.3 13.47 7.28E-35 7.02E-28 SVA trans 
chr8 71914591 ALU_umary_ALU_6806 XKR9 12.07 3.54E-29 2.05E-22 ALU cis 
chr1 75192907 L1_umary_LINE1_61 CRYZ -11.02 4.12E-25 1.84E-18 L1 cis 
chr22 19210913 L1_umary_LINE1_2986 CLTCL1 10.72 5.37E-24 2.22E-17 L1 cis 
chr7 32831241 ALU_umary_ALU_5939 DPY19L1P1 10.62 1.28E-23 4.93E-17 ALU cis 
chr4 185651677 ALU_umary_ALU_3997 CENPU -9.93 4.11E-21 1.40E-14 ALU cis 
chr9 33130564 SVA_umary_SVA_401 B4GALT1 -9.60 6.13E-20 1.87E-13 SVA cis 
chr6 130614798 ALU_umary_ALU_5583 TMEM200A -9.54 9.93E-20 2.87E-13 ALU cis 
chr9 98696746 ALU_umary_ALU_7578 LINC00476 9.33 5.29E-19 1.46E-12 ALU cis 
chr6 32657952 ALU_umary_ALU_5075 HLA-DQB1-AS1 -9.11 2.86E-18 7.52E-12 ALU cis 
chr6 29818872 ALU_umary_ALU_5053 HLA-J 9.04 5.03E-18 1.27E-11 ALU cis 
chr11 43877448 ALU_umary_ALU_8559 HSD17B12 -8.98 7.96E-18 1.92E-11 ALU cis 
chr14 92619420 SVA_umary_SVA_615 NDUFB1 -8.96 9.00E-18 2.08E-11 SVA cis 
chr13 21894780 ALU_umary_ALU_9602 LINC00422 -8.92 1.22E-17 2.72E-11 ALU cis 
chr3 48372326 ALU_umary_ALU_2337 FCF1P2 -8.53 2.39E-16 5.12E-10 ALU cis 
chr6 33030313 SVA_umary_SVA_282 HLA-DPB2 8.29 1.36E-15 2.71E-09 SVA cis 
chr12 56753252 ALU_umary_ALU_9228 RP11-977G19.11 -8.03 8.77E-15 1.59E-08 ALU cis 
chr15 41100332 ALU_umary_ALU_10654 ZFYVE19 -8.02 9.90E-15 1.74E-08 ALU cis 
chr10 70973334 SVA_umary_SVA_452 HKDC1 7.97 1.40E-14 2.32E-08 SVA cis 
chr18 59713734 ALU_umary_ALU_11754 PIGN -7.95 1.54E-14 2.47E-08 ALU cis 
chr7 23665685 ALU_umary_ALU_5888 CCDC126 7.90 2.29E-14 3.59E-08 ALU cis 
chr19 52888074 ALU_umary_ALU_11979 ZNF880 7.88 2.57E-14 3.81E-08 ALU cis 
chr2 191478717 L1_umary_LINE1_477 MFSD6 -7.72 7.82E-14 1.08E-07 L1 cis 
chr9 37596348 ALU_umary_ALU_7420 POLR1E -7.58 2.05E-13 2.76E-07 ALU cis 
chr6 32589834 ALU_umary_ALU_5072 HLA-DRB5 -7.47 4.31E-13 5.67E-07 ALU cis 
chr19 57023579 ALU_umary_ALU_11997 ZFP28 7.45 4.82E-13 6.20E-07 ALU cis 
chr1 11830220 SVA_umary_SVA_5 C1orf167 7.31 1.28E-12 1.61E-06 SVA cis 
chr13 50173371 ALU_umary_ALU_9777 ARL11 -7.21 2.41E-12 2.84E-06 ALU cis 
chr15 45569912 ALU_umary_ALU_10670 CTD-2651B20.3 7.18 2.90E-12 3.36E-06 ALU cis 
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Chr Pos TE Gene t Statistic P-value FDR TE subfamily eQTL type 
chr2 3630321 ALU_umary_ALU_970 RNASEH1-AS1 -7.18 3.03E-12 3.44E-06 ALU cis 
chr14 57744450 ALU_umary_ALU_10334 MAML2 7.08 5.87E-12 6.41E-06 ALU trans 
chr21 31411594 ALU_umary_ALU_12362 NCCRP1 7.00 9.38E-12 9.88E-06 ALU trans 
chr2 20085249 ALU_umary_ALU_1042 PATL1 6.84 2.64E-11 2.73E-05 ALU trans 
chr6 31250241 ALU_umary_ALU_5060 HCG4P7 6.71 5.88E-11 5.78E-05 ALU trans 
chr2 199988338 ALU_umary_ALU_1903 PIK3AP1 6.69 6.88E-11 6.64E-05 ALU trans 
chr4 56371962 ALU_umary_ALU_3295 SRD5A3 6.68 7.07E-11 6.71E-05 ALU cis 
chr11 65984338 ALU_umary_ALU_8622 RP11-755F10.1 6.65 8.76E-11 8.19E-05 ALU cis 
chr4 146749 SVA_umary_SVA_203 ZNF718 6.64 9.07E-11 8.34E-05 SVA cis 
chr7 125922888 ALU_umary_ALU_6374 IGLV3-27 6.64 9.47E-11 8.57E-05 ALU trans 
chr3 26906584 ALU_umary_ALU_2238 GPR128 6.61 1.11E-10 9.91E-05 ALU trans 
chr2 68733422 ALU_umary_ALU_1278 PVR 6.60 1.16E-10 1.02E-04 ALU trans 
chr12 58359071 ALU_umary_ALU_9234 XRCC6BP1 6.55 1.61E-10 1.40E-04 ALU cis 
chr9 76893085 ALU_umary_ALU_7481 PHF2 6.53 1.85E-10 1.58E-04 ALU trans 
chr5 124155349 L1_umary_LINE1_1205 IGKV2D-29 6.52 1.91E-10 1.60E-04 L1 trans 
chr1 234805728 ALU_umary_ALU_884 RP4-781K5.6 -6.47 2.65E-10 2.17E-04 ALU cis 
chr17 6538671 ALU_umary_ALU_11197 CTC-281F24.1 6.36 4.95E-10 3.98E-04 ALU cis 
chr5 36792620 ALU_umary_ALU_4218 CTD-2353F22.1 -6.34 5.70E-10 4.52E-04 ALU cis 
chr15 55129551 L1_umary_LINE1_2652 CRYBB2 6.31 6.85E-10 5.36E-04 L1 trans 
chr14 82223469 ALU_umary_ALU_10437 LRRC20 -6.29 7.57E-10 5.77E-04 ALU trans 
chr14 75499581 ALU_umary_ALU_10401 EIF2B2 6.29 7.79E-10 5.86E-04 ALU cis 
chr3 21234927 L1_umary_LINE1_558 MAML2 6.28 8.07E-10 5.91E-04 L1 trans 
chr2 227473038 ALU_umary_ALU_2029 IGLV3-27 6.28 8.35E-10 6.04E-04 ALU trans 
chr9 87506228 ALU_umary_ALU_7533 ST8SIA1 6.27 8.83E-10 6.31E-04 ALU trans 
chr2 65163783 ALU_umary_ALU_1256 SLC1A4 -6.25 9.54E-10 6.66E-04 ALU cis 
chr8 133725454 ALU_umary_ALU_7169 FAM65B 6.23 1.06E-09 7.30E-04 ALU trans 
chr9 97710713 ALU_umary_ALU_7572 CROCCP2 6.22 1.15E-09 7.77E-04 ALU trans 
chr12 97526402 ALU_umary_ALU_9451 GJA4 6.22 1.15E-09 7.77E-04 ALU trans 
chr7 91751552 ALU_umary_ALU_6200 CYP51A1P2 -6.22 1.19E-09 7.89E-04 ALU trans 
chr7 63880180 ALU_umary_ALU_6074 TRIM60P18 6.20 1.32E-09 8.66E-04 ALU cis 
chr8 35244893 L1_umary_LINE1_1650 LRP2 6.18 1.48E-09 9.63E-04 L1 trans 
chr13 60032561 ALU_umary_ALU_9825 HTR3A 6.17 1.56E-09 1.00E-03 ALU trans 
chr6 131028588 ALU_umary_ALU_5587 ZNF462 6.17 1.57E-09 1.00E-03 ALU trans 
chr15 53941096 ALU_umary_ALU_10715 TPCN2 -6.16 1.68E-09 1.04E-03 ALU trans 
chr10 6271127 ALU_umary_ALU_7761 FRAS1 6.15 1.78E-09 1.09E-03 ALU trans 
chr5 118097178 ALU_umary_ALU_4615 LRRC20 -6.13 1.91E-09 1.14E-03 ALU trans 
chr11 86195336 ALU_umary_ALU_8700 IGLV7-46 6.13 2.00E-09 1.18E-03 ALU trans 
chr7 22799818 ALU_umary_ALU_5885 SMPDL3A 6.11 2.15E-09 1.26E-03 ALU trans 
chr12 80480726 ALU_umary_ALU_9371 TPCN2 -6.07 2.68E-09 1.54E-03 ALU trans 
chr12 4742915 SVA_umary_SVA_532 AKAP3 -6.06 2.89E-09 1.61E-03 SVA cis 
chr4 185875956 ALU_umary_ALU_3998 TEPP 6.05 3.03E-09 1.66E-03 ALU trans 
chr6 32449301 ALU_umary_ALU_5065 HLA-DRB1 6.02 3.68E-09 1.97E-03 ALU cis 
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chr3 86264950 L1_umary_LINE1_634 ATP6V0E2-AS1 6.02 3.71E-09 1.97E-03 L1 trans 
chr7 18345324 ALU_umary_ALU_5870 RP11-777B9.5 6.01 3.82E-09 2.01E-03 ALU trans 
chr8 2275573 ALU_umary_ALU_6535 ENPEP 5.98 4.65E-09 2.40E-03 ALU trans 
chr4 95413280 ALU_umary_ALU_3517 FREM1 5.96 5.07E-09 2.55E-03 ALU trans 
chr1 40524704 ALU_umary_ALU_114 RP11-386M24.6 5.96 5.14E-09 2.56E-03 ALU trans 
chr4 74430433 ALU_umary_ALU_3402 CRYBB2 5.96 5.18E-09 2.56E-03 ALU trans 
chr5 95394266 ALU_umary_ALU_4487 CCL1 5.96 5.26E-09 2.57E-03 ALU trans 
chr3 165336826 ALU_umary_ALU_2883 LZIC 5.95 5.34E-09 2.57E-03 ALU trans 
chr5 37648672 ALU_umary_ALU_4220 CRYBB2P1 5.94 5.78E-09 2.72E-03 ALU trans 
chr17 35210358 ALU_umary_ALU_11294 ASB14 5.94 5.93E-09 2.77E-03 ALU trans 
chr12 84955216 L1_umary_LINE1_2324 FAM153B 5.91 6.74E-09 3.12E-03 L1 trans 
chr1 36474694 ALU_umary_ALU_102 CLEC4A 5.90 7.13E-09 3.28E-03 ALU trans 
chr1 249191472 L1_umary_LINE1_242 LRRC20 -5.90 7.45E-09 3.40E-03 L1 trans 
chr6 32514622 SVA_umary_SVA_280 HLA-DRB5 -5.89 7.54E-09 3.41E-03 SVA cis 
chr3 66951653 ALU_umary_ALU_2413 IGHV3-64 5.87 8.45E-09 3.78E-03 ALU trans 
chr2 213168133 ALU_umary_ALU_1964 IGLV4-60 5.87 8.48E-09 3.78E-03 ALU trans 
chr3 180190410 ALU_umary_ALU_2977 GAPT 5.86 8.97E-09 3.94E-03 ALU trans 
chr4 40235018 ALU_umary_ALU_3239 NR2F2 5.84 1.03E-08 4.50E-03 ALU trans 
chr6 80086769 ALU_umary_ALU_5318 RP4-756H11.3 5.83 1.05E-08 4.52E-03 ALU trans 
chr17 735172 ALU_umary_ALU_11176 XCL1 5.83 1.07E-08 4.57E-03 ALU trans 
chr2 129573988 L1_umary_LINE1_398 RCCD1 5.82 1.11E-08 4.67E-03 L1 trans 
chr8 69587130 ALU_umary_ALU_6797 FAT1 5.82 1.14E-08 4.68E-03 ALU trans 
chr8 80466350 ALU_umary_ALU_6867 RP11-435B5.5 5.80 1.30E-08 5.31E-03 ALU trans 
chr3 132577737 ALU_umary_ALU_2718 VIL1 5.79 1.36E-08 5.48E-03 ALU trans 
chr7 125861744 ALU_umary_ALU_6372 ACSM1 5.78 1.43E-08 5.72E-03 ALU trans 
chr6 44114176 SVA_umary_SVA_289 RP11-793H13.8 5.78 1.44E-08 5.72E-03 SVA trans 
chr15 80662580 ALU_umary_ALU_10836 LGALS9B 5.77 1.47E-08 5.78E-03 ALU trans 
chr11 5126963 SVA_umary_SVA_482 HERC2P8 5.75 1.66E-08 6.33E-03 SVA trans 
chr6 103871467 L1_umary_LINE1_1371 FITM1 5.75 1.67E-08 6.33E-03 L1 trans 
chr3 109697784 ALU_umary_ALU_2606 CD2 5.74 1.72E-08 6.37E-03 ALU trans 
chr11 82657872 ALU_umary_ALU_8680 XCL1 5.74 1.73E-08 6.37E-03 ALU trans 
chr7 123194557 ALU_umary_ALU_6352 VARS 5.74 1.75E-08 6.37E-03 ALU trans 
chr6 26962174 ALU_umary_ALU_5039 RP11-457M11.5 -5.73 1.86E-08 6.73E-03 ALU cis 
chr3 6525411 ALU_umary_ALU_2124 GCLM 5.73 1.87E-08 6.73E-03 ALU trans 
chr15 76826019 ALU_umary_ALU_10819 IGKV1D-13 5.71 2.05E-08 7.32E-03 ALU trans 
chr22 23872686 ALU_umary_ALU_12453 RP11-124N14.3 5.70 2.14E-08 7.60E-03 ALU trans 
chr5 148917332 ALU_umary_ALU_4754 WSCD1 5.70 2.19E-08 7.72E-03 ALU trans 
chr6 141414904 ALU_umary_ALU_5647 PSORS1C3 5.69 2.27E-08 7.97E-03 ALU trans 
chr8 111644268 ALU_umary_ALU_7045 GDAP1 5.69 2.31E-08 8.08E-03 ALU trans 
chr3 192376526 ALU_umary_ALU_3032 IGKV2-29 5.68 2.40E-08 8.26E-03 ALU trans 
chr12 58458223 ALU_umary_ALU_9236 XRCC6BP1 5.68 2.41E-08 8.27E-03 ALU cis 
chr15 81392597 ALU_umary_ALU_10841 PSD4 -5.68 2.47E-08 8.38E-03 ALU trans 
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chr1 165553149 L1_umary_LINE1_157 IGLC2 5.67 2.57E-08 8.60E-03 L1 trans 
chr13 36325342 SVA_umary_SVA_566 NEDD9 5.67 2.57E-08 8.60E-03 SVA trans 
chr10 68217408 ALU_umary_ALU_8046 CAND2 5.66 2.68E-08 8.83E-03 ALU trans 
chr12 61247559 ALU_umary_ALU_9258 CRYBB2P1 5.66 2.68E-08 8.83E-03 ALU trans 
chr6 104772669 ALU_umary_ALU_5447 HSPE1P8 -5.66 2.74E-08 8.92E-03 ALU trans 
chr12 46175166 ALU_umary_ALU_9193 IGLV3-27 -5.66 2.78E-08 8.96E-03 ALU trans 
chr1 97717644 ALU_umary_ALU_379 IGLV1-50 5.66 2.80E-08 8.96E-03 ALU trans 
chr5 5279799 ALU_umary_ALU_4046 WEE2 5.66 2.80E-08 8.96E-03 ALU trans 
chr10 9683707 ALU_umary_ALU_7780 IGHV1-58 5.65 2.89E-08 9.19E-03 ALU trans 
chr12 21006856 ALU_umary_ALU_9055 IGHV3-20 5.65 2.94E-08 9.30E-03 ALU trans 
chr3 169270604 ALU_umary_ALU_2911 BACE1 5.65 2.96E-08 9.30E-03 ALU trans 
chr1 38447717 ALU_umary_ALU_107 UBALD1 5.64 3.06E-08 9.42E-03 ALU trans 
chr4 5667998 L1_umary_LINE1_773 POC1B 5.64 3.09E-08 9.42E-03 L1 trans 
chr6 126509049 ALU_umary_ALU_5563 RP11-288E14.2 5.64 3.11E-08 9.42E-03 ALU trans 
chr5 63430716 ALU_umary_ALU_4330 SEC61A1 5.64 3.13E-08 9.42E-03 ALU trans 
chr18 56819477 ALU_umary_ALU_11733 PPIC 5.63 3.14E-08 9.42E-03 ALU trans 
chr16 79190739 ALU_umary_ALU_11136 PPP4R4 5.63 3.29E-08 9.82E-03 ALU trans 
chr9 118509752 ALU_umary_ALU_7676 HOXB7 5.62 3.37E-08 9.90E-03 ALU trans 
chr10 17712792 SVA_umary_SVA_438 TMEM236 5.61 3.65E-08 1.06E-02 SVA cis 
chr4 186361924 ALU_umary_ALU_4000 RP11-276H1.3 -5.60 3.77E-08 1.08E-02 ALU trans 
chr2 4256152 ALU_umary_ALU_974 RAB11FIP5 5.60 3.86E-08 1.10E-02 ALU trans 
chr3 112466720 SVA_umary_SVA_179 LILRA1 5.59 3.92E-08 1.10E-02 SVA trans 
chr15 28179379 ALU_umary_ALU_10586 CA9 5.59 3.92E-08 1.10E-02 ALU trans 
chr8 17943136 ALU_umary_ALU_6606 ARHGEF12 5.59 3.94E-08 1.10E-02 ALU trans 
chr7 6314063 ALU_umary_ALU_5788 REL 5.59 3.96E-08 1.10E-02 ALU trans 
chr16 52412371 ALU_umary_ALU_11042 EPHB2 5.59 4.00E-08 1.11E-02 ALU trans 
chr3 168199075 ALU_umary_ALU_2905 IQCA1 5.59 4.08E-08 1.12E-02 ALU trans 
chr18 50097757 L1_umary_LINE1_2823 TP53BP2 5.58 4.13E-08 1.13E-02 L1 trans 
chr3 144610083 L1_umary_LINE1_704 IGKV2-29 5.58 4.14E-08 1.13E-02 L1 trans 
chr14 66934461 ALU_umary_ALU_10374 SSPN 5.58 4.24E-08 1.14E-02 ALU trans 
chr20 32793460 ALU_umary_ALU_12140 UBLCP1 5.57 4.54E-08 1.21E-02 ALU trans 
chr13 90038686 ALU_umary_ALU_10010 PIM1 5.57 4.55E-08 1.21E-02 ALU trans 
chr11 13092200 ALU_umary_ALU_8387 RP5-902P8.10 5.56 4.70E-08 1.24E-02 ALU trans 
chr2 192982697 ALU_umary_ALU_1861 VCAN-AS1 5.55 4.83E-08 1.26E-02 ALU trans 
chr9 80704885 ALU_umary_ALU_7506 ZNF667-AS1 5.55 5.07E-08 1.32E-02 ALU trans 
chr7 65045619 SVA_umary_SVA_343 RP11-146F11.1 5.53 5.37E-08 1.38E-02 SVA trans 
chr7 85013802 ALU_umary_ALU_6166 CLCN2 5.53 5.51E-08 1.41E-02 ALU trans 
chr8 128119620 ALU_umary_ALU_7140 DHRS4-AS1 -5.53 5.53E-08 1.41E-02 ALU trans 
chr11 25108568 ALU_umary_ALU_8453 U1 5.52 5.74E-08 1.43E-02 ALU trans 
chr4 134922359 ALU_umary_ALU_3724 EGFL7 5.52 5.89E-08 1.45E-02 ALU trans 
chr7 18273084 ALU_umary_ALU_5868 TIMP2 5.51 6.11E-08 1.47E-02 ALU trans 
chr6 72753379 ALU_umary_ALU_5270 MT3 5.51 6.15E-08 1.47E-02 ALU trans 
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chr10 73193547 ALU_umary_ALU_8081 MAML2 -5.50 6.36E-08 1.51E-02 ALU trans 
chr5 116763098 ALU_umary_ALU_4607 SPTLC3 5.50 6.42E-08 1.52E-02 ALU trans 
chr14 30525258 L1_umary_LINE1_2526 TMEM63C 5.50 6.53E-08 1.54E-02 L1 trans 
chr8 122155287 ALU_umary_ALU_7101 P2RY2 5.49 6.64E-08 1.56E-02 ALU trans 
chr10 21192833 ALU_umary_ALU_7830 TMEM38A 5.49 6.81E-08 1.59E-02 ALU trans 
chr8 8920127 ALU_umary_ALU_6560 AF131215.2 5.48 7.12E-08 1.64E-02 ALU trans 
chr20 3242418 ALU_umary_ALU_12024 IGKV2-29 5.48 7.17E-08 1.65E-02 ALU trans 
chr6 32773435 ALU_umary_ALU_5079 TAP2 5.47 7.70E-08 1.76E-02 ALU cis 
chr5 146369626 ALU_umary_ALU_4737 RALA -5.46 7.88E-08 1.79E-02 ALU trans 
chr7 126661404 ALU_umary_ALU_6375 OTOF 5.46 7.94E-08 1.79E-02 ALU trans 
chr3 155818384 ALU_umary_ALU_2834 IGHV1-69 5.46 8.01E-08 1.79E-02 ALU trans 
chr3 44340304 ALU_umary_ALU_2324 MAPK9 5.46 8.02E-08 1.79E-02 ALU trans 
chr4 106550763 ALU_umary_ALU_3575 SEMA5A 5.45 8.45E-08 1.86E-02 ALU trans 
chr12 75931101 ALU_umary_ALU_9345 ENPP5 -5.44 8.76E-08 1.91E-02 ALU trans 
chr8 88410445 ALU_umary_ALU_6917 SNORA57 5.43 9.22E-08 1.99E-02 ALU trans 
chr11 114686177 ALU_umary_ALU_8857 RP11-566K19.6 5.43 9.30E-08 1.99E-02 ALU trans 
chr7 52789472 L1_umary_LINE1_1509 N6AMT2 5.43 9.33E-08 1.99E-02 L1 trans 
chr2 212707197 L1_umary_LINE1_504 GNG12 5.43 9.36E-08 1.99E-02 L1 trans 
chr14 51719000 ALU_umary_ALU_10302 TMX1 5.43 9.41E-08 2.00E-02 ALU cis 
chr4 86099317 ALU_umary_ALU_3472 PPFIBP1 5.43 9.49E-08 2.00E-02 ALU trans 
chr11 73562793 ALU_umary_ALU_8639 MRPL48 5.42 9.84E-08 2.04E-02 ALU cis 
chr1 51029967 ALU_umary_ALU_156 EPCAM 5.42 9.93E-08 2.05E-02 ALU trans 
chr5 122976151 ALU_umary_ALU_4639 RP11-575G13.2 5.42 9.95E-08 2.05E-02 ALU trans 
chr8 42039906 ALU_umary_ALU_6700 ENPP4 -5.41 1.03E-07 2.10E-02 ALU trans 
chr1 65572274 ALU_umary_ALU_214 MCOLN2 5.40 1.09E-07 2.16E-02 ALU trans 
chr2 189853875 ALU_umary_ALU_1846 SLC5A5 5.40 1.09E-07 2.16E-02 ALU trans 
chr1 169524859 L1_umary_LINE1_164 ATP5H 5.40 1.11E-07 2.17E-02 L1 trans 
chr10 105817214 ALU_umary_ALU_8203 AC005740.3 -5.40 1.11E-07 2.17E-02 ALU trans 
chr5 116897151 ALU_umary_ALU_4608 LRRC20 -5.39 1.12E-07 2.17E-02 ALU trans 
chr14 30854683 L1_umary_LINE1_2529 ADAD2 5.39 1.13E-07 2.17E-02 L1 trans 
chr3 5484122 ALU_umary_ALU_2116 RANBP17 5.39 1.15E-07 2.20E-02 ALU trans 
chr10 97668538 ALU_umary_ALU_8182 ENTPD1 5.39 1.16E-07 2.21E-02 ALU cis 
chr3 193354185 L1_umary_LINE1_769 RP11-175P19.2 5.39 1.16E-07 2.22E-02 L1 cis 
chr4 86607956 L1_umary_LINE1_885 IGHV3-32 5.38 1.19E-07 2.26E-02 L1 trans 
chr1 184950473 ALU_umary_ALU_643 MDK 5.38 1.19E-07 2.26E-02 ALU trans 
chr20 17860937 L1_umary_LINE1_2915 NPRL3 -5.37 1.26E-07 2.35E-02 L1 trans 
chr22 35180750 ALU_umary_ALU_12488 CCDC3 5.37 1.26E-07 2.35E-02 ALU trans 
chr17 49408800 ALU_umary_ALU_11342 POTEE 5.37 1.27E-07 2.36E-02 ALU trans 
chr2 186001780 ALU_umary_ALU_1824 GPR183 5.37 1.28E-07 2.36E-02 ALU trans 
chr7 142673652 ALU_umary_ALU_6458 RP4-730K3.3 5.37 1.28E-07 2.36E-02 ALU trans 
chr12 78396948 ALU_umary_ALU_9357 TIMP2 5.37 1.30E-07 2.39E-02 ALU trans 
chr7 46504534 ALU_umary_ALU_6008 RP11-452L6.7 5.36 1.32E-07 2.39E-02 ALU trans 
 110 
Chr Pos TE Gene t Statistic P-value FDR TE subfamily eQTL type 
chr15 79167169 ALU_umary_ALU_10832 ADAMTS7 5.36 1.35E-07 2.44E-02 ALU cis 
chr20 26190974 ALU_umary_ALU_12132 LINC00969 5.36 1.36E-07 2.44E-02 ALU trans 
chr11 90530723 ALU_umary_ALU_8730 FN1 5.36 1.37E-07 2.45E-02 ALU trans 
chr6 102220590 ALU_umary_ALU_5428 CLDN12 5.35 1.39E-07 2.48E-02 ALU trans 
chr11 88908952 ALU_umary_ALU_8717 HMGB1P1 5.35 1.40E-07 2.48E-02 ALU trans 
chr3 76222309 ALU_umary_ALU_2455 CREM 5.35 1.40E-07 2.48E-02 ALU trans 
chr11 100911793 ALU_umary_ALU_8790 USP32 -5.34 1.46E-07 2.57E-02 ALU trans 
chr21 28249247 ALU_umary_ALU_12342 LZIC 5.34 1.49E-07 2.59E-02 ALU trans 
chr21 26354237 ALU_umary_ALU_12333 NEDD9 -5.34 1.50E-07 2.59E-02 ALU trans 
chr13 50912089 ALU_umary_ALU_9780 FBN2 5.34 1.52E-07 2.61E-02 ALU trans 
chr15 53956115 L1_umary_LINE1_2651 TPCN2 -5.33 1.58E-07 2.68E-02 L1 trans 
chr21 27163622 SVA_umary_SVA_808 RP11-22P6.3 5.32 1.65E-07 2.76E-02 SVA trans 
chr11 23572069 ALU_umary_ALU_8441 SEMA3A 5.31 1.73E-07 2.85E-02 ALU trans 
chr19 18835612 SVA_umary_SVA_743 SSTR3 5.31 1.73E-07 2.85E-02 SVA trans 
chr1 112992009 ALU_umary_ALU_454 CTTNBP2NL -5.31 1.74E-07 2.85E-02 ALU cis 
chr17 70696176 ALU_umary_ALU_11447 TMEM159 5.31 1.74E-07 2.85E-02 ALU trans 
chr11 117683506 ALU_umary_ALU_8864 TINAG 5.31 1.77E-07 2.88E-02 ALU trans 
chr8 115604486 ALU_umary_ALU_7074 RASSF8 5.31 1.79E-07 2.89E-02 ALU trans 
chr3 195829642 SVA_umary_SVA_202 PDLIM4 5.30 1.79E-07 2.89E-02 SVA trans 
chr20 47206176 ALU_umary_ALU_12190 IGHV1OR15-2 5.30 1.80E-07 2.89E-02 ALU trans 
chr1 112103110 ALU_umary_ALU_444 NPIPB15 5.30 1.80E-07 2.89E-02 ALU trans 
chr11 47806655 ALU_umary_ALU_8566 TBC1D1 -5.30 1.83E-07 2.90E-02 ALU trans 
chr1 102920544 ALU_umary_ALU_412 RP11-670E13.5 5.30 1.84E-07 2.90E-02 ALU trans 
chr8 87770103 ALU_umary_ALU_6912 IGKV1-13 5.30 1.88E-07 2.94E-02 ALU trans 
chr5 56830734 ALU_umary_ALU_4298 CXCL9 5.29 1.95E-07 3.03E-02 ALU trans 
chr6 153633385 ALU_umary_ALU_5701 TRAPPC8 5.29 1.97E-07 3.04E-02 ALU trans 
chr4 190684483 SVA_umary_SVA_231 IGLV10-54 -5.28 2.02E-07 3.09E-02 SVA trans 
chr6 114091219 L1_umary_LINE1_1379 GVINP1 5.28 2.02E-07 3.09E-02 L1 trans 
chr4 79289449 ALU_umary_ALU_3430 RP11-165P7.1 5.28 2.04E-07 3.11E-02 ALU trans 
chr2 114106446 ALU_umary_ALU_1441 ACY1 5.28 2.05E-07 3.12E-02 ALU trans 
chr10 83042769 ALU_umary_ALU_8107 NEK4 5.28 2.08E-07 3.14E-02 ALU trans 
chr1 212765848 ALU_umary_ALU_767 AC007551.2 5.27 2.10E-07 3.16E-02 ALU trans 
chr20 15513281 ALU_umary_ALU_12084 CTD-3065B20.2 5.27 2.19E-07 3.26E-02 ALU trans 
chr18 15325826 ALU_umary_ALU_11565 FXR2 5.26 2.23E-07 3.30E-02 ALU trans 
chr3 157369140 ALU_umary_ALU_2844 RGS22 5.26 2.26E-07 3.31E-02 ALU trans 
chr3 144308219 ALU_umary_ALU_2765 FITM1 5.26 2.27E-07 3.31E-02 ALU trans 
chr4 43399986 ALU_umary_ALU_3259 TPCN2 5.25 2.32E-07 3.34E-02 ALU trans 
chr8 87315040 L1_umary_LINE1_1704 EMBP1 -5.25 2.32E-07 3.34E-02 L1 trans 
chr8 110101605 ALU_umary_ALU_7037 AC007881.4 5.25 2.32E-07 3.34E-02 ALU trans 
chr11 103736375 ALU_umary_ALU_8803 RP11-578F21.9 5.25 2.36E-07 3.37E-02 ALU trans 
chr8 75448823 ALU_umary_ALU_6841 HNRNPA1P10 5.25 2.39E-07 3.40E-02 ALU trans 
chr3 186372141 L1_umary_LINE1_761 TBC1D1 5.25 2.40E-07 3.40E-02 L1 trans 
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chr12 43256994 L1_umary_LINE1_2278 MAML2 -5.25 2.40E-07 3.40E-02 L1 trans 
chr15 62606061 ALU_umary_ALU_10767 SNORA73B 5.24 2.44E-07 3.44E-02 ALU trans 
chr21 28221359 ALU_umary_ALU_12341 KANSL1-AS1 5.24 2.45E-07 3.46E-02 ALU trans 
chr12 70788935 ALU_umary_ALU_9313 CDC5L -5.24 2.46E-07 3.46E-02 ALU trans 
chr6 126423676 ALU_umary_ALU_5562 WSCD1 5.24 2.47E-07 3.47E-02 ALU trans 
chr1 156705360 ALU_umary_ALU_528 CEP72 5.24 2.49E-07 3.48E-02 ALU trans 
chr11 7352462 ALU_umary_ALU_8361 PCDHGA7 5.24 2.52E-07 3.49E-02 ALU trans 
chr10 48419952 ALU_umary_ALU_7936 UAP1L1 5.24 2.55E-07 3.52E-02 ALU trans 
chr5 169376692 SVA_umary_SVA_268 PPFIA3 5.23 2.60E-07 3.54E-02 SVA trans 
chr7 42647660 ALU_umary_ALU_5994 RP11-336N8.4 -5.23 2.61E-07 3.54E-02 ALU trans 
chr4 26438630 ALU_umary_ALU_3159 RALA -5.23 2.61E-07 3.54E-02 ALU trans 
chr2 126051106 ALU_umary_ALU_1497 ATP8B1 5.23 2.61E-07 3.54E-02 ALU trans 
chr8 17336021 ALU_umary_ALU_6603 PKIB 5.23 2.63E-07 3.56E-02 ALU trans 
chr6 124865521 ALU_umary_ALU_5553 SOX30 5.23 2.68E-07 3.60E-02 ALU trans 
chr5 137130159 L1_umary_LINE1_1215 RP11-578F21.10 5.23 2.68E-07 3.60E-02 L1 trans 
chr4 100740869 ALU_umary_ALU_3545 AOAH 5.22 2.71E-07 3.64E-02 ALU trans 
chr6 122157421 SVA_umary_SVA_305 RP11-124N14.3 -5.22 2.79E-07 3.71E-02 SVA trans 
chr20 9605206 ALU_umary_ALU_12057 IGHV4-61 5.22 2.82E-07 3.74E-02 ALU trans 
chr1 100994221 ALU_umary_ALU_402 PHF2 -5.22 2.82E-07 3.74E-02 ALU trans 
chr3 29550384 ALU_umary_ALU_2253 ST3GAL6-AS1 5.21 2.86E-07 3.77E-02 ALU trans 
chr6 87678642 ALU_umary_ALU_5348 IGHV7-81 5.21 2.90E-07 3.82E-02 ALU trans 
chr3 47782873 ALU_umary_ALU_2333 PLA2G4C -5.21 2.95E-07 3.87E-02 ALU trans 
chr2 226970099 ALU_umary_ALU_2028 FERMT1 5.21 2.96E-07 3.88E-02 ALU trans 
chr1 58071869 ALU_umary_ALU_182 CD86 -5.20 2.99E-07 3.90E-02 ALU trans 
chr10 14396698 ALU_umary_ALU_7798 ZBTB38 5.20 3.05E-07 3.95E-02 ALU trans 
chr16 74897618 ALU_umary_ALU_11115 GUCY1B3 5.20 3.05E-07 3.95E-02 ALU trans 
chr8 79813676 L1_umary_LINE1_1693 ABCA4 5.20 3.11E-07 3.97E-02 L1 trans 
chr4 81899822 ALU_umary_ALU_3448 SAPCD2 -5.19 3.14E-07 3.99E-02 ALU trans 
chr8 77248370 ALU_umary_ALU_6854 SPRED2 5.19 3.15E-07 3.99E-02 ALU trans 
chr4 135130281 ALU_umary_ALU_3726 EGFL7 5.19 3.19E-07 4.03E-02 ALU trans 
chr5 89450997 L1_umary_LINE1_1164 ST8SIA1 -5.19 3.20E-07 4.03E-02 L1 trans 
chr18 5411665 ALU_umary_ALU_11513 RHBDL1 5.19 3.20E-07 4.03E-02 ALU trans 
chr2 160159011 ALU_umary_ALU_1684 LINC00638 5.19 3.30E-07 4.11E-02 ALU trans 
chr6 46310306 L1_umary_LINE1_1293 MAML2 -5.17 3.49E-07 4.29E-02 L1 trans 
chr5 33633348 L1_umary_LINE1_1089 MAML2 -5.17 3.55E-07 4.32E-02 L1 trans 
chr8 50147620 ALU_umary_ALU_6712 RP11-124N14.3 -5.17 3.55E-07 4.32E-02 ALU trans 
chr5 91031026 ALU_umary_ALU_4463 NRIP1 5.17 3.56E-07 4.32E-02 ALU trans 
chr15 24591239 ALU_umary_ALU_10560 LINC00649 5.17 3.61E-07 4.36E-02 ALU trans 
chr1 64850193 SVA_umary_SVA_35 NMT2 -5.17 3.61E-07 4.36E-02 SVA trans 
chr11 25605138 ALU_umary_ALU_8456 AC078899.1 -5.16 3.70E-07 4.42E-02 ALU trans 
chr17 54947583 ALU_umary_ALU_11371 DGKE -5.16 3.70E-07 4.42E-02 ALU cis 
chr14 22578806 ALU_umary_ALU_10141 PRIM1 -5.16 3.70E-07 4.42E-02 ALU trans 
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chr3 82615586 SVA_umary_SVA_174 BTG1 5.16 3.70E-07 4.42E-02 SVA trans 
chr5 55167661 ALU_umary_ALU_4287 RP11-122K13.12 5.16 3.74E-07 4.45E-02 ALU trans 
chr1 64958078 ALU_umary_ALU_211 SAPCD2 5.16 3.76E-07 4.46E-02 ALU trans 
chr4 76993824 ALU_umary_ALU_3412 RAB3IP 5.16 3.83E-07 4.51E-02 ALU trans 
chr9 94058487 L1_umary_LINE1_1863 IGLV2-34 5.15 3.84E-07 4.51E-02 L1 trans 
chr10 29105298 ALU_umary_ALU_7874 FTH1P12 -5.15 3.86E-07 4.52E-02 ALU trans 
chr1 178495286 ALU_umary_ALU_620 BRD7P3 5.15 3.91E-07 4.56E-02 ALU trans 
chr3 124568685 ALU_umary_ALU_2682 CHI3L1 5.15 3.92E-07 4.56E-02 ALU trans 
chr8 50550379 ALU_umary_ALU_6716 LGALS4 5.15 3.96E-07 4.58E-02 ALU trans 
chr10 58902214 ALU_umary_ALU_7994 DDI2 5.15 3.98E-07 4.59E-02 ALU trans 
chr10 94571333 ALU_umary_ALU_8168 ANKRD36BP2 5.14 4.13E-07 4.70E-02 ALU trans 
chr6 32687172 ALU_umary_ALU_5076 ATP4B 5.14 4.18E-07 4.73E-02 ALU trans 
chr3 137565396 ALU_umary_ALU_2733 FAM151B 5.14 4.18E-07 4.73E-02 ALU trans 
chr13 55438087 ALU_umary_ALU_9798 PCDHGA3 5.14 4.20E-07 4.73E-02 ALU trans 
chr6 153859178 ALU_umary_ALU_5702 PCBP3 5.14 4.20E-07 4.73E-02 ALU trans 
chr8 1310538 ALU_umary_ALU_6532 SAMD3 5.13 4.35E-07 4.83E-02 ALU trans 
chr11 9758001 ALU_umary_ALU_8374 SOCS2-AS1 5.13 4.36E-07 4.83E-02 ALU trans 
chr7 10215359 ALU_umary_ALU_5815 MEST 5.13 4.36E-07 4.83E-02 ALU trans 
chr8 107230078 ALU_umary_ALU_7010 TBC1D9B 5.13 4.37E-07 4.83E-02 ALU trans 
chr12 10234202 ALU_umary_ALU_8992 DHRS4-AS1 5.13 4.40E-07 4.85E-02 ALU trans 
chr7 128215395 SVA_umary_SVA_355 IGLL1 5.12 4.49E-07 4.91E-02 SVA trans 
chr4 176281836 ALU_umary_ALU_3956 SLC22A31 5.12 4.52E-07 4.93E-02 ALU trans 
chr17 43818955 ALU_umary_ALU_11327 AC022182.1 5.12 4.55E-07 4.94E-02 ALU trans 
chr4 180698483 ALU_umary_ALU_3979 CTSF 5.12 4.56E-07 4.94E-02 ALU trans 
chr9 72777422 L1_umary_LINE1_1833 SNORD3B-2 5.12 4.58E-07 4.94E-02 L1 trans 
chr4 123796599 ALU_umary_ALU_3659 PNPLA3 5.12 4.60E-07 4.94E-02 ALU trans 
chr11 55771332 ALU_umary_ALU_8585 CXCL12 5.12 4.62E-07 4.94E-02 ALU trans 
chr2 212708356 ALU_umary_ALU_1959 CECR2 5.12 4.67E-07 4.97E-02 ALU trans 
chr6 101194045 SVA_umary_SVA_298 PDK2 5.11 4.71E-07 4.99E-02 SVA trans 




Table 4 Functional enrichment of genes that are associated with TE-eQTL  









k/K p-value FDR q-value 
KEGG INTESTINAL 




network for IgA 
production 
11 0.2292 4.08E-14 4.40E-11 
KEGG TYPE I DIABETES 
MELLITUS 44 
Type I diabetes 
mellitus 8 0.1818 9.41E-10 5.07E-07 
KEGG CELL ADHESION 




11 0.0821 4.29E-09 1.54E-06 
KEGG ALLOGRAFT 
REJECTION 38 Allograft rejection 7 0.1842 9.83E-09 2.65E-06 
KEGG GRAFT VERSUS 
HOST DISEASE 42 
Graft-versus-host 
disease 7 0.1667 2.05E-08 4.42E-06 
REACTOME 
TRANSLOCATION OF ZAP 
70 TO IMMUNOLOGICAL 
SYNAPSE 
14 









infection 8 0.1111 5.34E-08 8.21E-06 
KEGG ASTHMA 30 Asthma 6 0.2 6.85E-08 9.21E-06 
REACTOME 
PHOSPHORYLATION OF 
CD3 AND TCR ZETA 
CHAINS 
16 
Genes involved in 
Phosphorylation 
of CD3 and TCR 
zeta chains 
5 0.3125 7.70E-08 9.21E-06 
KEGG AUTOIMMUNE 
THYROID DISEASE 53 
Autoimmune 
thyroid disease 7 0.1321 1.09E-07 1.18E-05 
REACTOME PD1 
SIGNALING 18 
Genes involved in 
PD-1 signaling 5 0.2778 1.49E-07 1.46E-05 
REACTOME 
COSTIMULATION BY THE 
CD28 FAMILY 
63 
Genes involved in 
Costimulation by 
the CD28 family 
7 0.1111 3.70E-07 3.32E-05 
KEGG VIRAL 
MYOCARDITIS 73 Viral myocarditis 7 0.0959 1.02E-06 8.48E-05 
REACTOME GENERATION 
OF SECOND MESSENGER 
MOLECULES 
27 




5 0.1852 1.33E-06 1.03E-04 
REACTOME ADAPTIVE 
IMMUNE SYSTEM 539 
Genes involved in 
Adaptive Immune 
System 








7 0.0787 3.92E-06 2.64E-04 
REACTOME MHC CLASS II 
ANTIGEN PRESENTATION 91 
Genes involved in 
MHC class II 
antigen 
presentation 
7 0.0769 4.55E-06 2.88E-04 
REACTOME IMMUNE 
SYSTEM 933 
Genes involved in 
Immune System 21 0.0225 5.29E-06 3.17E-04 
REACTOME INTERFERON 
GAMMA SIGNALING 63 
Genes involved in 
Interferon gamma 
signaling 
6 0.0952 6.42E-06 3.64E-04 
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Genes involved in 
Downstream TCR 
signaling 
5 0.1351 6.78E-06 3.65E-04 
REACTOME TCR 
SIGNALING 54 
Genes involved in 
TCR signaling 5 0.0926 4.45E-05 2.28E-03 
KEGG SYSTEMIC LUPUS 
ERYTHEMATOSUS 140 
Systemic lupus 




































4 0.0702 7.73E-04 2.97E-02 
REACTOME GAP 
JUNCTION TRAFFICKING 27 
Genes involved in 
Gap junction 
trafficking 




metabolism 6 0.0377 1.08E-03 3.76E-02 
REACTOME INTERFERON 
SIGNALING 159 
Genes involved in 
Interferon 
Signaling 





Table 5 Results for conditional association controls 
SNP TE Gene Gene ID Conditional P-value Group 
rs113175928 ALU_umary_ALU_6806 XKR9 ENSG00000221947 1.12E-22 EUR 
rs56289286 SVA_umary_SVA_706 LRRC37A4P ENSG00000214425 7.36E-15 EUR 
rs140032472 ALU_umary_ALU_9602 LINC00422 ENSG00000224429 2.81E-14 EUR 
rs150156751 ALU_umary_ALU_11979 ZNF880 ENSG00000221923 4.93E-13 EUR 
rs11485298 L1_umary_LINE1_61 CRYZ ENSG00000116791 1.67E-12 EUR 
rs138311123 SVA_umary_SVA_706 LRRC37A ENSG00000176681 1.21E-10 EUR 
rs138311123 SVA_umary_SVA_705 LRRC37A ENSG00000176681 2.81E-09 EUR 
rs56289286 SVA_umary_SVA_705 LRRC37A4P ENSG00000214425 8.64E-09 EUR 
rs9892659 ALU_umary_ALU_11371 DGKE ENSG00000153933 7.31E-08 EUR 
rs138311123 SVA_umary_SVA_704 LRRC37A ENSG00000176681 1.37E-07 EUR 
rs56289286 SVA_umary_SVA_704 LRRC37A4P ENSG00000214425 4.27E-07 EUR 
rs116628019 SVA_umary_SVA_282 HLA-DPA1 ENSG00000231389 5.16E-07 EUR 
rs12104210 ALU_umary_ALU_11997 ZFP28 ENSG00000196867 6.41E-07 EUR 
rs12150699 ALU_umary_ALU_11754 PIGN ENSG00000197563 7.27E-07 EUR 
rs138311123 SVA_umary_SVA_706 LRRC37A2 ENSG00000238083 1.37E-06 EUR 
rs35854157 ALU_umary_ALU_1256 SLC1A4 ENSG00000115902 3.79E-06 EUR 
rs71664293 ALU_umary_ALU_3295 SRD5A3 ENSG00000128039 6.06E-06 EUR 
rs138311123 SVA_umary_SVA_705 LRRC37A2 ENSG00000238083 7.40E-06 EUR 
rs9399043 ALU_umary_ALU_5602 RPS12 ENSG00000112306 9.13E-06 EUR 
rs140032472 ALU_umary_ALU_9603 LINC00422 ENSG00000224429 1.19E-05 EUR 
rs142039218 SVA_umary_SVA_706 GOSR2 ENSG00000108433 1.44E-05 EUR 
rs11714944 ALU_umary_ALU_2337 NME6 ENSG00000172113 2.11E-05 EUR 
rs116405062 ALU_umary_ALU_5075 HLA-DRB1 ENSG00000196126 4.54E-05 EUR 
rs9274660 ALU_umary_ALU_5075 HLA-DQB1 ENSG00000179344 6.26E-05 EUR 
rs116786525 ALU_umary_ALU_5053 HLA-G ENSG00000204632 9.13E-05 EUR 
rs35801758 ALU_umary_ALU_12145 CPNE1 ENSG00000214078 1.03E-04 EUR 
rs11070297 ALU_umary_ALU_10654 ZFYVE19 ENSG00000166140 3.16E-04 EUR 
rs175037 ALU_umary_ALU_10401 EIF2B2 ENSG00000119718 3.72E-04 EUR 
rs1660559 ALU_umary_ALU_884 RP4-781K5.6 ENSG00000230628 8.37E-04 EUR 
rs399970 ALU_umary_ALU_11997 ZNF470 ENSG00000197016 9.49E-04 EUR 
rs1061810 ALU_umary_ALU_8559 HSD17B12 ENSG00000149084 1.93E-03 EUR 
rs11160042 SVA_umary_SVA_615 NDUFB1 ENSG00000183648 2.31E-03 EUR 
rs2647071 SVA_umary_SVA_280 HLA-DRB5 ENSG00000198502 2.61E-03 EUR 
rs10193212 L1_umary_LINE1_477 MFSD6 ENSG00000151690 2.88E-03 EUR 
rs10431506 ALU_umary_ALU_9236 XRCC6BP1 ENSG00000166896 3.26E-03 EUR 
rs2647071 ALU_umary_ALU_5072 HLA-DRB5 ENSG00000198502 4.17E-03 EUR 
rs12629 ALU_umary_ALU_970 RNASEH1-AS1 ENSG00000234171 4.24E-03 EUR 
rs3824458 SVA_umary_SVA_401 B4GALT1 ENSG00000086062 4.25E-03 EUR 
rs2647071 ALU_umary_ALU_5079 HLA-DRB5 ENSG00000198502 5.18E-03 EUR 
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rs10431506 ALU_umary_ALU_9234 XRCC6BP1 ENSG00000166896 5.51E-03 EUR 
rs139480590 SVA_umary_SVA_706 CRHR1 ENSG00000120088 7.85E-03 EUR 
rs74687091 ALU_umary_ALU_7578 LINC00476 ENSG00000175611 1.19E-02 EUR 
rs2621323 ALU_umary_ALU_5079 TAP2 ENSG00000204267 1.39E-02 EUR 
rs4634177 SVA_umary_SVA_203 ZNF718 ENSG00000250312 2.40E-02 EUR 
rs56298119 ALU_umary_ALU_10302 TMX1 ENSG00000139921 2.70E-02 EUR 
rs7679215 ALU_umary_ALU_3997 CENPU ENSG00000151725 3.72E-02 EUR 
rs4309324 ALU_umary_ALU_10302 TRIM9 ENSG00000100505 5.14E-02 EUR 
rs71526018 ALU_umary_ALU_5888 CCDC126 ENSG00000169193 5.61E-02 EUR 
rs12200674 ALU_umary_ALU_5583 TMEM200A ENSG00000164484 6.92E-02 EUR 
rs74904447 ALU_umary_ALU_6178 TP53TG1 ENSG00000182165 7.76E-02 AFR 
rs10973388 ALU_umary_ALU_7420 POLR1E ENSG00000137054 1.38E-01 EUR 
rs7326010 ALU_umary_ALU_9777 ARL11 ENSG00000152213 2.26E-01 AFR 
rs3176891 ALU_umary_ALU_8182 ENTPD1 ENSG00000138185 2.53E-01 EUR 
rs199444 SVA_umary_SVA_706 WNT3 ENSG00000108379 2.71E-01 EUR 
rs2647071 ALU_umary_ALU_5075 HLA-DRB5 ENSG00000198502 3.07E-01 EUR 
rs35084227 L1_umary_LINE1_353 PLGLB1 ENSG00000183281 4.77E-01 EUR 
rs887307 SVA_umary_SVA_532 AKAP3 ENSG00000111254 4.90E-01 EUR 
rs139348312 SVA_umary_SVA_5 C1orf167 ENSG00000215910 5.52E-01 EUR 




Table 6 Results for regional association controls 







chr14 82223469 ALU_umary_ALU_10437 LRRC20 7.57E-10 1.09E-05 5.77E-04 ALU trans 
chr8 133725454 ALU_umary_ALU_7169 FAM65B 1.06E-09 9.31E-06 7.30E-04 ALU trans 
chr15 80662580 ALU_umary_ALU_10836 LGALS9B 1.47E-08 2.20E-04 5.78E-03 ALU trans 
chr3 6525411 ALU_umary_ALU_2124 GCLM 1.87E-08 3.24E-04 6.73E-03 ALU trans 
chr15 81392597 ALU_umary_ALU_10841 PSD4 2.47E-08 3.53E-04 8.38E-03 ALU trans 
chr6 104772669 ALU_umary_ALU_5447 HSPE1P8 2.74E-08 3.80E-04 8.92E-03 ALU trans 
chr7 6314063 ALU_umary_ALU_5788 REL 3.96E-08 4.24E-04 1.10E-02 ALU trans 
chr18 50097757 L1_umary_LINE1_2823 TP53BP2 4.13E-08 2.54E-04 1.13E-02 L1 trans 
chr14 66934461 ALU_umary_ALU_10374 SSPN 4.24E-08 2.60E-04 1.14E-02 ALU trans 
chr3 44340304 ALU_umary_ALU_2324 MAPK9 8.02E-08 9.20E-04 1.79E-02 ALU trans 
chr12 75931101 ALU_umary_ALU_9345 ENPP5 8.76E-08 1.21E-03 1.91E-02 ALU trans 
chr7 52789472 L1_umary_LINE1_1509 N6AMT2 9.33E-08 1.57E-03 1.99E-02 L1 trans 
chr4 86099317 ALU_umary_ALU_3472 PPFIBP1 9.49E-08 1.15E-03 2.00E-02 ALU trans 
chr10 105817214 ALU_umary_ALU_8203 
AC005740
.3 1.11E-07 1.46E-03 2.17E-02 ALU trans 
chr20 17860937 L1_umary_LINE1_2915 NPRL3 1.26E-07 9.48E-04 2.35E-02 L1 trans 
chr11 88908952 ALU_umary_ALU_8717 
HMGB1P
1 1.40E-07 2.11E-03 2.48E-02 ALU trans 
chr11 100911793 ALU_umary_ALU_8790 USP32 1.46E-07 5.68E-04 2.57E-02 ALU trans 
chr19 18835612 SVA_umary_SVA_743 SSTR3 1.73E-07 2.56E-03 2.85E-02 SVA trans 
chr17 70696176 ALU_umary_ALU_11447 TMEM159 1.74E-07 2.73E-03 2.85E-02 ALU trans 
chr1 102920544 ALU_umary_ALU_412 
RP11-
670E13.5 1.84E-07 2.75E-03 2.90E-02 ALU trans 
chr8 87315040 L1_umary_LINE1_1704 EMBP1 2.32E-07 2.02E-03 3.34E-02 L1 trans 
chr3 186372141 L1_umary_LINE1_761 TBC1D1 2.40E-07 3.56E-03 3.40E-02 L1 trans 
chr21 28221359 ALU_umary_ALU_12341 
KANSL1-
AS1 2.45E-07 1.82E-03 3.46E-02 ALU trans 
chr12 70788935 ALU_umary_ALU_9313 CDC5L 2.46E-07 2.52E-03 3.46E-02 ALU trans 
chr7 42647660 ALU_umary_ALU_5994 
RP11-
336N8.4 2.61E-07 3.70E-03 3.54E-02 ALU trans 
chr10 14396698 ALU_umary_ALU_7798 ZBTB38 3.05E-07 2.90E-03 3.95E-02 ALU trans 
chr2 160159011 ALU_umary_ALU_1684 
LINC0063
8 3.30E-07 4.47E-03 4.11E-02 ALU trans 
chr3 82615586 SVA_umary_SVA_174 BTG1 3.70E-07 5.18E-03 4.42E-02 SVA trans 
chr4 76993824 ALU_umary_ALU_3412 RAB3IP 3.83E-07 5.26E-03 4.51E-02 ALU trans 
chr1 178495286 ALU_umary_ALU_620 BRD7P3 3.91E-07 2.63E-03 4.56E-02 ALU trans 
chr8 107230078 ALU_umary_ALU_7010 TBC1D9B 4.37E-07 5.80E-03 4.83E-02 ALU trans 
chr6 101194045 SVA_umary_SVA_298 PDK2 4.71E-07 6.17E-03 4.99E-02 SVA trans 
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chr4 175534305 ALU_umary_ALU_3953 CDK11A 4.71E-07 6.61E-03 4.99E-02 ALU trans 
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Table 7 eQTL results for known Pax5 target genes that are associated with Alu-7481 
Gene t Statistic P-value FDR eQTL type 
PIK3AP1 5.63 3.13E-08 9.42E-03 trans 
ZSCAN23 5.45 8.54E-08 1.87E-02 trans 
REL 5.43 9.55E-08 2.00E-02 trans 
TBC1D1 5.03 7.15E-07 6.16E-02 trans 
GPR183 4.84 1.80E-06 9.49E-02 trans 
CCDC19 4.78 2.43E-06 1.08E-01 trans 
RAB27A 4.74 2.93E-06 1.18E-01 trans 
MYO7B 4.71 3.30E-06 1.24E-01 trans 
ARHGEF7 4.67 3.92E-06 1.33E-01 trans 
C7orf50 4.47 9.93E-06 1.89E-01 trans 
STK17B 4.43 1.18E-05 2.03E-01 trans 
CHMP4B 4.36 1.63E-05 2.26E-01 trans 
TMEM38A 4.36 1.65E-05 2.26E-01 trans 
ACTR2 4.30 2.08E-05 2.44E-01 trans 
TMEM37 4.28 2.27E-05 2.51E-01 trans 
BMPR1A 4.24 2.75E-05 2.66E-01 trans 
NOL7 4.16 3.82E-05 2.91E-01 trans 
SEMA7A 4.15 4.00E-05 2.94E-01 trans 
B3GNT2 4.06 5.72E-05 3.26E-01 trans 
PIKFYVE 4.06 5.77E-05 3.27E-01 trans 
CAPZA1 4.06 5.86E-05 3.27E-01 trans 
ESAM 4.06 5.88E-05 3.27E-01 trans 
DOCK9 4.05 5.94E-05 3.28E-01 trans 
UBL3 4.05 5.97E-05 3.28E-01 trans 
TMEM123 4.04 6.25E-05 3.32E-01 trans 
CD40 4.03 6.49E-05 3.36E-01 trans 
PTPN2 4.01 7.00E-05 3.43E-01 trans 
CD82 4.01 7.10E-05 3.44E-01 trans 
CSK 4.00 7.28E-05 3.47E-01 trans 
KLF3 4.00 7.48E-05 3.50E-01 trans 
UBE3A 3.94 9.33E-05 3.69E-01 trans 
ARHGEF1 3.93 9.81E-05 3.74E-01 trans 
NT5C 3.93 1.00E-04 3.76E-01 trans 
STRN 3.93 1.00E-04 3.76E-01 trans 
HIVEP2 3.91 1.05E-04 3.80E-01 trans 
STAP1 3.89 1.16E-04 3.90E-01 trans 
MGAT5 3.88 1.23E-04 3.95E-01 trans 
TSSC1 3.86 1.30E-04 4.02E-01 trans 
LILRB2 3.83 1.44E-04 4.13E-01 trans 
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DNAJA2 3.82 1.52E-04 4.18E-01 trans 
DHRS7 3.81 1.58E-04 4.21E-01 trans 
LEMD3 3.79 1.69E-04 4.27E-01 trans 
PRMT6 3.77 1.83E-04 4.35E-01 trans 
RBM43 3.74 2.09E-04 4.47E-01 trans 
TET3 3.74 2.11E-04 4.48E-01 trans 
RAB28 3.73 2.18E-04 4.51E-01 trans 
SH2D3A 3.73 2.18E-04 4.51E-01 trans 
NXPH3 3.72 2.29E-04 4.56E-01 trans 
HESX1 3.71 2.30E-04 4.57E-01 trans 
CR2 3.71 2.31E-04 4.57E-01 trans 
GADD45B 3.71 2.38E-04 4.60E-01 trans 
JAK1 3.69 2.55E-04 4.67E-01 trans 
DTNBP1 3.67 2.68E-04 4.72E-01 trans 
AGGF1 3.66 2.86E-04 4.78E-01 trans 
CHMP2A 3.65 2.96E-04 4.82E-01 trans 
INO80C 3.64 3.03E-04 4.84E-01 trans 
SLC46A3 3.63 3.13E-04 4.87E-01 trans 
VANGL1 3.63 3.15E-04 4.88E-01 trans 
COASY 3.62 3.25E-04 4.91E-01 trans 
SFT2D2 3.61 3.35E-04 4.95E-01 trans 
GPSM3 3.61 3.44E-04 4.97E-01 trans 
KIF26B 3.60 3.55E-04 5.00E-01 trans 
RCSD1 3.59 3.71E-04 5.04E-01 trans 
MRPS18A 3.58 3.85E-04 5.08E-01 trans 
IFT52 3.58 3.87E-04 5.08E-01 trans 
SETBP1 3.56 4.12E-04 5.15E-01 trans 
ASPHD2 3.54 4.37E-04 5.21E-01 trans 
FRY 3.54 4.40E-04 5.22E-01 trans 
PTPN22 3.54 4.49E-04 5.24E-01 trans 
SH3RF1 3.53 4.51E-04 5.24E-01 trans 
LNPEP 3.51 4.89E-04 5.33E-01 trans 
FAM188B 3.50 5.08E-04 5.37E-01 trans 
PSAP 3.50 5.20E-04 5.40E-01 trans 
CD38 3.48 5.50E-04 5.45E-01 trans 
RAB8B 3.48 5.54E-04 5.46E-01 trans 
ATF6 3.48 5.57E-04 5.46E-01 trans 
OXCT1 3.48 5.58E-04 5.47E-01 trans 
XPR1 3.47 5.76E-04 5.50E-01 trans 
DEK 3.46 5.90E-04 5.52E-01 trans 
ZCCHC7 3.43 6.68E-04 5.65E-01 trans 
CD19 3.42 6.88E-04 5.68E-01 trans 
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PHOSPHO1 3.41 7.03E-04 5.70E-01 trans 
PLCL2 3.41 7.20E-04 5.72E-01 trans 
P2RX5 3.39 7.64E-04 5.78E-01 trans 
ASB7 3.39 7.68E-04 5.79E-01 trans 
TNIP2 3.38 7.76E-04 5.80E-01 trans 
RHOH 3.38 7.86E-04 5.82E-01 trans 
SNAPC4 3.38 7.92E-04 5.82E-01 trans 
MRPS23 3.38 8.01E-04 5.83E-01 trans 
NAT14 3.37 8.06E-04 5.84E-01 trans 
FCRL3 3.37 8.14E-04 5.85E-01 trans 
T 3.37 8.15E-04 5.85E-01 trans 
KIAA0226L 3.36 8.49E-04 5.89E-01 trans 
PPP1R18 3.36 8.50E-04 5.89E-01 trans 
KCNN1 3.36 8.58E-04 5.90E-01 trans 
USP18 3.35 8.64E-04 5.91E-01 trans 
ATP6V0E2 3.35 8.81E-04 5.93E-01 trans 
AP1B1 3.34 8.96E-04 5.95E-01 trans 
PLEKHF2 3.33 9.29E-04 5.99E-01 trans 
ACTB 3.33 9.35E-04 5.99E-01 trans 
BAD 3.29 1.07E-03 6.11E-01 trans 
FAM96A 3.29 1.09E-03 6.13E-01 trans 
PDCD2 3.29 1.09E-03 6.14E-01 trans 
TMEM131 3.27 1.17E-03 6.20E-01 trans 
DDX21 3.26 1.20E-03 6.23E-01 trans 
FAM65B 3.26 1.22E-03 6.25E-01 trans 
RALA 3.25 1.24E-03 6.26E-01 trans 
ZNF837 3.25 1.26E-03 6.28E-01 trans 
ILK 3.24 1.28E-03 6.30E-01 trans 
RNF146 3.24 1.31E-03 6.32E-01 trans 
MYBL1 3.23 1.33E-03 6.34E-01 trans 
KIAA1147 3.22 1.36E-03 6.36E-01 trans 
SLC35A4 3.22 1.37E-03 6.37E-01 trans 
LAMP3 3.22 1.39E-03 6.38E-01 trans 
SAMD10 3.21 1.42E-03 6.39E-01 trans 
GEMIN7 3.20 1.47E-03 6.42E-01 trans 
EBI3 3.20 1.48E-03 6.43E-01 trans 
MYL12A 3.19 1.52E-03 6.46E-01 trans 
LSM11 3.19 1.53E-03 6.47E-01 trans 
TET2 3.18 1.56E-03 6.48E-01 trans 
IPO8 3.17 1.61E-03 6.51E-01 trans 
C19orf84 3.17 1.61E-03 6.51E-01 trans 
BCL2A1 3.17 1.61E-03 6.52E-01 trans 
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CYCS 3.17 1.63E-03 6.52E-01 trans 
ZNF608 3.16 1.66E-03 6.54E-01 trans 
GUCY1B3 3.16 1.69E-03 6.55E-01 trans 
ZNF783 3.15 1.73E-03 6.57E-01 trans 
MRS2 3.15 1.76E-03 6.60E-01 trans 
TMEM154 3.13 1.89E-03 6.66E-01 trans 
MATN1 3.12 1.95E-03 6.69E-01 trans 
TMEM230 3.12 1.96E-03 6.69E-01 trans 
UBASH3A 3.11 2.02E-03 6.72E-01 trans 
RGS3 3.10 2.03E-03 6.72E-01 trans 
ZNF717 3.10 2.04E-03 6.73E-01 trans 
DBNDD1 3.09 2.12E-03 6.76E-01 trans 
PAN3 3.09 2.14E-03 6.77E-01 trans 
ACTR3 3.09 2.15E-03 6.77E-01 trans 
COPS3 3.09 2.15E-03 6.77E-01 trans 
VPS13D 3.08 2.17E-03 6.78E-01 trans 
BNIP1 3.08 2.21E-03 6.79E-01 trans 
HEATR6 3.07 2.27E-03 6.82E-01 trans 
MARCKS 3.07 2.31E-03 6.83E-01 trans 
SLC37A1 3.06 2.33E-03 6.84E-01 trans 
LATS2 3.06 2.34E-03 6.84E-01 trans 
NUS1 3.06 2.36E-03 6.85E-01 trans 
PIP5K1B 3.06 2.37E-03 6.85E-01 trans 
MTPN 3.06 2.38E-03 6.86E-01 trans 
CSNK1G2 3.03 2.62E-03 6.94E-01 trans 
WDSUB1 3.03 2.62E-03 6.95E-01 trans 
ADAP1 3.03 2.63E-03 6.95E-01 trans 
MAPKAPK2 3.02 2.65E-03 6.95E-01 trans 
ID3 3.01 2.77E-03 6.99E-01 trans 
ATP5L 3.01 2.79E-03 6.99E-01 trans 
VASP 3.00 2.81E-03 7.00E-01 trans 
RBM38 3.00 2.83E-03 7.01E-01 trans 
PPFIBP1 3.00 2.84E-03 7.01E-01 trans 
FIG4 2.99 2.92E-03 7.04E-01 trans 
ZNF621 2.99 2.92E-03 7.04E-01 trans 
SCIMP 2.99 2.93E-03 7.04E-01 trans 
RIN3 2.99 2.94E-03 7.04E-01 trans 
EML3 2.99 2.94E-03 7.04E-01 trans 
SMIM11 2.99 2.98E-03 7.05E-01 trans 
GNG2 2.98 3.09E-03 7.07E-01 trans 
KLF13 2.97 3.10E-03 7.08E-01 trans 
SLC16A11 2.97 3.11E-03 7.08E-01 trans 
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TTC39B 2.97 3.15E-03 7.09E-01 trans 
BTF3 2.96 3.22E-03 7.11E-01 trans 
FBXW11 2.96 3.25E-03 7.11E-01 trans 
LYRM9 2.96 3.26E-03 7.12E-01 trans 
CMKLR1 2.96 3.27E-03 7.12E-01 trans 
ZNF215 2.95 3.31E-03 7.13E-01 trans 
TTC38 2.95 3.33E-03 7.14E-01 trans 
ABHD17B 2.95 3.38E-03 7.15E-01 trans 
TINF2 2.94 3.40E-03 7.16E-01 trans 
OSBPL3 2.94 3.45E-03 7.17E-01 trans 
LBH 2.94 3.49E-03 7.18E-01 trans 
TRIP10 2.93 3.57E-03 7.19E-01 trans 
DBT 2.92 3.73E-03 7.22E-01 trans 
C20orf196 2.91 3.78E-03 7.23E-01 trans 
C9orf9 2.91 3.79E-03 7.24E-01 trans 
UBAC2 2.90 3.98E-03 7.28E-01 trans 
ATP6V1E2 2.90 3.98E-03 7.28E-01 trans 
MAP2K6 2.89 3.98E-03 7.28E-01 trans 
POMP 2.89 3.99E-03 7.29E-01 trans 
TWISTNB 2.89 4.10E-03 7.30E-01 trans 
TTC24 2.88 4.13E-03 7.31E-01 trans 
SLC10A7 2.88 4.14E-03 7.31E-01 trans 
SC5D 2.88 4.22E-03 7.32E-01 trans 
LYN 2.88 4.23E-03 7.33E-01 trans 
FLYWCH2 2.87 4.29E-03 7.34E-01 trans 
CNP 2.86 4.40E-03 7.36E-01 trans 
CD83 2.86 4.40E-03 7.36E-01 trans 
ALDH3A1 2.85 4.56E-03 7.39E-01 trans 
BCL2L13 2.85 4.58E-03 7.39E-01 trans 
IFITM3 2.84 4.72E-03 7.42E-01 trans 
MTA2 2.84 4.77E-03 7.42E-01 trans 
PHLDB3 2.83 4.80E-03 7.43E-01 trans 
EIF1B 2.83 4.87E-03 7.44E-01 trans 
VTI1A 2.83 4.89E-03 7.44E-01 trans 
CSTF3 2.83 4.93E-03 7.45E-01 trans 
RASD1 2.82 5.02E-03 7.46E-01 trans 
PAK1IP1 2.82 5.02E-03 7.46E-01 trans 
PARP12 2.82 5.07E-03 7.47E-01 trans 
GRK5 2.81 5.14E-03 7.48E-01 trans 
TIGIT 2.81 5.15E-03 7.48E-01 trans 
FBXL14 2.81 5.16E-03 7.49E-01 trans 
SNX3 2.81 5.16E-03 7.49E-01 trans 
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FASTKD2 2.81 5.20E-03 7.49E-01 trans 
PIK3R5 2.80 5.29E-03 7.51E-01 trans 
GHITM 2.80 5.34E-03 7.51E-01 trans 
RFX3 2.80 5.36E-03 7.52E-01 trans 
ST3GAL2 2.79 5.47E-03 7.53E-01 trans 
ABHD3 2.79 5.47E-03 7.53E-01 trans 
PSMD6 2.79 5.50E-03 7.53E-01 trans 
CDKN2D 2.79 5.51E-03 7.53E-01 trans 
CWC22 2.79 5.54E-03 7.54E-01 trans 
MMD 2.78 5.61E-03 7.55E-01 trans 
ACYP2 2.78 5.64E-03 7.55E-01 trans 
MED13 2.78 5.66E-03 7.56E-01 trans 
TAOK1 2.78 5.71E-03 7.56E-01 trans 
SRP19 2.78 5.73E-03 7.57E-01 trans 
DCXR 2.77 5.91E-03 7.59E-01 trans 
PTPN12 2.77 5.92E-03 7.59E-01 trans 
EFHD2 2.75 6.15E-03 7.62E-01 trans 
CTDSPL2 2.75 6.18E-03 7.62E-01 trans 
NEK7 2.75 6.29E-03 7.64E-01 trans 
MAPK6 2.74 6.36E-03 7.65E-01 trans 
KCNC3 2.74 6.43E-03 7.66E-01 trans 
TAF10 2.74 6.44E-03 7.66E-01 trans 
CHST2 2.74 6.46E-03 7.66E-01 trans 
GRK4 2.73 6.64E-03 7.68E-01 trans 
ANAPC13 2.73 6.65E-03 7.68E-01 trans 
ILKAP 2.72 6.77E-03 7.70E-01 trans 
PPP4R2 2.72 6.78E-03 7.70E-01 trans 
STT3B 2.71 6.94E-03 7.72E-01 trans 
MYO1G 2.71 6.96E-03 7.72E-01 trans 
RCAN1 2.71 6.98E-03 7.72E-01 trans 
DCK 2.71 7.03E-03 7.73E-01 trans 
TBC1D12 2.71 7.06E-03 7.73E-01 trans 
ELOVL6 2.70 7.10E-03 7.74E-01 trans 
SRD5A1 2.70 7.25E-03 7.75E-01 trans 
MFN1 2.70 7.28E-03 7.76E-01 trans 
GIPR 2.69 7.32E-03 7.76E-01 trans 
ETF1 2.69 7.40E-03 7.77E-01 trans 
SPN 2.69 7.45E-03 7.77E-01 trans 
SEPP1 2.68 7.54E-03 7.78E-01 trans 
HECA 2.68 7.66E-03 7.79E-01 trans 
CBX5 2.68 7.70E-03 7.80E-01 trans 
NRSN2 2.67 7.83E-03 7.81E-01 trans 
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PRR14 2.67 7.84E-03 7.81E-01 trans 
TIMM8B 2.67 7.88E-03 7.82E-01 trans 
CCDC71 2.67 7.97E-03 7.82E-01 trans 
MVD 2.66 8.01E-03 7.83E-01 trans 
CDYL 2.65 8.27E-03 7.85E-01 trans 
SLC50A1 2.65 8.40E-03 7.86E-01 trans 
MYL12B 2.64 8.49E-03 7.87E-01 trans 
C17orf62 2.64 8.49E-03 7.87E-01 trans 
LDLR 2.64 8.53E-03 7.88E-01 trans 
GPR63 2.63 8.80E-03 7.90E-01 trans 
MCOLN2 2.63 8.86E-03 7.91E-01 trans 
IFNGR1 2.63 8.93E-03 7.91E-01 trans 
ALAD 2.62 8.99E-03 7.92E-01 trans 
PNKP 2.62 9.00E-03 7.92E-01 trans 
SNAPC2 2.62 9.04E-03 7.92E-01 trans 
GTF3C1 2.62 9.05E-03 7.92E-01 trans 
CRTC3 2.62 9.17E-03 7.93E-01 trans 
PPP6R3 2.62 9.22E-03 7.94E-01 trans 
MIOS 2.62 9.23E-03 7.94E-01 trans 
MOB3C 2.60 9.58E-03 7.96E-01 trans 
RSL24D1 2.60 9.64E-03 7.97E-01 trans 
COX16 2.60 9.65E-03 7.97E-01 trans 
MFSD3 2.60 9.68E-03 7.97E-01 trans 
TBCA 2.59 9.89E-03 7.98E-01 trans 





APPENDIX C.  
SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
Table 8 Top LD results for polyTE for African population 
TE GWAS hits GWAS phenotype GWAS gene r 
ALU_umary_ALU_64 rs4654899 Superior frontal gyrus grey matter volume EIF4G3 0.46 
ALU_umary_ALU_102 rs96067 Corneal structure COL8A2 0.65 
ALU_umary_ALU_153 rs17106184 Type 2 diabetes FAF1 0.43 
ALU_umary_ALU_216 rs10889569 C-reactive protein LEPR -0.59 
ALU_umary_ALU_224 rs1417437 Orofacial clefts LRRC7 0.50 
ALU_umary_ALU_226 rs11809230 Cannabis use (initiation) . 0.74 
ALU_umary_ALU_250 rs10789369 Schizophrenia KRT8P21,LRRIQ3 0.51 
ALU_umary_ALU_267 rs1857353 MRI atrophy measures SLC44A5 0.40 
ALU_umary_ALU_335 rs17131547 Bone mineral density TGFBR3 0.41 
ALU_umary_ALU_368 rs6675668 Stearic acid (18:0) plasma levels ALG14 0.45 
L1_umary_LINE1_99 rs11578152 Menarche (age at onset) DNAJA1P5,COL11A1 0.53 
SVA_umary_SVA_45 rs7411387 Interferon alpha levels in systemic lupus erythematosus CHIA 0.40 
ALU_umary_ALU_542 rs6427528 Response to anti-TNF treatment in rheumatoid arthritis CD84 0.40 
SVA_umary_SVA_57 rs4657482 Testicular germ cell tumor UCK2 0.41 
ALU_umary_ALU_580 rs6687813 D-dimer levels SLC19A2,F5 0.63 
L1_umary_LINE1_164 rs6703865 Hippocampal atrophy F5 0.58 
ALU_umary_ALU_668 rs12720541 Epilepsy (generalized) PLA2G4A 0.41 
ALU_umary_ALU_676 rs10737562 Systemic lupus erythematosus RNA5SP73,BRINP3 0.59 
ALU_umary_ALU_689 rs10801047 Crohn's disease HNRNPA1P46,RGS18 0.51 
ALU_umary_ALU_699 rs6678275 Alzheimer's disease (late onset) B3GALT2,RPL23AP22 0.53 
ALU_umary_ALU_716 rs426736 Meningococcal disease CFHR3 0.65 
ALU_umary_ALU_717 rs426736 Meningococcal disease CFHR3 0.88 
ALU_umary_ALU_718 rs426736 Meningococcal disease CFHR3 0.89 
ALU_umary_ALU_842 rs12410462 Major depressive disorder BTF3P9,TUBB8P10 0.64 
ALU_umary_ALU_884 rs482329 Life threatening arrhythmia LINC00184,LINC01132 -0.54 
ALU_umary_ALU_897 rs2820037 Hypertension RPL39P10,CHRM3 0.59 
ALU_umary_ALU_903 rs476141 Diabetic retinopathy LOC339529 0.45 
ALU_umary_ALU_940 rs10802346 Fractional exhaled nitric oxide (childhood) SMYD3 -0.46 
ALU_umary_ALU_971 rs11123610 
Response to inhaled corticosteroid 
treatment in asthma (percentage 
change of FEV1) 
ALLC -0.41 
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L1_umary_LINE1_266 rs17043947 Self-rated health RNA5SP87,KLHL29 0.61 
L1_umary_LINE1_267 rs2681019 Dialysis-related mortality RNA5SP87,KLHL29 -0.53 
ALU_umary_ALU_1078 rs7601155 Waist circumference BRE 0.44 
L1_umary_LINE1_286 rs6750486 Conduct disorder (symptom count) SLC25A5P2,MIR548AD 0.43 
ALU_umary_ALU_1156 rs4245791 LDL cholesterol ABCG8 0.60 
ALU_umary_ALU_1163 rs2341459 Height CAMKMT -0.58 
ALU_umary_ALU_1184 rs12987465 




ALU_umary_ALU_1207 rs2163237 IgG glycosylation PNPT1,EFEMP1 0.42 
ALU_umary_ALU_1221 rs889956 Educational attainment EIF2S2P7,VRK2 0.44 
ALU_umary_ALU_1224 rs17552189 Cannabis dependence LINC01122 0.45 
ALU_umary_ALU_1231 rs17552189 Cannabis dependence LINC01122 0.48 
ALU_umary_ALU_1273 rs4141819 Endometriosis ETAA1,C1D 0.71 
ALU_umary_ALU_1275 rs2901879 Colorectal cancer (diet interaction) MEIS1-AS2,DNMT3AP1 0.42 
ALU_umary_ALU_1277 rs6759808 Obesity-related traits PLEK,FBXO48 -0.45 
ALU_umary_ALU_1278 rs10208940 Urate levels in lean individuals . -0.56 
L1_umary_LINE1_337 rs13391552 Metabolic traits ALMS1 0.43 
ALU_umary_ALU_1324 rs2037723 
Lung function (forced expiratory 
volume in 1 second to forced vital 
capacity ratio) 
SNAR-H,CYCSP6 0.67 
L1_umary_LINE1_366 rs4321386 Hormone measurements IL1R2 0.42 
ALU_umary_ALU_1406 rs2163349 Addiction NCK2 -0.71 
ALU_umary_ALU_1517 rs17015535 Coronary artery calcification WDR33 0.56 
ALU_umary_ALU_1557 rs13405020 Non-small cell lung cancer THSD7B 0.64 
ALU_umary_ALU_1585 rs17515225 Motion sickness LRP1B 0.58 
ALU_umary_ALU_1621 rs7584099 Response to statin therapy PABPC1P2,RPL26P14 0.58 
ALU_umary_ALU_1623 rs2307394 Urate levels ORC4 0.70 
ALU_umary_ALU_1693 rs10192369 Amyotrophic lateral sclerosis MIR4785,TANK 0.43 
ALU_umary_ALU_1736 rs2102808 Parkinson's disease PHF5GP,CERS6 0.51 
ALU_umary_ALU_1740 rs16856332 Liver enzyme levels (alkaline phosphatase) ABCB11 0.41 
ALU_umary_ALU_1756 rs836589 Erectile dysfunction in type 1 diabetes PDK1,RAPGEF4-AS1 -0.57 
ALU_umary_ALU_1778 rs9287989 Periodontal microbiota EXTL2P1,KIAA1715 -0.60 
ALU_umary_ALU_1802 rs16867321 Obesity CWC22,SCHLAP1 0.68 
ALU_umary_ALU_1824 rs11678036 IgG glycosylation RPL23AP33,ELF2P4 -0.60 
ALU_umary_ALU_1843 rs2675399 Obesity-related traits DIRC1,COL3A1 0.65 
ALU_umary_ALU_1869 rs801350 
Response to anti-retroviral therapy 
(ddI/d4T) in HIV-1 infection 
(Grade 3 peripheral neuropathy) 
HNRNPA1P47,AHCYP5 0.68 
ALU_umary_ALU_1871 rs801350 
Response to anti-retroviral therapy 
(ddI/d4T) in HIV-1 infection 
(Grade 3 peripheral neuropathy) 
HNRNPA1P47,AHCYP5 0.49 
ALU_umary_ALU_1894 rs6434928 Schizophrenia SF3B1,COQ10B 0.48 
L1_umary_LINE1_488 rs988583 Neutrophil count PLCL1 0.60 
ALU_umary_ALU_1903 rs12471454 Insomnia PLCL1,SATB2 0.62 
ALU_umary_ALU_1943 rs13383928 Lung cancer-asbestos exposure interaction LOC101927960 0.77 
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ALU_umary_ALU_1963 rs4673659 Asthma (sex interaction) ERBB4 0.42 
ALU_umary_ALU_1971 rs9789347 Obesity-related traits SPAG16 0.64 
ALU_umary_ALU_1987 rs16857609 Breast cancer DIRC3 0.49 
ALU_umary_ALU_2009 rs10170846 Schizophrenia (inflammation and infection response interaction) . 0.52 
ALU_umary_ALU_2069 rs2292873 Obesity-related traits RAB17 0.47 
ALU_umary_ALU_2101 rs7652782 Serum uric acid levels CNTN4 0.62 
ALU_umary_ALU_2109 rs2587949 Periodontitis (DPAL) SUMF1 -0.72 
ALU_umary_ALU_2114 rs1810320 Breast cancer GRM7 0.43 
SVA_umary_SVA_157 rs3729931 Cardiac hypertrophy RAF1 0.56 
ALU_umary_ALU_2164 rs1318937 Alcohol dependence SH3BP5,SH3BP5-AS1 -0.66 
ALU_umary_ALU_2289 rs13072940 
Autism spectrum disorder  attention 
deficit-hyperactivity disorder  
bipolar disorder  major depressive 
disorder  and schizophrenia 
(combined) 
HSPD1P6,TRANK1 -0.60 
L1_umary_LINE1_580 rs3922844 PR interval SCN5A 0.82 
ALU_umary_ALU_2333 rs319690 Blood pressure MAP4 0.77 
SVA_umary_SVA_170 rs9876781 Longevity ATRIP 0.41 
ALU_umary_ALU_2340 rs11719291 Cognitive function IP6K2 0.47 
ALU_umary_ALU_2346 rs7613875 Body mass index . 0.48 
ALU_umary_ALU_2349 rs11130248 Keloid . 0.50 
ALU_umary_ALU_2371 rs6764184 Optic cup area . 0.63 
L1_umary_LINE1_629 rs17518584 Cognitive function CADM2 0.60 
ALU_umary_ALU_2504 rs9883474 Brain connectivity KRT8P25,APOOP2 -0.48 
ALU_umary_ALU_2577 rs10511217 Economic and political preferences (environmentalism) MIR548AB,RAP1BP2 0.66 
ALU_umary_ALU_2578 rs2677247 IgG glycosylation MIR548AB,RAP1BP2 0.70 
ALU_umary_ALU_2616 rs1881681 Current cigarettes per day in onic obstructive pulmonary disease PVRL3,CD96 0.41 
ALU_umary_ALU_2627 rs13092825 Dental caries . 0.46 
ALU_umary_ALU_2637 rs9841504 Gastric cancer LOC102723469,ZBTB20 0.57 
ALU_umary_ALU_2654 rs6804441 Systemic lupus erythematosus CD80 0.42 
ALU_umary_ALU_2693 rs13075436 Response to angiotensin II receptor blocker therapy C3orf56,TPRA1 0.42 
ALU_umary_ALU_2696 rs2687729 Menarche (age at onset) EEFSEC 0.50 
ALU_umary_ALU_2697 rs2712381 Monocyte count RPN1 -0.66 
ALU_umary_ALU_2698 rs1534166 Alcohol consumption (transferrin glycosylation) SRPRB 0.42 
ALU_umary_ALU_2757 rs3773506 Type 2 diabetes PLS1 0.78 
ALU_umary_ALU_2795 rs13072552 Serum ceruloplasmin levels CP 0.44 
ALU_umary_ALU_2810 rs1351267 Schizophrenia SUCNR1,MBNL1 -0.42 
ALU_umary_ALU_2838 rs12638253 Multiple sclerosis (severity) LEKR1 0.41 
ALU_umary_ALU_2842 rs13064954 Smoking cessation in onic obstructive pulmonary disease LINC00881,CCNL1 0.71 
L1_umary_LINE1_723 rs2362965 Height RSRC1 0.43 
ALU_umary_ALU_2847 rs2362965 Height RSRC1 0.49 
ALU_umary_ALU_2911 rs2201862 Myeloproliferative neoplasms . 0.42 
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ALU_umary_ALU_2929 rs3913363 Response to angiotensin II receptor blocker therapy TMEM212,FNDC3B 0.44 
L1_umary_LINE1_761 rs9898 Activated partial thromboplastin time HRG 0.46 
ALU_umary_ALU_3022 rs10937470 Total ventricular volume UTS2B 0.83 
ALU_umary_ALU_3079 rs4619890 Glaucoma (primary open-angle) AFAP1 0.46 
ALU_umary_ALU_3085 rs13142500 Rheumatoid arthritis CLNK,RNPS1P1 0.66 
ALU_umary_ALU_3178 rs7442317 Attention deficit hyperactivity disorder motor coordination EEF1A1P21,RPS3AP17 -0.65 
ALU_umary_ALU_3235 rs35141484 Asthma (childhood onset) KLHL5 0.56 
ALU_umary_ALU_3236 rs11096990 Cognitive function WDR19 0.42 
ALU_umary_ALU_3244 rs10938397 Body mass index PRDX4P1,PRKRIRP9 0.41 
ALU_umary_ALU_3246 rs114070671 Opioid sensitivity APBB2 0.45 
L1_umary_LINE1_831 rs2055942 Type 2 diabetes GABRA4 -0.54 
ALU_umary_ALU_3274 rs13106975 Sphingolipid levels ATP10D 0.42 
ALU_umary_ALU_3295 rs13113518 Height CLOCK 0.64 
ALU_umary_ALU_3340 rs7656244 Kawasaki disease TECRL -0.40 
ALU_umary_ALU_3393 rs7041 Serum vitamin D-binding protein levels GC 0.40 
ALU_umary_ALU_3402 rs1894292 Prostate cancer AFM -0.58 
ALU_umary_ALU_3412 rs2273 Longevity SDAD1 -0.42 
ALU_umary_ALU_3430 rs1268789 Hair morphology FRAS1 0.62 
ALU_umary_ALU_3479 rs6834314 Liver enzyme levels (alanine transaminase) GAPDHP60,MIR5705 0.60 
ALU_umary_ALU_3594 rs10033900 Age-related macular degeneration PLA2G12A,CFI 0.43 
SVA_umary_SVA_222 rs4698790 Fasting insulin (interaction) CFI,GAR1 0.40 
L1_umary_LINE1_928 rs1585471 Myopia (pathological) RPL36AP23,CCDC34P1 0.89 
ALU_umary_ALU_3601 rs10034228 Myopia (pathological) RPL36AP23,CCDC34P1 0.70 
ALU_umary_ALU_3688 rs724950 Obesity-related traits RBM48P1,INTU 0.43 
ALU_umary_ALU_3796 rs1395821 Coronary heart disease TTC29,MIR548G 0.71 
ALU_umary_ALU_3957 rs2333163 Obesity-related traits ADAM29,TSEN2P1 0.65 
ALU_umary_ALU_3997 rs2130392 Kawasaki disease CENPU -0.41 
ALU_umary_ALU_4046 rs16875288 
Functional impairment in major 
depressive disorder  bipolar 
disorder and schizophrenia 
ADAMTS16 0.49 
ALU_umary_ALU_4079 rs2607292 Body mass index 6-Mar 0.48 
L1_umary_LINE1_1051 rs20476 PR interval in Tripanosoma cruzi seropositivity CTNND2 0.49 
ALU_umary_ALU_4117 rs4866334 IgG glycosylation RPL36AP21,RPL32P14 0.52 
L1_umary_LINE1_1097 rs10053502 Myopia (pathological) INTS6P1,LINC00603 0.81 
ALU_umary_ALU_4266 rs9291768 Classic bladder exstrophy . -0.50 
ALU_umary_ALU_4267 rs4865673 Dental caries HMGB1P47,KATNBL1P4 0.43 
ALU_umary_ALU_4283 rs7716219 Height SLC38A9 -0.46 
ALU_umary_ALU_4289 rs16884711 IgG glycosylation FLJ31104,ANKRD55 0.56 
ALU_umary_ALU_4310 rs6859219 Rheumatoid arthritis ANKRD55 0.40 
ALU_umary_ALU_4329 rs1494630 Age-related hearing impairment HTR1A,RNF180 0.50 
ALU_umary_ALU_4333 rs1494630 Age-related hearing impairment HTR1A,RNF180 0.48 
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SVA_umary_SVA_245 rs7729539 QT interval CWC27,ADAMTS6 0.68 
ALU_umary_ALU_4367 rs10515148 Hip geometry YBX1P5,ZNF366 0.43 
ALU_umary_ALU_4449 rs6870983 Body mass index . -0.66 
ALU_umary_ALU_4535 rs1829883 Hemostatic factors and hematological phenotypes RPS9P3,GUSBP8 0.43 
ALU_umary_ALU_4563 rs112724034 Alzheimer's disease (cognitive decline) LOC100289673 0.45 
ALU_umary_ALU_4615 rs2376682 Diisocyanate-induced asthma . -0.41 
ALU_umary_ALU_4650 rs1910003 Antibody status in Tripanosoma cruzi seropositivity RPSAP37,GRAMD3 0.42 
ALU_umary_ALU_4684 rs7735563 Diisocyanate-induced asthma . 0.60 
ALU_umary_ALU_4773 rs727809 Age-related hearing impairment (interaction) TRNAC32P,GRIA1 0.62 
ALU_umary_ALU_4807 rs2853694 Psoriasis . 0.66 
ALU_umary_ALU_4976 rs204247 Breast cancer RANBP9,MCUR1 -0.67 
ALU_umary_ALU_5017 rs4712652 Obesity . 0.54 
ALU_umary_ALU_5040 rs3129055 Nasopharyngeal carcinoma TRNAI25 0.41 
ALU_umary_ALU_5044 rs172166 Cardiac Troponin-T levels TRNAI25 0.47 
ALU_umary_ALU_5053 rs2523822 Drug-induced liver injury (amoxicillin-clavulanate) TRNAI25 0.92 
ALU_umary_ALU_5054 rs1061235 Adverse response to carbamapezine HLA-A 0.79 
ALU_umary_ALU_5055 rs259919 HIV-1 control ZNRD1-AS1 0.58 
ALU_umary_ALU_5056 rs6935053 Ulcerative colitis TRNAI25 0.58 
ALU_umary_ALU_5060 rs12175489 Visceral adipose tissue adjusted for BMI MICA 0.46 
SVA_umary_SVA_278 rs9368677 Atopic dermatitis TRNAI25 0.82 
ALU_umary_ALU_5064 rs1055569 Psychotic symptoms and prion disease . -0.64 
ALU_umary_ALU_5075 rs7775228 Asthma TRNAI25 0.65 
ALU_umary_ALU_5076 rs2859113 IgG glycosylation TRNAI25 0.62 
ALU_umary_ALU_5077 rs7756516 Chronic hepatitis B infection HLA-DQB2 0.56 
ALU_umary_ALU_5079 rs2621416 Lymphoma TRNAI25 0.80 
SVA_umary_SVA_282 rs3077 Hepatitis B (viral clearance) HLA-DPA1 0.65 
ALU_umary_ALU_5127 rs10948222 Height SUPT3H 0.57 
ALU_umary_ALU_5132 rs10948222 Height SUPT3H 0.81 
L1_umary_LINE1_1293 rs9357506 Body mass index . 0.42 
L1_umary_LINE1_1317 rs9342616 QT interval NUFIP1P,RNA5SP208 0.45 
ALU_umary_ALU_5237 rs9354654 Classic bladder exstrophy . -0.47 
ALU_umary_ALU_5248 rs9346353 Sleep duration LMBRD1 0.43 
ALU_umary_ALU_5278 rs9447004 Calcium levels CD109 0.45 
ALU_umary_ALU_5280 rs9447004 Calcium levels CD109 0.72 
ALU_umary_ALU_5298 rs7738636 Acute lymphoblastic leukemia (childhood) IMPG1,HTR1B -0.40 
ALU_umary_ALU_5356 rs366676 Echocardiographic traits AKIRIN2,SPACA1 -0.44 
ALU_umary_ALU_5380 rs2506933 Cognitive performance ATF1P1,COPS5P1 0.53 
ALU_umary_ALU_5395 rs11757063 Migraine FUT9,UFL1 0.82 
ALU_umary_ALU_5415 rs4840097 Age-related macular degeneration (smoking status interaction) PRDM13,MCHR2 0.40 
ALU_umary_ALU_5429 rs484621 Glucose homeostasis traits ATG5 0.41 
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ALU_umary_ALU_5475 rs33980500 Psoriatic arthritis TRAF3IP2,TRAF3IP2-AS1 0.42 
ALU_umary_ALU_5495 rs9488822 Cholesterol  total FRK 0.42 
ALU_umary_ALU_5509 rs89107 Cardiac structure and function SLC35F1 -0.51 
SVA_umary_SVA_305 rs12110693 Biomedical quantitative traits RPL23AP48,HMGB3P18 -0.56 
ALU_umary_ALU_5565 rs13209747 Blood pressure RPS4XP9,RSPO3 0.44 
ALU_umary_ALU_5575 rs6938574 Menarche (age at onset) LOC101928140,PTPRK 0.42 
ALU_umary_ALU_5647 rs225675 
Thiazide-induced adverse 





metabolic effects in hypertensive 
patients 
VTA1 0.84 
SVA_umary_SVA_315 rs1933488 Prostate cancer RGS17 -0.58 
ALU_umary_ALU_5708 rs2275336 Parkinson's disease CNKSR3 0.47 
ALU_umary_ALU_5713 rs4269383 Pancreatic cancer LOC101928923 0.43 
SVA_umary_SVA_318 rs2451258 Rheumatoid arthritis TAGAP,FNDC1 0.42 
ALU_umary_ALU_5769 rs7762018 
Thiazide-induced adverse 
metabolic effects in hypertensive 
patients 
PHF10 0.60 
ALU_umary_ALU_5882 rs12670798 Cholesterol  total DNAH11 0.62 
ALU_umary_ALU_5886 rs2286503 Fibrinogen TOMM7 -0.56 
ALU_umary_ALU_5916 rs10486483 Crohn's disease SKAP2 0.61 
L1_umary_LINE1_1474 rs10486483 Crohn's disease SKAP2 0.49 
ALU_umary_ALU_5957 rs9648428 Obesity-related traits EEPD1 0.53 
ALU_umary_ALU_5967 rs2392510 Periodontitis GPR141 -0.40 
ALU_umary_ALU_5970 rs4723738 Treatment response for severe sepsis STARD3NL 0.65 
ALU_umary_ALU_6007 rs1722133 Sitting height ratio . 0.44 
ALU_umary_ALU_6013 rs10279826 Urate levels in obese individuals . 0.42 
ALU_umary_ALU_6059 rs7786410 Age-related hearing impairment 14-Sep 0.44 
ALU_umary_ALU_6100 rs7794356 Response to montelukast in asthma (change in FEV1) . 0.51 
ALU_umary_ALU_6200 rs1133906 Systemic lupus erythematosus and Systemic sclerosis SAMD9L -0.42 
L1_umary_LINE1_1577 rs10953730 Metabolite levels LINC00998,PPP1R3A 0.68 
ALU_umary_ALU_6320 rs41997 
Response to platinum-based 
chemotherapy in non-small-cell 
lung cancer 
ANKRD7,GTF3AP6 0.40 
ALU_umary_ALU_6359 rs4731207 Cutaneous malignant melanoma . 0.48 
ALU_umary_ALU_6369 rs7458938 
Response to efavirenz-containing 
treatment in HIV 1 infection 
(virologic failure) 
RPL31P39,GRM8 0.53 
ALU_umary_ALU_6372 rs2687481 Hearing function RPL31P39,GRM8 0.73 
ALU_umary_ALU_6373 rs2687481 Hearing function RPL31P39,GRM8 0.70 
ALU_umary_ALU_6375 rs17864092 Depression (quantitative trait) GRM8 0.42 
ALU_umary_ALU_6427 rs10250997 
Autism spectrum disorder  attention 
deficit-hyperactivity disorder  
bipolar disorder  major depressive 
disorder  and schizophrenia 
(combined) 
MTPN,PSMC1P3 0.51 
ALU_umary_ALU_6521 rs10274279 Myopia (pathological) PTPRN2 0.58 
ALU_umary_ALU_6531 rs11986414 Gaucher disease severity CLN8,MIR3674 0.41 
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ALU_umary_ALU_6563 rs6601327 Multiple myeloma (hyperdiploidy) PPP1R3B,TNKS -0.55 
ALU_umary_ALU_6564 rs6601327 Multiple myeloma (hyperdiploidy) PPP1R3B,TNKS 0.51 
ALU_umary_ALU_6565 rs6601327 Multiple myeloma (hyperdiploidy) PPP1R3B,TNKS -0.45 
ALU_umary_ALU_6611 rs920590 Acute lymphoblastic leukemia (childhood) CSGALNACT1,INTS10 0.45 
SVA_umary_SVA_369 rs7843479 Mean corpuscular volume XPO7 0.41 
ALU_umary_ALU_6662 rs2439312 Dialysis-related mortality NRG1 -0.48 
ALU_umary_ALU_6669 rs11997175 Body mass index . 0.62 
ALU_umary_ALU_6673 rs6990255 
Autism spectrum disorder  attention 
deficit-hyperactivity disorder  
bipolar disorder  major depressive 
disorder  and schizophrenia 
(combined) 
CYCSP3,RPL10AP3 0.47 
ALU_umary_ALU_6674 rs6987004 Pulmonary function decline RPL10AP3,RPL21P80 0.78 
ALU_umary_ALU_6695 rs7829127 Refractive error ZMAT4 0.51 
ALU_umary_ALU_6769 rs9650199 Response to amphetamines PDCL3P1,RAB2A -0.45 
ALU_umary_ALU_6806 rs7017914 Bone mineral density XKR9 0.62 
ALU_umary_ALU_6820 rs11994034 Attention deficit hyperactivity disorder (combined symptoms) TRPA1,RNA5SP271 0.54 
ALU_umary_ALU_6893 rs7015622 
Response to anti-depressant 
treatment in major depressive 
disorder 
HNRNPA1P4,RALYL 0.81 
ALU_umary_ALU_6951 rs278567 Bipolar disorder and schizophrenia C8orf87 0.76 
ALU_umary_ALU_6990 rs2033562 IgA nephropathy . 0.52 
ALU_umary_ALU_7003 rs284489 Glaucoma (primary open-angle) LRP12,RPL23P9 -0.44 
ALU_umary_ALU_7007 rs12541635 Age of smoking initiation RPL12P24,SLC16A14P1 -0.50 
SVA_umary_SVA_389 rs374810 Ossification of the posterior longitudinal ligament of the spine RSPO2 0.68 
ALU_umary_ALU_7037 rs7832552 Body mass (lean) TRHR 0.60 
ALU_umary_ALU_7106 rs3870371 Periodontal disease-related phenotypes HAS2-AS1,MRPS36P3 0.53 
ALU_umary_ALU_7140 rs7830341 Body mass index . 0.57 
ALU_umary_ALU_7143 rs13281615 Breast cancer LOC101930033 0.47 
ALU_umary_ALU_7218 rs10962181 Superior frontal gyrus grey matter volume RNA5SP279,SMARCA2 -0.43 
L1_umary_LINE1_1778 rs10814916 Type 2 diabetes GLIS3 0.50 
L1_umary_LINE1_1783 rs16924631 Periodontal microbiota UHRF2 -0.42 
ALU_umary_ALU_7256 rs4742269 Radiation response KDM4C 0.42 
ALU_umary_ALU_7311 rs3904778 Adolescent idiopathic scoliosis . -0.45 
ALU_umary_ALU_7331 rs7867456 Axial length HACD4,IFNNP1,PTPLAD2 -0.48 
ALU_umary_ALU_7339 rs10738626 Atopic dermatitis UBA52P6,DMRTA1 -0.58 
ALU_umary_ALU_7381 rs10969853 Alcohol dependence (age at onset) RBMXP2,KRT18P66 0.57 
SVA_umary_SVA_401 rs10758189 IgG glycosylation B4GALT1 -0.63 
L1_umary_LINE1_1831 rs11145465 Refractive error . 0.41 
ALU_umary_ALU_7499 rs79460104 Response to amphetamines . 0.50 
L1_umary_LINE1_1854 rs12554999 
Plasma omega-6 polyunsaturated 
fatty acid levels (gamma-linolenic 
acid) 
CHCHD2P9,TLE4 0.87 
ALU_umary_ALU_7555 rs883924 Hepatitis C induced liver fibrosis LINC01508,LOC101927873 0.45 
L1_umary_LINE1_1867 rs10122541 Thyroid cancer . 0.57 
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ALU_umary_ALU_7593 rs7028939 Preeclampsia ERP44 -0.71 
ALU_umary_ALU_7594 rs7028939 Preeclampsia ERP44 -0.77 
ALU_umary_ALU_7615 rs7848024 Tourette's syndrome or obsessive-compulsive disorder ZYG11AP1,CYLC2 0.53 
ALU_umary_ALU_7658 rs10980800 Monocyte count RNY4P18,MIR7702 0.41 
ALU_umary_ALU_7756 rs7086888 Multiple myeloma (IgH translocation) LINC00703,LINC00704 0.41 
ALU_umary_ALU_7783 rs11256676 Dental caries CUX2P1,SFTA1P 0.48 
ALU_umary_ALU_7866 rs927675 MRI atrophy measures MPP7 0.48 
ALU_umary_ALU_8021 rs442309 Vogt-Koyanagi-Harada syndrome ZNF365,ALDH7A1P4 0.62 
ALU_umary_ALU_8046 rs2441727 Interstitial lung disease CTNNA3 0.42 
ALU_umary_ALU_8048 rs2441727 Interstitial lung disease CTNNA3 0.43 
ALU_umary_ALU_8056 rs16926246 Hemoglobin HK1 0.43 
SVA_umary_SVA_449 rs58180147 Parasitemia in Tripanosoma cruzi seropositivity MYPN 0.42 
ALU_umary_ALU_8112 rs1414874 Self-reported allergy MARK2P15,HMGN2P8 0.60 
ALU_umary_ALU_8178 rs1934951 Osteonecrosis of the jaw CYP2C8 -0.41 
ALU_umary_ALU_8182 rs56322409 Blood metabolite levels ALDH18A1 0.73 
ALU_umary_ALU_8232 rs11195062 Multiple myeloma MXI1 0.52 
ALU_umary_ALU_8297 rs7069346 Migraine without aura C10orf88,PSTK -0.59 
ALU_umary_ALU_8344 rs2213169 Hematology traits LCRB 0.43 
ALU_umary_ALU_8398 rs1330 Height NUCB2 0.40 
L1_umary_LINE1_2073 rs12788764 Age-related nuclear cataracts LUZP2,RPL36AP40 0.52 
ALU_umary_ALU_8456 rs10834691 IgG glycosylation LUZP2,RPL36AP40 0.73 
ALU_umary_ALU_8509 rs1355223 Systemic lupus erythematosus and Systemic sclerosis LOC102723568 0.41 
ALU_umary_ALU_8532 rs7951105 Free thyroxine concentration RPL7AP56,RPL18P8 -0.44 
L1_umary_LINE1_2104 rs1484948 RR interval (heart rate) RPL9P23,HNRNPKP3 0.79 
ALU_umary_ALU_8559 rs2176598 Body mass index . 0.71 
ALU_umary_ALU_8572 rs1351696 D-dimer levels OR4C4P,OR4C5 0.58 
ALU_umary_ALU_8574 rs1814175 Height CBX3P8,TRIM51FP 0.81 
ALU_umary_ALU_8590 rs11228719 Orofacial clefts OR2AH1P,OR9G1 0.48 
ALU_umary_ALU_8620 rs478304 Acne (severe) RNASEH2C,KRT8P26 -0.73 
ALU_umary_ALU_8692 rs17148090 Phospholipid levels (plasma) DLG2 0.47 
ALU_umary_ALU_8712 rs1386330 Multiple sclerosis (age of onset) HMGB3P25,RAB38 0.58 
ALU_umary_ALU_8716 rs2658782 Pulmonary function decline CCDC67 0.42 
ALU_umary_ALU_8717 rs10830228 Age-related macular degeneration RNU6-16P,TYR 0.68 
ALU_umary_ALU_8799 rs7947821 Tuberculosis . 0.88 
ALU_umary_ALU_8801 rs313426 Toenail selenium levels DYNC2H1 -0.44 
L1_umary_LINE1_2187 rs326946 Alzheimer's disease (cognitive decline) ARHGAP20 0.46 
L1_umary_LINE1_2191 rs2250417 Protein quantitative trait loci BCO2 0.85 
ALU_umary_ALU_8954 rs2007044 Schizophrenia . 0.43 
ALU_umary_ALU_8998 rs1031391 Bitter taste perception PRH1-PRR4 0.46 
ALU_umary_ALU_9001 rs2908835 Information processing speed HIGD1AP8,IQSEC3P2 0.52 
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ALU_umary_ALU_9108 rs1979679 Ossification of the posterior longitudinal ligament of the spine CCDC91 0.81 
ALU_umary_ALU_9143 rs11170468 Body mass index . 0.48 
ALU_umary_ALU_9156 rs11170468 Body mass index . 0.41 
ALU_umary_ALU_9158 rs76904798 Parkinson's disease RPL30P13,LRRK2 0.54 
ALU_umary_ALU_9177 rs275380 Adverse response to lamotrigine and phenytoin ADAMTS20 0.52 
ALU_umary_ALU_9214 rs59448276 Diisocyanate-induced asthma . 0.51 
ALU_umary_ALU_9233 rs1633360 Rheumatoid arthritis OS9 -0.41 
ALU_umary_ALU_9243 rs17121944 Temperament (bipolar disorder) RPS6P22,METTL15P2 0.49 
ALU_umary_ALU_9286 rs6581612 Hippocampal volume APOOP3,LEMD3 0.54 
ALU_umary_ALU_9348 rs2669010 Systemic lupus erythematosus RPL7AP9,YWHAQP7 0.46 
ALU_umary_ALU_9371 rs10778699 
Thiazide-induced adverse 
metabolic effects in hypertensive 
patients 
RPL7P38,RPL26P32 -0.47 
ALU_umary_ALU_9388 rs1511589 Optic cup area . 0.72 
ALU_umary_ALU_9431 rs11106179 Expressive vocabulary in infants DCN,C12orf79 0.45 
ALU_umary_ALU_9450 rs7953959 IgG glycosylation TRNAQ46P,RMST,TRQ-TTG9-1 0.65 
ALU_umary_ALU_9636 rs509915 Urate levels (BMI interaction) . 0.45 
SVA_umary_SVA_566 rs7328278 Asthma (childhood onset) DCLK1 0.44 
L1_umary_LINE1_2401 rs4142110 Nephrolithiasis DGKH 0.80 
ALU_umary_ALU_9813 rs9537938 Educational attainment RNA5SP30,CTAGE16P 0.61 
ALU_umary_ALU_9857 rs1340490 Response to platinum-based chemotherapy (cisplatin) RPL32P28,LINC00395 0.84 
L1_umary_LINE1_2432 rs1340490 Response to platinum-based chemotherapy (cisplatin) RPL32P28,LINC00395 0.58 
ALU_umary_ALU_9861 rs11148643 Rheumatoid arthritis NFYAP1,LGMNP1 -0.45 
ALU_umary_ALU_9863 rs9540294 Recalcitrant atopic dermatitis . 0.74 
ALU_umary_ALU_9886 rs2991396 Male fertility RPSAP53,NPM1P22 0.45 
ALU_umary_ALU_9941 rs975739 Hair color MIR3665,EDNRB-AS1 -0.41 
ALU_umary_ALU_9995 rs4773460 Hippocampal atrophy DDX6P2,TXNL1P1 -0.62 
ALU_umary_ALU_9998 rs9589866 Diisocyanate-induced asthma . -0.51 
ALU_umary_ALU_10028 rs4771859 




ALU_umary_ALU_10095 rs1509091 Metabolite levels (Pyroglutamine) FAM155A 0.46 
ALU_umary_ALU_10151 rs1950500 Height RIPK3,NFATC4 0.45 
ALU_umary_ALU_10167 rs7493138 Longevity RPL26P3,EIF4A1P12 0.41 
ALU_umary_ALU_10255 rs2488856 Osteoprotegerin levels YWHAQP1,TUBBP3 0.58 
ALU_umary_ALU_10284 rs7159841 Hemostatic factors and hematological phenotypes MDGA2 -0.45 
ALU_umary_ALU_10285 rs7159841 Hemostatic factors and hematological phenotypes MDGA2 0.45 
ALU_umary_ALU_10299 rs1959536 Psychosis (atypical) TRIM9 0.48 
ALU_umary_ALU_10334 rs11851015 Alcohol consumption EXOC5 0.56 
ALU_umary_ALU_10353 rs7153648 Prostate cancer SIX1,SIX4 0.46 
ALU_umary_ALU_10368 rs10498514 Cognitive performance MTHFD1 -0.49 
ALU_umary_ALU_10374 rs8020095 Depression (quantitative trait) GPHN 0.64 
L1_umary_LINE1_2583 rs8017304 Age-related macular degeneration RAD51B 0.57 
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ALU_umary_ALU_10396 rs55951657 Hippocampal volume ACOT4,ACOT6 0.44 
ALU_umary_ALU_10401 rs910316 Height TMED10 0.67 
SVA_umary_SVA_613 rs6574644 Obesity-related traits STON2 -0.53 
ALU_umary_ALU_10482 rs17124955 Obesity-related traits TTC8,TRA-AGC15-1,TRNAA17 0.53 
ALU_umary_ALU_10518 rs7140601 Immune response to smallpox vaccine (IL-6) C14orf64,C14orf177,LINC01550 0.81 
ALU_umary_ALU_10580 rs61996546 Response to methotrexate in juvenile idiopathic arthritis GABRB3 0.45 
L1_umary_LINE1_2647 rs2414095 Follicule stimulating hormone CYP19A1 0.47 
SVA_umary_SVA_632 rs2553218 Immune response to smallpox vaccine (IL-6) UNC13C 0.55 
ALU_umary_ALU_10715 rs491567 Chronic kidney disease WDR72 -0.50 
L1_umary_LINE1_2651 rs491567 Chronic kidney disease WDR72 -0.41 
ALU_umary_ALU_10766 rs1436958 IgG glycosylation VPS13C 0.60 
SVA_umary_SVA_640 rs1549318 Proinsulin levels RPL29P30,LARP6 0.41 
ALU_umary_ALU_10812 rs8038465 Liver enzyme levels (gamma-glutamyl transferase) CD276 0.74 
ALU_umary_ALU_10819 rs3099143 Recalcitrant atopic dermatitis . 0.60 
ALU_umary_ALU_10885 rs7495052 Inattentive symptoms SLCO3A1 0.40 
ALU_umary_ALU_11100 rs8047014 Attention deficit hyperactivity disorder RPS2P45,HAS3 0.53 
ALU_umary_ALU_11101 rs12149862 Blood pressure (smoking interaction) CYB5B 0.46 
ALU_umary_ALU_11136 rs8050187 Anorexia nervosa WWOX 0.48 
ALU_umary_ALU_11154 rs12933472 Glucose homeostasis traits CDH13 0.52 
SVA_umary_SVA_683 rs781856 Glucose homeostasis traits ZZEF1 0.72 
ALU_umary_ALU_11196 rs73976923 Diisocyanate-induced asthma . 0.59 
ALU_umary_ALU_11238 rs7211756 Blood pressure (smoking interaction) ZSWIM7 0.64 
ALU_umary_ALU_11275 rs225212 Hypertension risk in short sleep duration MYO1D 0.69 
ALU_umary_ALU_11276 rs379123 Local histogram emphysema pattern MYO1D 0.50 
ALU_umary_ALU_11327 rs7207400 Alzheimer's disease in APOE e4- carriers . -0.54 
ALU_umary_ALU_11330 rs2935183 Multiple sclerosis or amyotrophic lateral sclerosis NPEPPS -0.56 
ALU_umary_ALU_11333 rs9303542 Ovarian cancer SKAP1 -0.64 
ALU_umary_ALU_11353 rs9635759 Menarche (age at onset) RPL7P48,CA10 0.42 
ALU_umary_ALU_11384 rs7224438 Immune reponse to smallpox (secreted IL-2) BCAS3 0.41 
ALU_umary_ALU_11398 rs4329 Metabolic traits ACE 0.62 
ALU_umary_ALU_11400 rs7223966 Body mass index . 0.66 
ALU_umary_ALU_11422 rs817565 
Response to anti-retroviral therapy 
(ddI/d4T) in HIV-1 infection 
(Grade 1 peripheral neuropathy) 
MAP2K6 0.48 
ALU_umary_ALU_11427 rs10775360 QT interval CALM2P1,CASC17 0.51 
ALU_umary_ALU_11428 rs10775360 QT interval CALM2P1,CASC17 0.42 
ALU_umary_ALU_11462 rs16970672 Psychosis and Alzheimer's disease FLJ45079,TNRC6C 0.42 
ALU_umary_ALU_11474 rs7220048 Obesity-related traits AATK -0.45 
ALU_umary_ALU_11492 rs2345595 PR interval in Tripanosoma cruzi seropositivity LINC00470,METTL4 0.53 
ALU_umary_ALU_11552 rs1893217 Celiac disease or Rheumatoid arthritis PTPN2 0.77 
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ALU_umary_ALU_11628 rs7239368 Response to citalopram treatment NOL4 0.61 
ALU_umary_ALU_11673 rs1398217 Menarche (age at onset) SKOR2 0.45 
ALU_umary_ALU_11704 rs4940203 Obesity-related traits DCC 0.51 
ALU_umary_ALU_11708 rs11876941 Body mass index (interaction) DCC 0.42 
ALU_umary_ALU_11760 rs11152166 Major depressive disorder CCBE1 0.41 
ALU_umary_ALU_11766 rs4553720 





Adverse response to chemotherapy 




ALU_umary_ALU_11899 rs1865075 Dental caries RPL34P34,ZNF98 0.44 
ALU_umary_ALU_12007 rs6117615 
Adverse response to chemotherapy 
in breast cancer (alopecia) 
(docetaxel) 
SLC52A3,FAM110A 0.89 
ALU_umary_ALU_12018 rs6139030 Response to hepatitis C treatment ITPA 0.44 
ALU_umary_ALU_12039 rs6054383 Optic cup area . 0.40 
ALU_umary_ALU_12074 rs6042314 Intelligence (childhood) ESF1 0.51 
ALU_umary_ALU_12101 rs6044112 Response to taxane treatment (docetaxel) KIF16B 0.46 
ALU_umary_ALU_12132 rs816535 Parkinson disease and lewy body pathology . 0.87 
ALU_umary_ALU_12143 rs6088765 Ulcerative colitis PROCR 0.45 
ALU_umary_ALU_12183 rs6065906 Triglycerides PLTP,PCIF1 0.49 
ALU_umary_ALU_12184 rs6065906 HDL cholesterol PLTP,PCIF1 0.60 
ALU_umary_ALU_12208 rs6091737 Calcium levels RNU7-14P,SUMO1P1 0.56 
ALU_umary_ALU_12366 rs458685 Breast cancer GRIK1 0.44 
L1_umary_LINE1_2980 rs12483205 HIV-1 replication DYRK1A 0.41 
ALU_umary_ALU_12465 rs132390 Breast cancer EMID1 0.55 




Table 9 Top LD results for polyTE for European population 
TE GWAS hits GWAS phenotype GWAS gene r 
ALU_umary_ALU_14 rs11120822 Stearic acid (18:0) plasma levels CAMTA1,LOC100129476 0.43 
ALU_umary_ALU_19 rs12711517 Breast cancer SLC45A1 -0.55 
ALU_umary_ALU_20 rs301799 Thyroid peroxidase antibody positivity LOC102724552,RERE 0.44 
SVA_umary_SVA_5 rs17367504 Blood pressure MTHFR 0.70 
ALU_umary_ALU_33 rs2489260 Obesity-related traits AADACL4,AADACL3 0.82 
ALU_umary_ALU_64 rs4654899 Superior frontal gyrus grey matter volume EIF4G3 0.70 
SVA_umary_SVA_18 rs28411352 Rheumatoid arthritis MTF1 -0.48 
ALU_umary_ALU_127 rs2274465 Menarche (age at onset) KDM4A 0.65 
ALU_umary_ALU_139 rs11588062 Age-related hearing impairment (interaction) UQCRH 0.51 
ALU_umary_ALU_189 rs2811893 Diabetic retinopathy MYSM1 0.45 
ALU_umary_ALU_194 rs7534016 Obesity-related traits FGGY 0.87 
ALU_umary_ALU_216 rs1751492 Soluble leptin receptor levels LEPR 0.45 
ALU_umary_ALU_224 rs1417437 Orofacial clefts LRRC7 0.59 
ALU_umary_ALU_226 rs11809230 Cannabis use (initiation) . 0.49 
ALU_umary_ALU_244 rs2568958 Weight GDI2P2,RPL31P12 -0.44 
ALU_umary_ALU_288 rs12024204 Endometriosis ADH5P2,HMGB1P18 -0.65 
ALU_umary_ALU_342 rs12091709 Cognitive function LRRC8D 0.65 
ALU_umary_ALU_390 rs303386 





L1_umary_LINE1_98 rs1948368 Bipolar disorder PPIAP7,RPSAP19 0.77 
L1_umary_LINE1_99 rs11578152 Menarche (age at onset) DNAJA1P5,COL11A1 0.63 
ALU_umary_ALU_412 rs10874639 Protein quantitative trait loci DNAJA1P5,COL11A1 0.55 
ALU_umary_ALU_417 rs3934285 Obesity-related traits AMY1C,FTLP17 0.74 
SVA_umary_SVA_45 rs7411387 




ALU_umary_ALU_446 rs10776733 Obesity-related traits ADORA3 0.46 
ALU_umary_ALU_464 rs11102807 Autism EIF2S2P5,PKMP1 0.42 
ALU_umary_ALU_481 rs10802047 Relative hand skill in reading disability RNA5SP56,PSMC1P12 -0.69 
ALU_umary_ALU_510 rs12403795 Illicit drug use MRPS21 0.49 
ALU_umary_ALU_534 rs857684 Red blood cell traits OR10Z1 0.45 
SVA_umary_SVA_57 rs3790672 Testicular germ cell tumor UCK2 0.83 
ALU_umary_ALU_585 rs3903239 Atrial fibrillation GORAB,PRRX1 -0.42 
ALU_umary_ALU_589 rs28588043 Number of children (6+ vs. 0 or 1) . 0.86 
ALU_umary_ALU_602 rs17301853 Migraine - clinic-based RABGAP1L 0.57 
ALU_umary_ALU_618 rs12760731 Obesity-related traits LINC00083,TEX35 0.62 
ALU_umary_ALU_632 rs199950 Body mass index (change over time) CACNA1E 0.55 
ALU_umary_ALU_659 rs12125250 Economic and political preferences SLC4A1APP2,RPS3AP9 0.43 
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ALU_umary_ALU_660 rs12125250 Economic and political preferences SLC4A1APP2,RPS3AP9 0.46 
ALU_umary_ALU_664 rs10489764 Amyotrophic lateral sclerosis (sporadic) SLC4A1APP2,RPS3AP9 0.49 
ALU_umary_ALU_672 rs12408261 Number of pregnancies . -0.68 
ALU_umary_ALU_689 rs10801047 Crohn's disease HNRNPA1P46,RGS18 0.67 
ALU_umary_ALU_713 rs1890645 Neonatal lupus EEF1A1P14,KCNT2 0.43 
ALU_umary_ALU_716 rs426736 Meningococcal disease CFHR3 0.76 
ALU_umary_ALU_717 rs426736 Meningococcal disease CFHR3 0.71 
ALU_umary_ALU_718 rs426736 Meningococcal disease CFHR3 0.74 
ALU_umary_ALU_795 rs12120588 Urate levels in overweight individuals . 0.57 
ALU_umary_ALU_796 rs12120588 Urate levels in overweight individuals . -0.50 
ALU_umary_ALU_841 rs12410462 Major depressive disorder BTF3P9,TUBB8P10 0.44 
ALU_umary_ALU_842 rs12410462 Major depressive disorder BTF3P9,TUBB8P10 0.40 
ALU_umary_ALU_845 rs801114 Basal cell carcinoma FTH1P2,ISCA1P2 0.57 
ALU_umary_ALU_884 rs482329 Life threatening arrhythmia LINC00184,LINC01132 -0.72 
SVA_umary_SVA_79 rs12135191 Urate levels (BMI interaction) . -0.44 
ALU_umary_ALU_897 rs2820037 Hypertension RPL39P10,CHRM3 0.92 
ALU_umary_ALU_958 rs10189761 Obesity FAM150B,TMEM18 0.88 
ALU_umary_ALU_971 rs11123610 
Response to inhaled 
corticosteroid treatment in 
asthma (percentage change 
of FEV1) 
ALLC 0.59 
ALU_umary_ALU_1048 rs4635554 Hypertriglyceridemia TDRD15,RNA5SP87 -0.46 
L1_umary_LINE1_267 rs2681019 Dialysis-related mortality RNA5SP87,KLHL29 -0.87 
ALU_umary_ALU_1070 rs3795958 Metabolite levels (HVA/MHPG ratio) DRC1 0.48 
ALU_umary_ALU_1128 rs1863080 Anthropometric traits MRPL50P1,RPL21P36 0.66 
ALU_umary_ALU_1149 rs3816183 Hypospadias HAAO -0.50 
ALU_umary_ALU_1163 rs2341459 Height CAMKMT -0.52 
ALU_umary_ALU_1171 rs12474201 Height CRIPT,SOCS5 0.57 
ALU_umary_ALU_1173 rs34198350 QT interval in Tripanosoma cruzi seropositivity RPS27AP7,VN1R18P 0.74 
ALU_umary_ALU_1211 rs12713280 Economic and political preferences EML6 0.51 
ALU_umary_ALU_1216 rs6751715 HIV-1 control MIR216B,CCDC85A -0.40 
ALU_umary_ALU_1221 rs889956 Educational attainment EIF2S2P7,VRK2 0.73 
SVA_umary_SVA_110 rs3845817 Bipolar disorder RPS15AP15,KRT18P33 0.60 
ALU_umary_ALU_1273 rs4141819 Endometriosis ETAA1,C1D 0.48 
ALU_umary_ALU_1287 rs432203 Longevity . -0.51 
ALU_umary_ALU_1336 rs10496262 Aging traits LRRTM1,MTND4P25 0.85 
ALU_umary_ALU_1337 rs10496262 Aging traits LRRTM1,MTND4P25 0.75 
L1_umary_LINE1_346 rs12052359 Bilirubin levels LRRTM1,MTND4P25 0.51 
L1_umary_LINE1_348 rs10496289 Hypertension MTND5P27,RPL37P10 0.61 
ALU_umary_ALU_1350 rs7581224 Coronary artery calcification SUCLG1,DNAH6 -0.41 
ALU_umary_ALU_1388 rs7583877 Type 1 diabetes nephropathy AFF3 -0.50 
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L1_umary_LINE1_366 rs1558648 Serum protein levels (sST2) IL1RL2 0.53 
ALU_umary_ALU_1406 rs2163349 Addiction NCK2 0.88 
ALU_umary_ALU_1429 rs13401811 Chronic lymphocytic leukemia ACOXL 0.66 
ALU_umary_ALU_1433 rs11122895 Allergic sensitization RPL34P8,ANAPC1 0.61 
ALU_umary_ALU_1441 rs1823125 Sleep duration LOC101927400 0.63 
ALU_umary_ALU_1555 rs13405020 Non-small cell lung cancer THSD7B -0.53 
ALU_umary_ALU_1557 rs13405020 Non-small cell lung cancer THSD7B 0.61 
ALU_umary_ALU_1585 rs17515225 Motion sickness LRP1B -0.77 
ALU_umary_ALU_1621 rs7584099 Response to statin therapy PABPC1P2,RPL26P14 0.64 
ALU_umary_ALU_1623 rs2307394 Urate levels ORC4 0.71 
ALU_umary_ALU_1628 rs10191411 Protein quantitative trait loci RPS29P8,EPC2 0.43 
L1_umary_LINE1_426 rs7594648 Age-related hearing impairment MTND5P30,NR4A2 0.84 
ALU_umary_ALU_1709 rs1424760 Phospholipid levels (plasma) RNA5SP109,RPL7P61 -0.48 
ALU_umary_ALU_1740 rs2268365 Blood pressure (smoking interaction) LRP2 0.51 
ALU_umary_ALU_1778 rs9287989 Periodontal microbiota EXTL2P1,KIAA1715 -0.43 
L1_umary_LINE1_455 rs13413635 Heart rate PDE11A 0.73 
ALU_umary_ALU_1824 rs6741522 Cervical artery dissection RPL23AP33,ELF2P4 0.58 
ALU_umary_ALU_1838 rs2675399 Obesity-related traits DIRC1,COL3A1 0.56 
ALU_umary_ALU_1843 rs2675399 Obesity-related traits DIRC1,COL3A1 0.46 
ALU_umary_ALU_1867 rs2176528 Bipolar disorder RPS17P8,GLULP6 0.57 
ALU_umary_ALU_1894 rs6738825 Crohn's disease . -0.81 
L1_umary_LINE1_489 rs17266097 Menarche (age at onset) SATB2 0.41 
ALU_umary_ALU_1947 rs12478665 Hippocampal volume MEAF6P1,MAP2 0.65 
ALU_umary_ALU_1961 rs1464443 Amyotrophic lateral sclerosis (sporadic) ERBB4 -0.48 
ALU_umary_ALU_1964 rs4673659 Asthma (sex interaction) ERBB4 0.66 
ALU_umary_ALU_1987 rs16857609 Breast cancer DIRC3 0.74 
ALU_umary_ALU_1992 rs492400 Body mass index . 0.72 
ALU_umary_ALU_2011 rs12621643 Acute lymphoblastic leukemia (childhood) KCNE4 -0.42 
ALU_umary_ALU_2101 rs7652782 Serum uric acid levels CNTN4 0.70 
ALU_umary_ALU_2109 rs2587949 Periodontitis (DPAL) SUMF1 -0.55 
ALU_umary_ALU_2123 rs271066 Alzheimer's disease (age of onset) MRPS35P1,MRPS36P1 0.50 
SVA_umary_SVA_157 rs3729931 Cardiac hypertrophy RAF1 -0.42 
ALU_umary_ALU_2169 rs6771632 
Lung function (forced 
expiratory flow between 
25%25 and 75%25 of forced 
vital capacity) 
IMPDH1P8,GALNT15 -0.42 
ALU_umary_ALU_2247 rs7617877 Parkinson's disease LINC00693 -0.59 
ALU_umary_ALU_2251 rs4680719 Metabolite levels (HVA) MESTP4,RBMS3-AS3 -0.41 
ALU_umary_ALU_2289 rs75968099 Schizophrenia HSPD1P6,TRANK1 0.83 
L1_umary_LINE1_580 rs11708996 QT interval SCN5A 0.57 
ALU_umary_ALU_2319 rs10865924 Clozapine-induced agranulocytosis ACKR2 0.88 
ALU_umary_ALU_2333 rs319690 Blood pressure MAP4 -0.52 
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ALU_umary_ALU_2337 rs319690 Blood pressure MAP4 0.47 
ALU_umary_ALU_2340 rs11719291 Cognitive function IP6K2 0.80 
ALU_umary_ALU_2349 rs1031925 Melanoma . 0.75 
ALU_umary_ALU_2352 rs2029213 Heart rate DCP1A 0.60 
ALU_umary_ALU_2371 rs6764184 Optic cup area . 0.72 
L1_umary_LINE1_629 rs17518584 Cognitive function CADM2 -0.51 
ALU_umary_ALU_2515 rs7632427 Orofacial clefts EPHA3,PROS2P,PROSP 0.48 
ALU_umary_ALU_2575 rs1397924 









ALU_umary_ALU_2578 rs2677247 IgG glycosylation MIR548AB,RAP1BP2 0.65 
ALU_umary_ALU_2591 rs12491921 Cannabis dependence CBLB,FCF1P3 -0.43 
ALU_umary_ALU_2627 rs7611694 Prostate cancer SIDT1 0.43 
ALU_umary_ALU_2637 rs9841504 Gastric cancer LOC102723469,ZBTB20 0.86 
ALU_umary_ALU_2667 rs13077101 Obesity-related traits RABL3 0.84 
ALU_umary_ALU_2697 rs2712381 Monocyte count RPN1 -0.55 
ALU_umary_ALU_2733 rs16847609 Alzheimer's disease in APOE e4- carriers . 0.82 
ALU_umary_ALU_2743 rs908821 Multiple sclerosis TRIM42,RPL23AP41 0.50 
ALU_umary_ALU_2757 rs9826463 




ALU_umary_ALU_2770 rs345013 Prostate cancer RNA5SP144,LARP7P4 0.90 
ALU_umary_ALU_2810 rs1351267 Schizophrenia SUCNR1,MBNL1 -0.52 
ALU_umary_ALU_2845 rs7646881 Tetralogy of Fallot LOC100287290 0.52 
ALU_umary_ALU_2909 rs9864370 Multiple myeloma (hyperdiploidy) MECOM 0.67 
ALU_umary_ALU_2913 rs13097028 Melanoma SDHDP3,TERC 0.83 
ALU_umary_ALU_2925 rs3913363 Response to angiotensin II receptor blocker therapy TMEM212,FNDC3B 0.79 
ALU_umary_ALU_3022 rs10937470 Total ventricular volume UTS2B -0.77 
SVA_umary_SVA_203 rs11723261 Immune response to smallpox vaccine (IL-6) . 0.61 
ALU_umary_ALU_3058 rs11723261 Immune response to smallpox vaccine (IL-6) . 0.61 
ALU_umary_ALU_3062 rs13108904 Obesity-related traits LOC101928676,MAEA -0.77 
ALU_umary_ALU_3085 rs16872571 Vitiligo CLNK,RNPS1P1 -0.69 
L1_umary_LINE1_786 rs1503874 Illicit drug use KRT18P63,RPL21P46 0.47 
ALU_umary_ALU_3139 rs4697263 Age-related hearing impairment (interaction) KCNIP4-IT1,GPR125 0.84 
ALU_umary_ALU_3178 rs7442317 
Attention deficit 




Very long-chain saturated 
fatty acid levels (fatty acid 
22:0) 
PCDH7,MAPRE1P2 0.53 
L1_umary_LINE1_818 rs10010758 Periodontal microbiota TBC1D1 0.44 
L1_umary_LINE1_831 rs2055942 Type 2 diabetes GABRA4 0.52 
ALU_umary_ALU_3287 rs6820391 Cervical artery dissection LNX1 -0.45 
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ALU_umary_ALU_3295 rs13113518 Height CLOCK 0.71 
ALU_umary_ALU_3340 rs7656244 Kawasaki disease TECRL 0.49 
ALU_umary_ALU_3360 rs1155865 Cognitive test performance RPS23P3,CENPC 0.77 
ALU_umary_ALU_3378 rs4356975 Obesity-related traits UGT2B7 0.44 




(moderate to severe) 
FAM13A 0.40 
ALU_umary_ALU_3554 rs17030795 Anorexia nervosa PPP3CA 0.80 
L1_umary_LINE1_913 rs6533014 
Homeostasis model 
assessment of beta-cell 
function (interaction) 
SLC39A8,NFKB1 0.54 
L1_umary_LINE1_915 rs4699052 Testicular germ cell tumor CENPE,DDX3P3,DDX3YP3 0.45 
L1_umary_LINE1_928 rs10034228 Myopia (pathological) RPL36AP23,CCDC34P1 0.93 
ALU_umary_ALU_3601 rs10034228 Myopia (pathological) RPL36AP23,CCDC34P1 0.82 
L1_umary_LINE1_942 rs6838310 Cognitive function NT5C3AP1,NDST3 0.45 
ALU_umary_ALU_3643 rs10028773 Educational attainment KLHL2P1 -0.40 
ALU_umary_ALU_3782 rs1512281 Percentage gas trapping . 0.71 
ALU_umary_ALU_3796 rs1395821 Coronary heart disease TTC29,MIR548G 0.54 
ALU_umary_ALU_3944 rs6835098 




ALU_umary_ALU_3997 rs2130392 Kawasaki disease CENPU 0.61 
ALU_umary_ALU_4041 rs11748327 Myocardial infarction IRX1,LINC01020 0.72 
ALU_umary_ALU_4046 rs16875288 
Functional impairment in 
major depressive 
disorder%2C bipolar 
disorder and schizophrenia 
ADAMTS16 0.54 
ALU_umary_ALU_4055 rs7729273 Cognitive performance RNA5SP176,ADCY2 0.59 
ALU_umary_ALU_4195 rs1173766 Blood pressure NPR3,RPS8P8 -0.54 
ALU_umary_ALU_4218 rs293748 Obesity-related traits NIPBL 0.74 
ALU_umary_ALU_4266 rs9291768 Classic bladder exstrophy . 0.43 
ALU_umary_ALU_4267 rs4865673 Dental caries HMGB1P47,KATNBL1P4 0.64 
ALU_umary_ALU_4270 rs4348174 Serum thyroid-stimulating hormone levels KATNBL1P4,RPS17P11 0.42 
ALU_umary_ALU_4283 rs7716219 Height SLC38A9 0.60 
ALU_umary_ALU_4294 rs16886364 Breast cancer (early onset) MAP3K1 0.87 
ALU_umary_ALU_4375 rs295688 Dysphagia . 0.48 
ALU_umary_ALU_4403 rs672413 Blood and toenail selenium levels ARSB 0.52 
SVA_umary_SVA_248 rs506500 Blood trace element (Se levels) BHMT -0.50 
ALU_umary_ALU_4406 rs567754 Toenail selenium levels BHMT 0.40 
ALU_umary_ALU_4449 rs6452790 Cognitive function RPS3AP22,LINC00461 0.68 
ALU_umary_ALU_4509 rs10067427 Non-alcoholic fatty liver disease histology (lobular) EEF1A1P20,MTND5P10 0.68 
ALU_umary_ALU_4510 rs10067427 Non-alcoholic fatty liver disease histology (lobular) EEF1A1P20,MTND5P10 0.65 
ALU_umary_ALU_4514 rs4702982 Panic disorder FAM174A,ST8SIA4 0.68 
ALU_umary_ALU_4562 rs4388249 Schizophrenia MAN2A1 0.89 
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ALU_umary_ALU_4571 rs3853750 Asthma and hay fever SLC25A46,TSLP 0.44 
ALU_umary_ALU_4589 rs55670112 Epilepsy KCNN2,TRIM36 0.45 
ALU_umary_ALU_4624 rs255788 Response to platinum-based chemotherapy (carboplatin) FAM170A,PRR16 0.55 
ALU_umary_ALU_4646 rs6595551 Type 2 diabetes (young onset) and obesity ZNF608,RPL28P3 0.59 
ALU_umary_ALU_4684 rs6890695 Alzheimer's disease in APOE e4- carriers . 0.68 
ALU_umary_ALU_4717 rs3776331 Uric acid levels ARHGAP26 0.44 
ALU_umary_ALU_4737 rs9325032 Cognitive test performance PPP2R2B -0.51 
ALU_umary_ALU_4773 rs727809 Age-related hearing impairment (interaction) TRNAC32P,GRIA1 0.77 
ALU_umary_ALU_4796 rs411174 Personality traits in bipolar disorder ITK 0.47 
ALU_umary_ALU_4807 rs2082412 Psoriasis UBLCP1,IL12B -0.48 
L1_umary_LINE1_1242 rs17504106 Post-traumatic stress disorder . 0.81 
ALU_umary_ALU_4959 rs2236212 Phospholipid levels (plasma) ELOVL2 0.47 
ALU_umary_ALU_4976 rs204247 Breast cancer RANBP9,MCUR1 -0.75 
ALU_umary_ALU_4993 rs2274136 Obesity-related traits NUP153 0.56 
ALU_umary_ALU_5002 rs664154 Information processing speed . -0.42 
ALU_umary_ALU_5053 rs2523822 Drug-induced liver injury (amoxicillin-clavulanate) TRNAI25 0.88 
ALU_umary_ALU_5055 rs259919 HIV-1 control ZNRD1-AS1 0.56 
ALU_umary_ALU_5058 rs12526186 Response to antipsychotic treatment HCG20,TRNAI25 0.58 
ALU_umary_ALU_5060 rs9263739 Ulcerative colitis CCHCR1 0.58 
SVA_umary_SVA_278 rs9368677 Atopic dermatitis TRNAI25 0.75 
ALU_umary_ALU_5064 rs1055569 Psychotic symptoms and prion disease . 0.69 
ALU_umary_ALU_5065 rs2157337 Rheumatoid arthritis TRNAI25 0.52 
SVA_umary_SVA_280 rs10484561 Follicular lymphoma TRNAI25 0.78 
ALU_umary_ALU_5072 rs4530903 Lymphoma TRNAI25 0.88 
ALU_umary_ALU_5075 rs2858870 Nodular sclerosis Hodgkin lymphoma TRNAI25 0.69 
ALU_umary_ALU_5076 rs7756516 Chronic hepatitis B infection HLA-DQB2 -0.71 
ALU_umary_ALU_5077 rs7756516 Chronic hepatitis B infection HLA-DQB2 -0.66 
ALU_umary_ALU_5079 rs2621416 Lymphoma TRNAI25 0.62 
SVA_umary_SVA_282 rs3077 Chronic hepatitis B infection HLA-DPA1 0.90 
ALU_umary_ALU_5106 rs9296295 Obesity-related traits KIF6 0.48 
ALU_umary_ALU_5120 rs9472155 Vascular endothelial growth factor levels 
LINC01512,LOC1001323
54 0.58 
ALU_umary_ALU_5132 rs10948222 Height SUPT3H 0.87 
L1_umary_LINE1_1293 rs9357506 Body mass index . -0.87 
ALU_umary_ALU_5165 rs1161397 Overweight status TRNAI25 0.59 
ALU_umary_ALU_5209 rs9475752 Menarche (age at onset) DST 0.58 
ALU_umary_ALU_5213 rs9500256 Eosinophilic esophagitis (pediatric) GAPDHP15,RBBP4P4 0.48 
ALU_umary_ALU_5237 rs4710654 Response to amphetamines RNA5SP208,ADGRB3,BAI3 0.72 
ALU_umary_ALU_5239 rs875033 Response to amphetamines RNA5SP208,ADGRB3,BAI3 0.55 
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ALU_umary_ALU_5259 rs1048886 Type 2 diabetes C6orf57,SDHAF4 0.76 
ALU_umary_ALU_5262 rs6922893 Obesity-related traits B3GAT2 0.79 
ALU_umary_ALU_5264 rs9351814 Coronary artery disease or ischemic stroke LINC00472,KRT19P1 0.42 
ALU_umary_ALU_5280 rs9447004 Calcium levels CD109 0.78 
ALU_umary_ALU_5296 rs12198063 Capecitabine sensitivity IMPG1,HTR1B 0.42 
ALU_umary_ALU_5324 rs10943724 
Thiazide-induced adverse 
metabolic effects in 
hypertensive patients 
RPL17P25,FAM46A 0.54 
ALU_umary_ALU_5395 rs11757063 Migraine FUT9,UFL1 0.85 
ALU_umary_ALU_5402 rs6924808 
Response to inhaled 
glucocorticoid treatment in 
asthma (percentage change 
of FEV1) 
. 0.49 
SVA_umary_SVA_298 rs239198 Menarche (age at onset) ASCC3 0.44 
L1_umary_LINE1_1370 rs1416280 Longevity (90 years and older) GRIK2,R3HDM2P2 0.43 
ALU_umary_ALU_5490 rs9488343 Gray matter volume (schizophrenia interaction) HS3ST5 0.55 
ALU_umary_ALU_5509 rs11153730 Heart rate RPL29P4,CEP85L -0.58 
ALU_umary_ALU_5582 rs7749983 Periodontal disease-related phenotypes LOC102723409 0.53 
ALU_umary_ALU_5583 rs10447419 PR interval SAMD3 0.68 
L1_umary_LINE1_1418 rs225675 
Thiazide-induced adverse 
metabolic effects in 
hypertensive patients 
VTA1 0.79 
ALU_umary_ALU_5657 rs10979 Hypospadias LOC285740 -0.45 
SVA_umary_SVA_315 rs1933488 Prostate cancer RGS17 0.73 
ALU_umary_ALU_5713 rs1449672 Trans fatty acid levels LOC101928923 0.41 
SVA_umary_SVA_320 rs1620921 Lipoprotein (a) - cholesterol levels PLG,MAP3K4 -0.60 
ALU_umary_ALU_5742 rs13191362 Body mass index . 0.69 
ALU_umary_ALU_5746 rs9364687 Body mass index . 0.55 
L1_umary_LINE1_1448 rs59072263 Intraocular pressure GLCCI1,ICA1 0.51 
ALU_umary_ALU_5809 rs9918508 Hippocampal atrophy RPL9P19,GAPDHP68 0.59 
L1_umary_LINE1_1460 rs6961860 





ALU_umary_ALU_5868 rs12666612 Obesity-related traits HDAC9 0.89 
ALU_umary_ALU_5886 rs2286503 Fibrinogen TOMM7 0.69 
ALU_umary_ALU_5967 rs2392510 Periodontitis GPR141 -0.40 
ALU_umary_ALU_5969 rs16879765 Dupuytren's disease EPDR1 0.62 
ALU_umary_ALU_5970 rs4723738 Treatment response for severe sepsis STARD3NL 0.47 
ALU_umary_ALU_6007 rs1722133 Sitting height ratio . 0.47 
ALU_umary_ALU_6015 rs1551277 Anxiety disorder PKD1L1 0.41 
ALU_umary_ALU_6027 rs4132601 Acute lymphoblastic leukemia (childhood) IKZF1 0.42 
ALU_umary_ALU_6074 rs10266483 Response to statin therapy ZNF679,VN1R39P 0.69 
ALU_umary_ALU_6114 rs2245368 Body mass index . 0.67 
ALU_umary_ALU_6127 rs62468577 Bronchopulmonary dysplasia MAGI2 0.72 
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ALU_umary_ALU_6148 rs2715148 Major depressive disorder PCLO 0.55 
ALU_umary_ALU_6185 rs17301259 Heschl's gyrus morphology ZNF804B 0.71 
ALU_umary_ALU_6272 rs1404697 Smoking behavior C7orf66,EIF3IP1 0.90 
ALU_umary_ALU_6316 rs757278 Response to methotrexate in juvenile idiopathic arthritis CTTNBP2 0.67 
ALU_umary_ALU_6320 rs41997 
Response to platinum-based 
chemotherapy in non-small-
cell lung cancer 
ANKRD7,GTF3AP6 -0.62 
ALU_umary_ALU_6359 rs4731207 Cutaneous malignant melanoma . -0.65 
ALU_umary_ALU_6372 rs2687481 Hearing function RPL31P39,GRM8 0.46 
ALU_umary_ALU_6373 rs2687481 Hearing function RPL31P39,GRM8 0.74 







depressive disorder%2C and 
schizophrenia (combined) 
MTPN,PSMC1P3 0.52 
ALU_umary_ALU_6482 rs2708240 QT interval (interaction) CNTNAP2 -0.46 
ALU_umary_ALU_6493 rs17173637 HDL cholesterol AOC1 0.65 
ALU_umary_ALU_6560 rs1045529 Myopia (pathological) ERI1 0.76 
ALU_umary_ALU_6563 rs12545912 Multiple myeloma (hyperdiploidy) TNKS 0.82 
ALU_umary_ALU_6564 rs6601327 Multiple myeloma (hyperdiploidy) PPP1R3B,TNKS -0.53 
ALU_umary_ALU_6594 rs4831760 Pulmonary function decline TUSC3 0.75 
ALU_umary_ALU_6595 rs4831760 Pulmonary function decline TUSC3 -0.41 
ALU_umary_ALU_6611 rs920590 Acute lymphoblastic leukemia (childhood) CSGALNACT1,INTS10 0.78 
ALU_umary_ALU_6645 rs4732957 Response to amphetamines ADRA1A 0.43 
ALU_umary_ALU_6669 rs11997175 Body mass index . -0.58 
ALU_umary_ALU_6674 rs6987004 Pulmonary function decline RPL10AP3,RPL21P80 0.74 
ALU_umary_ALU_6760 rs1387221 Clozapine-induced cytotoxicity . -0.60 
ALU_umary_ALU_6766 rs6984242 Schizophrenia NUDT15P1,CA8 0.56 
ALU_umary_ALU_6805 rs13272623 IgG glycosylation LACTB2-AS1,LOC286190 0.60 
ALU_umary_ALU_6806 rs7017914 Bone mineral density XKR9 -0.74 
ALU_umary_ALU_6814 rs13263568 Migraine EYA1 0.59 
ALU_umary_ALU_6846 rs16939046 Information processing speed CASC9 0.85 
ALU_umary_ALU_6919 rs9969524 Optic disc area . -0.43 
ALU_umary_ALU_6932 rs160451 Leprosy RNA5SP272,RIPK2 -0.73 
ALU_umary_ALU_6951 rs278567 Bipolar disorder and schizophrenia C8orf87 0.76 
ALU_umary_ALU_6959 rs7818688 
Vincristine-induced 




ALU_umary_ALU_6965 rs3104964 Colorectal cancer C8orf37-AS1,LOC100616530 0.56 
ALU_umary_ALU_6990 rs2033562 IgA nephropathy . -0.42 
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SVA_umary_SVA_389 rs374810 
Ossification of the posterior 
longitudinal ligament of the 
spine 
RSPO2 0.56 
ALU_umary_ALU_7045 rs36068923 Schizophrenia RPSAP48,EEF1A1P37 0.62 
ALU_umary_ALU_7125 rs13268726 Amyotrophic lateral sclerosis SQLE 0.51 
ALU_umary_ALU_7143 rs13281615 Breast cancer LOC101930033 0.62 
ALU_umary_ALU_7145 rs4733601 Diffuse large B cell lymphoma 
MIR1208,LINC00824,LIN
C01263 0.53 
L1_umary_LINE1_1761 rs16904191 Migraine MIR5194,ASAP1 0.66 
ALU_umary_ALU_7166 rs7004484 Survival in rectal cancer . 0.83 
L1_umary_LINE1_1787 rs4626664 Restless legs syndrome PTPRD 0.82 
ALU_umary_ALU_7311 rs3904778 Adolescent idiopathic scoliosis . 0.54 
ALU_umary_ALU_7320 rs10810865 Cognitive performance PABPC1P11,PUS7P1 0.54 
ALU_umary_ALU_7331 rs7867456 Axial length HACD4,IFNNP1,PTPLAD2 -0.56 
ALU_umary_ALU_7381 rs10969853 Alcohol dependence (age at onset) RBMXP2,KRT18P66 0.40 
SVA_umary_SVA_401 rs10758189 IgG glycosylation B4GALT1 0.82 
SVA_umary_SVA_402 rs11574914 Rheumatoid arthritis CCL21,LOC101929761 0.84 
ALU_umary_ALU_7420 rs4878712 HIV-1 susceptibility . -0.45 
ALU_umary_ALU_7547 rs2814828 Height SPATA31C2,RPSAP49 0.44 
ALU_umary_ALU_7555 rs883924 Hepatitis C induced liver fibrosis 
LINC01508,LOC1019278
73 -0.43 
L1_umary_LINE1_1863 rs4743820 Inflammatory bowel disease SYK,AUH 0.45 
ALU_umary_ALU_7564 rs944990 Body mass index . 0.55 
L1_umary_LINE1_1867 rs755109 Quantitative traits HEMGN 0.56 
ALU_umary_ALU_7593 rs7028939 Preeclampsia ERP44 0.72 
ALU_umary_ALU_7594 rs7028939 Preeclampsia ERP44 0.88 
ALU_umary_ALU_7615 rs10990268 Tourette syndrome ZYG11AP1,CYLC2 0.54 
ALU_umary_ALU_7620 rs144649413 Metabolite levels (MHPG) CYLC2,RNA5SP291 0.59 
ALU_umary_ALU_7645 rs7048146 Vascular brain injury YBX1P6,PALM2 0.46 
ALU_umary_ALU_7653 rs1889321 Pulmonary function decline SVEP1 0.56 
ALU_umary_ALU_7654 rs10980508 Type 2 diabetes (dietary heme iron intake interaction) SVEP1,MUSK 0.46 
ALU_umary_ALU_7709 rs888219 Response to antipsychotic treatment PBX3,MVB12B -0.40 
ALU_umary_ALU_7750 rs7092929 Coronary artery calcification PITRM1-AS1,KLF6 -0.44 
ALU_umary_ALU_7864 rs10508727 Immune response to smallpox vaccine (IL-6) MKX 0.57 
ALU_umary_ALU_7994 rs11005694 




ALU_umary_ALU_8012 rs10761482 Schizophrenia ANK3 -0.51 
ALU_umary_ALU_8021 rs224136 Crohn's disease ZNF365,ALDH7A1P4 0.58 
ALU_umary_ALU_8022 rs442309 Vogt-Koyanagi-Harada syndrome ZNF365,ALDH7A1P4 -0.52 
ALU_umary_ALU_8067 rs1900005 Vertical cup-disc ratio ATOH7,KRT19P4 -0.55 
SVA_umary_SVA_450 rs12571093 Optic nerve measurement (disc area) ATOH7,KRT19P4 0.43 
ALU_umary_ALU_8138 rs791888 Magnesium levels . 0.64 
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ALU_umary_ALU_8178 rs1934955 Blood metabolite levels CYP2C59P,CYP2C8 0.74 
ALU_umary_ALU_8182 rs56322409 Blood metabolite levels ALDH18A1 0.68 
ALU_umary_ALU_8202 rs7069733 
Autism spectrum disorder, 
attention deficit-
hyperactivity disorder, 
bipolar disorder, major 
depressive disorder, and 
schizophrenia (combined) 
. 0.47 
ALU_umary_ALU_8232 rs11195062 Multiple myeloma MXI1 0.48 






ALU_umary_ALU_8387 rs2727405 Obesity-related traits RASSF10,ARNTL 0.55 
ALU_umary_ALU_8392 rs12287212 Vitamin D levels RRAS2,COPB1 0.68 
L1_umary_LINE1_2073 rs12788764 Age-related nuclear cataracts LUZP2,RPL36AP40 -0.48 
ALU_umary_ALU_8454 rs11602337 Vascular brain injury LUZP2,RPL36AP40 0.74 
ALU_umary_ALU_8457 rs10834691 IgG glycosylation LUZP2,RPL36AP40 0.43 
ALU_umary_ALU_8468 rs12295638 Obesity (extreme) ANO3 0.72 
ALU_umary_ALU_8489 rs2057178 Tuberculosis RCN1,WT1 0.41 
ALU_umary_ALU_8490 rs2057178 Tuberculosis RCN1,WT1 0.44 
ALU_umary_ALU_8492 rs10767971 Parkinson's disease (age of onset) PRRG4,QSER1 -0.49 
L1_umary_LINE1_2092 rs331463 Rheumatoid arthritis PRR5L,TRAF6 0.81 
L1_umary_LINE1_2104 rs10768747 Post-traumatic stress disorder . 0.94 
ALU_umary_ALU_8549 rs9300039 Type 2 diabetes RPL9P23,HNRNPKP3 0.58 
ALU_umary_ALU_8559 rs2176598 Body mass index . 0.72 
ALU_umary_ALU_8566 rs10838725 Alzheimer's disease (late onset) CELF1 0.53 
ALU_umary_ALU_8572 rs11246602 HDL cholesterol OR4C46,OR4C7P 0.84 
ALU_umary_ALU_8574 rs1814175 Height CBX3P8,TRIM51FP -0.74 
ALU_umary_ALU_8583 rs2220004 Odorant perception (&beta%3B-damascenone) OR8H3,OR5BN1P 0.56 
ALU_umary_ALU_8585 rs7927370 Systemic lupus erythematosus OR4A15 0.72 
L1_umary_LINE1_2125 rs7927370 Systemic lupus erythematosus OR4A15 0.70 
ALU_umary_ALU_8590 rs11228719 Orofacial clefts OR2AH1P,OR9G1 0.49 
ALU_umary_ALU_8591 rs7927370 Systemic lupus erythematosus OR4A15 0.61 
ALU_umary_ALU_8620 rs478304 Acne (severe) RNASEH2C,KRT8P26 -0.79 
ALU_umary_ALU_8622 rs524281 Electroencephalogram traits PACS1 0.77 
ALU_umary_ALU_8629 rs12808519 Urate levels in overweight individuals . 0.42 
ALU_umary_ALU_8698 rs17817600 Alzheimer's disease PICALM 0.47 
ALU_umary_ALU_8717 rs10830228 Age-related macular degeneration RNU6-16P,TYR -0.72 
ALU_umary_ALU_8801 rs313426 Toenail selenium levels DYNC2H1 0.56 
ALU_umary_ALU_8804 rs10895547 LDL cholesterol PDGFD 0.80 
L1_umary_LINE1_2187 rs7945071 Cognitive function RDX,FDX1 0.42 
L1_umary_LINE1_2191 rs2250417 Inflammatory biomarkers BCO2 -0.57 
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ALU_umary_ALU_8951 rs11062040 Response to gemcitabine in pancreatic cancer . -0.59 
ALU_umary_ALU_9052 rs7134375 HDL cholesterol TCP1P3,PDE3A 0.51 
ALU_umary_ALU_9104 rs12371778 Breast size PTHLH,CCDC91 0.90 
ALU_umary_ALU_9105 rs11049611 Height CCDC91 0.76 
ALU_umary_ALU_9107 rs11049611 Height CCDC91 0.84 
ALU_umary_ALU_9108 rs1979679 
Ossification of the posterior 
longitudinal ligament of the 
spine 
CCDC91 0.86 
ALU_umary_ALU_9150 rs826838 Heart rate CPNE8 0.53 
ALU_umary_ALU_9158 rs10467147 Obesity-related traits LRRK2,MUC19 0.58 
ALU_umary_ALU_9169 rs285575 Body mass index . 0.76 
ALU_umary_ALU_9177 rs7978895 Type 2 diabetes . -0.53 
ALU_umary_ALU_9215 rs17655565 Plasma amyloid beta peptide concentrations (ABx-42) KRT86 0.50 
ALU_umary_ALU_9228 rs11575234 Inflammatory skin disease . 0.91 
ALU_umary_ALU_9233 rs10876993 Celiac disease or Rheumatoid arthritis B4GALNT1,RPL13AP23 0.67 
ALU_umary_ALU_9268 rs7301016 IgG glycosylation MON2 0.69 
ALU_umary_ALU_9310 rs2904524 Amyotrophic lateral sclerosis (age of onset) CNOT2 0.78 
ALU_umary_ALU_9320 rs1495377 Creutzfeldt-Jakob disease (variant) TSPAN8,LGR5 -0.54 
ALU_umary_ALU_9331 rs7964120 Obesity-related traits RPL31P48,VENTXP3 0.52 
ALU_umary_ALU_9355 rs17788937 Myopia (pathological) NAV3 0.89 
ALU_umary_ALU_9388 rs1511589 Optic disc area . 0.78 
L1_umary_LINE1_2324 rs1545843 Major depressive disorder RPL6P25,SLC6A15 0.43 
ALU_umary_ALU_9398 rs7132746 Lewy body disease N/A 0.76 
ALU_umary_ALU_9450 rs7953959 IgG glycosylation TRNAQ46P,RMST,TRQ-TTG9-1 0.74 
ALU_umary_ALU_9499 rs10444533 Social autistic-like traits RIC8B 0.53 
ALU_umary_ALU_9509 rs59227481 Age-related nuclear cataracts MMAB 0.43 
ALU_umary_ALU_9517 rs6490294 Mean platelet volume ACAD10 0.53 
ALU_umary_ALU_9537 rs11064768 Schizophrenia CCDC60 0.64 
ALU_umary_ALU_9553 rs1716403 Response to fenofibrate (adiponectin levels) ZNF664-FAM101A 0.47 
ALU_umary_ALU_9589 rs12282 Immune response to smallpox vaccine (IL-6) GOLGA3 0.44 
ALU_umary_ALU_9602 rs9788333 
Thiazide-induced adverse 
metabolic effects in 
hypertensive patients 
MIPEPP3 0.53 
ALU_umary_ALU_9625 rs17079928 Orofacial clefts SPATA13 0.45 
SVA_umary_SVA_560 rs1816752 Obesity-related traits CYCSP33,PARP4 0.41 
ALU_umary_ALU_9639 rs10507349 Type 2 diabetes RNF6 -0.41 
ALU_umary_ALU_9670 rs7331540 IgG glycosylation FRY 0.43 
ALU_umary_ALU_9701 rs6563569 




ALU_umary_ALU_9724 rs7336933 Calcium levels VWA8-AS1,RPS28P8 0.41 
ALU_umary_ALU_9726 rs4142110 Nephrolithiasis DGKH 0.50 
L1_umary_LINE1_2401 rs4142110 Nephrolithiasis DGKH 0.69 
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ALU_umary_ALU_9727 rs9594738 Bone mineral density FABP3P2,TNFSF11 -0.42 
ALU_umary_ALU_9775 rs9568281 Multiple sclerosis RCBTB1,ARL11 0.52 
ALU_umary_ALU_9789 rs9536318 Airflow obstruction PCDH8,OLFM4 0.65 
ALU_umary_ALU_9798 rs1116255 Post-traumatic stress disorder . 0.78 
ALU_umary_ALU_9803 rs9527419 Response to platinum-based chemotherapy (cisplatin) MIR5007,HNF4GP1 0.60 
ALU_umary_ALU_9813 rs9537938 Educational attainment RNA5SP30,CTAGE16P -0.60 
ALU_umary_ALU_9815 rs9563576 Body mass index . 0.68 
ALU_umary_ALU_9834 rs4886238 Menopause (age at onset) TDRD3 0.52 
L1_umary_LINE1_2422 rs1847505 Polychlorinated biphenyl levels . 0.50 
ALU_umary_ALU_9847 rs9528384 Verbal declarative memory PCDH20,RAC1P8 0.54 
ALU_umary_ALU_9863 rs9540294 Recalcitrant atopic dermatitis . 0.83 
ALU_umary_ALU_9869 rs1333026 Body mass index STARP1,HNRNPA3P5 0.54 
L1_umary_LINE1_2451 rs1324913 Menarche (age at onset) KLF12 0.40 
ALU_umary_ALU_9941 rs975739 Hair color MIR3665,EDNRB-AS1 -0.61 
ALU_umary_ALU_9943 rs975739 Hair color MIR3665,EDNRB-AS1 -0.50 
ALU_umary_ALU_9951 rs9601248 Major depressive disorder NDFIP2,LINC00382 0.56 
ALU_umary_ALU_9959 rs11149178 Major depressive disorder PWWP2AP1,ARF4P4 0.54 
ALU_umary_ALU_9960 rs6563199 Height ARF4P4,HIGD1AP2 -0.47 
ALU_umary_ALU_10026 rs2352028 Lung cancer GPC5 -0.48 
ALU_umary_ALU_10031 rs4771859 












depressive disorder%2C and 
schizophrenia (combined) 
FAM155A-IT1,LIG4 0.65 
ALU_umary_ALU_10121 rs1278769 Interstitial lung disease ATP11A -0.42 
ALU_umary_ALU_10152 rs10147992 White blood cell types STXBP6 0.48 






ALU_umary_ALU_10258 rs2488856 Osteoprotegerin levels YWHAQP1,TUBBP3 0.57 
ALU_umary_ALU_10284 rs7144383 Idiopathic pulmonary fibrosis MDGA2 0.48 
ALU_umary_ALU_10312 rs12434047 Economic and political preferences (fairness) DDHD1,RPS3AP46 0.47 
ALU_umary_ALU_10325 rs2274273 Protein biomarker DLGAP5 0.72 
ALU_umary_ALU_10401 rs910316 Height TMED10 0.75 
SVA_umary_SVA_613 rs6574644 Obesity-related traits STON2 -0.47 
ALU_umary_ALU_10518 rs4900384 Type 1 diabetes C14orf64,C14orf177,LINC01550 0.69 
ALU_umary_ALU_10560 rs11858159 Platelet thrombus formation . -0.41 
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TE GWAS hits GWAS phenotype GWAS gene r 
ALU_umary_ALU_10562 rs35600665 Obesity-related traits PWRN3,PWRN1 0.48 
L1_umary_LINE1_2634 rs587847 Intraocular pressure MIR8063,RPS15P8 0.66 
ALU_umary_ALU_10670 rs2467853 Renal function and chronic kidney disease SPATA5L1 -0.51 
SVA_umary_SVA_630 rs12594515 Weight SQRDL,SEMA6D 0.57 
ALU_umary_ALU_10674 rs11633886 Diisocyanate-induced asthma . 0.54 
ALU_umary_ALU_10693 rs8023445 Major depressive disorder SHC4 0.88 
ALU_umary_ALU_10695 rs10519227 Thyroid hormone levels FAM227B,FGF7 0.81 
L1_umary_LINE1_2647 rs1124769 Cognitive performance TNFAIP8L3 0.72 
ALU_umary_ALU_10749 rs7179456 Asperger disorder SLTM 0.54 
L1_umary_LINE1_2659 rs7172342 Schizophrenia RORA 0.59 
ALU_umary_ALU_10766 rs1436958 IgG glycosylation VPS13C 0.84 
ALU_umary_ALU_10778 rs7170930 




ALU_umary_ALU_10786 rs2241423 Body mass index MAP2K5 0.44 
ALU_umary_ALU_10812 rs8038465 




ALU_umary_ALU_10819 rs3099143 Recalcitrant atopic dermatitis . 0.72 
ALU_umary_ALU_10821 rs2404602 Blood metabolite levels SCAPER -0.67 
ALU_umary_ALU_10824 rs2137111 Anticoagulant levels HMG20A,LINGO1 0.47 
ALU_umary_ALU_10830 rs950776 Sudden cardiac arrest CHRNB4 0.50 
ALU_umary_ALU_10832 rs2289700 Bipolar disorder CTSH 0.61 
ALU_umary_ALU_10841 rs2663905 QT interval (interaction) MESDC1,ANP32BP3 -0.44 
ALU_umary_ALU_10855 rs6496044 Interstitial lung disease AKAP13,LOC101929656 0.48 
ALU_umary_ALU_10921 rs4533267 Height ADAMTS17 -0.42 
ALU_umary_ALU_10963 rs7200786 Multiple sclerosis CLEC16A 0.65 
ALU_umary_ALU_11003 rs7404095 Inflammatory bowel disease PRKCB -0.71 
ALU_umary_ALU_11054 rs17291845 Information processing speed IRX5,IRX6 0.73 
SVA_umary_SVA_673 rs2865531 Pulmonary function CFDP1 -0.49 
ALU_umary_ALU_11154 rs12933472 Glucose homeostasis traits CDH13 0.69 
ALU_umary_ALU_11164 rs17789174 Dysphagia . 0.62 
ALU_umary_ALU_11244 rs8082590 Schizophrenia GID4 -0.55 
ALU_umary_ALU_11275 rs225212 Hypertension risk in short sleep duration MYO1D 0.83 
ALU_umary_ALU_11298 rs6607284 Bipolar disorder and schizophrenia . 0.45 
SVA_umary_SVA_704 rs199533 Parkinson's disease NSF 0.65 
SVA_umary_SVA_705 rs12185268 Parkinson's disease MAPT-AS1,SPPL2C 0.71 
SVA_umary_SVA_706 rs12373124 Male-pattern baldness MAPT-AS1,SPPL2C 0.92 
ALU_umary_ALU_11330 rs8070463 Ankylosing spondylitis KPNB1,TBKBP1 0.43 
ALU_umary_ALU_11333 rs9303542 Ovarian cancer SKAP1 0.85 
ALU_umary_ALU_11336 rs2411984 Sex hormone-binding globulin levels LOC102724596 0.41 
ALU_umary_ALU_11398 rs4351 Blood metabolite levels ACE 0.68 
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ALU_umary_ALU_11400 rs11658329 Height LOC101927898,MAP3K3 0.65 
ALU_umary_ALU_11428 rs10775360 QT interval CALM2P1,CASC17 0.65 
L1_umary_LINE1_2778 rs8066985 Waist-to-hip ratio adjusted for body mass index . 0.56 
ALU_umary_ALU_11447 rs8066857 Amyotrophic lateral sclerosis SLC39A11 0.41 
ALU_umary_ALU_11484 rs1291183 Pulmonary function in asthmatics YES1,ADCYAP1 0.46 
ALU_umary_ALU_11492 rs1992269 Alzheimer's disease (late onset) . 0.44 
ALU_umary_ALU_11525 rs7244245 
Response to anti-retroviral 
therapy (ddI/d4T) in HIV-1 
infection (Grade 1 peripheral 
neuropathy) 
MTCL1,RPS4XP19 0.45 
ALU_umary_ALU_11576 rs7235440 Obesity-related traits HRH4,RAC1P1 0.44 
ALU_umary_ALU_11598 rs11083271 Non-alcoholic fatty liver disease histology (lobular) CDH2,ARIH2P1 0.72 
ALU_umary_ALU_11708 rs11876941 Body mass index (interaction) DCC -0.52 
ALU_umary_ALU_11719 rs12959570 






containing treatment in HIV-















ALU_umary_ALU_11946 rs11673344 Obesity-related traits ZNF585B 0.48 
L1_umary_LINE1_2883 rs2288912 
Very long-chain saturated 




ALU_umary_ALU_12024 rs965469 IFN-related cytopenia C20orf194 0.44 
ALU_umary_ALU_12050 rs6077414 Estradiol plasma levels (breast cancer) PLCB1 0.42 
ALU_umary_ALU_12052 rs6056209 Cognitive performance PLCB1 -0.60 
ALU_umary_ALU_12098 rs932541 Intelligence KIF16B 0.41 
ALU_umary_ALU_12132 rs816535 Parkinson disease and lewy body pathology . 0.90 
ALU_umary_ALU_12143 rs17310467 Hemostatic factors and hematological phenotypes MYH7B 0.50 
ALU_umary_ALU_12145 rs11906854 Migraine - clinic-based PHF20 0.58 
ALU_umary_ALU_12207 rs2041278 Obesity-related traits ZNF217,RNU7-14P 0.49 
ALU_umary_ALU_12382 rs2833607 Vitiligo HUNK,LINC00159 0.64 
L1_umary_LINE1_2987 rs11089937 Periodontitis (PAL4Q3) IGL 0.69 
ALU_umary_ALU_12449 rs11089937 Periodontitis (PAL4Q3) IGL 0.70 
ALU_umary_ALU_12461 rs739310 Obesity-related traits ISCA2P1,MIAT 0.50 
ALU_umary_ALU_12480 rs12530 IgG glycosylation RTCB 0.87 
ALU_umary_ALU_12481 rs12530 IgG glycosylation RTCB 0.75 




Table 10 Genome-wide significant TE-eQTL for African population  
Chr Pos TE Gene t Statistic P-value FDR 
13 49536621 ALU_umary_ALU_9771 SLC7A2 7.98 7.27E-12 6.29E-05 
6 29892872 ALU_umary_ALU_5054 JPH1 7.64 3.37E-11 1.46E-04 
20 52273671 ALU_umary_ALU_12207 EPB41L4B 7.51 6.18E-11 1.78E-04 
19 30850007 ALU_umary_ALU_11922 LILRA1 7.20 2.49E-10 4.75E-04 
12 92483455 ALU_umary_ALU_9431 IGHV3-20 7.18 2.75E-10 4.75E-04 
11 7435902 L1_umary_LINE1_2054 IMPG1 7.12 3.59E-10 5.17E-04 
2 161430249 ALU_umary_ALU_1693 IGKV1D-12 7.01 5.90E-10 6.80E-04 
1 116548031 L1_umary_LINE1_118 IGHV2-26 6.99 6.28E-10 6.80E-04 
2 161430249 ALU_umary_ALU_1693 IGKV1-12 6.84 1.24E-09 1.20E-03 
18 12884841 ALU_umary_ALU_11552 RP4-614O4.11 6.66 2.84E-09 2.42E-03 
19 30850007 ALU_umary_ALU_11922 RP11-304L19.5 6.64 3.08E-09 2.42E-03 
19 30850007 ALU_umary_ALU_11922 TEX22 6.53 5.02E-09 3.59E-03 
4 9704849 SVA_umary_SVA_206 KIAA1462 6.51 5.39E-09 3.59E-03 
19 30850007 ALU_umary_ALU_11922 SCNN1D 6.46 6.62E-09 4.09E-03 
11 7435902 L1_umary_LINE1_2054 SLC35F4 6.45 7.13E-09 4.11E-03 
19 30850007 ALU_umary_ALU_11922 ZNF667 6.34 1.15E-08 6.05E-03 
11 35348849 ALU_umary_ALU_8504 ABCC3 6.33 1.19E-08 6.05E-03 
19 30850007 ALU_umary_ALU_11922 RP11-122K13.12 6.31 1.29E-08 6.20E-03 
19 30850007 ALU_umary_ALU_11922 HAUS3 6.26 1.65E-08 7.51E-03 
8 122731020 ALU_umary_ALU_7106 RP4-669L17.2 6.20 2.11E-08 8.94E-03 
19 30850007 ALU_umary_ALU_11922 ZNF667-AS1 6.19 2.17E-08 8.94E-03 
4 9704849 SVA_umary_SVA_206 IGLV3-21 6.17 2.41E-08 9.08E-03 
10 78496693 ALU_umary_ALU_8096 SYT5 6.17 2.41E-08 9.08E-03 
13 49536621 ALU_umary_ALU_9771 FERMT1 6.14 2.73E-08 9.85E-03 
20 52273671 ALU_umary_ALU_12207 LHFPL3 6.07 3.62E-08 1.25E-02 
6 32657952 ALU_umary_ALU_5075 HLA-DQB1-AS1 -6.06 3.89E-08 1.30E-02 
13 49536621 ALU_umary_ALU_9771 SNORD116-20 6.03 4.45E-08 1.38E-02 
20 2371733 ALU_umary_ALU_12019 ZCCHC17 6.02 4.46E-08 1.38E-02 
20 42310903 ALU_umary_ALU_12175 ALPL 6.01 4.68E-08 1.40E-02 
6 29892872 ALU_umary_ALU_5054 GHRLOS 6.00 5.05E-08 1.44E-02 
11 7435902 L1_umary_LINE1_2054 NEB 5.99 5.17E-08 1.44E-02 
12 92483455 ALU_umary_ALU_9431 PXMP2 5.98 5.32E-08 1.44E-02 
3 72016139 ALU_umary_ALU_2429 MCEE 5.96 5.88E-08 1.54E-02 
11 7435902 L1_umary_LINE1_2054 RBM44 5.92 6.98E-08 1.69E-02 
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11 7435902 L1_umary_LINE1_2054 RP4-738P11.3 5.92 6.98E-08 1.69E-02 
2 102912450 L1_umary_LINE1_366 DPPA3P2 5.92 7.05E-08 1.69E-02 
2 56373531 ALU_umary_ALU_1216 TNS1 5.90 7.59E-08 1.78E-02 
11 7435902 L1_umary_LINE1_2054 SLC15A2 5.86 9.04E-08 2.06E-02 
1 116548031 L1_umary_LINE1_118 TMEM56 5.83 1.02E-07 2.26E-02 
11 7435902 L1_umary_LINE1_2054 RP11-409I10.2 5.81 1.11E-07 2.39E-02 
15 66921115 ALU_umary_ALU_10780 RP11-829H16.2 5.80 1.15E-07 2.43E-02 
19 30850007 ALU_umary_ALU_11922 HMX2 5.80 1.19E-07 2.45E-02 
10 73193547 ALU_umary_ALU_8081 NRP2 5.75 1.42E-07 2.86E-02 
2 161430249 ALU_umary_ALU_1693 GALNT9 5.73 1.60E-07 3.05E-02 
1 116548031 L1_umary_LINE1_118 RP11-303E16.3 5.72 1.61E-07 3.05E-02 
20 42310903 ALU_umary_ALU_12175 IGKV2D-28 5.72 1.63E-07 3.05E-02 
11 7435902 L1_umary_LINE1_2054 RP4-738P11.4 5.72 1.67E-07 3.05E-02 
20 52369852 ALU_umary_ALU_12208 CTC-248O19.1 5.70 1.75E-07 3.05E-02 
4 9704849 SVA_umary_SVA_206 STRC 5.70 1.79E-07 3.05E-02 
11 7435902 L1_umary_LINE1_2054 IGDCC4 5.70 1.82E-07 3.05E-02 
20 52369852 ALU_umary_ALU_12208 BDKRB2 5.69 1.83E-07 3.05E-02 
3 72016139 ALU_umary_ALU_2429 EEF1E1 5.69 1.88E-07 3.05E-02 
2 144010793 L1_umary_LINE1_410 EPS8L1 5.68 1.93E-07 3.05E-02 
19 30850007 ALU_umary_ALU_11922 RP11-166B2.1 5.68 1.93E-07 3.05E-02 
11 77905200 ALU_umary_ALU_8655 VPS13B 5.68 1.94E-07 3.05E-02 
19 30850007 ALU_umary_ALU_11922 ARVCF 5.68 1.98E-07 3.05E-02 
8 115604486 ALU_umary_ALU_7074 RPS15AP1 5.62 2.53E-07 3.84E-02 
20 52369852 ALU_umary_ALU_12208 PRKAG1 5.61 2.58E-07 3.84E-02 
17 43383714 ALU_umary_ALU_11326 TAT 5.61 2.62E-07 3.84E-02 
15 22797908 ALU_umary_ALU_10550 RP11-481K16.2 5.60 2.66E-07 3.84E-02 
19 30850007 ALU_umary_ALU_11922 ZNF10 5.60 2.71E-07 3.85E-02 
7 86968519 ALU_umary_ALU_6178 TP53TG1 -5.57 3.03E-07 4.21E-02 
10 130888837 ALU_umary_ALU_8317 FREM1 5.57 3.11E-07 4.21E-02 
11 7435902 L1_umary_LINE1_2054 CTA-134P22.2 5.56 3.15E-07 4.21E-02 
8 122731020 ALU_umary_ALU_7106 AC139099.5 5.56 3.16E-07 4.21E-02 
8 132942724 ALU_umary_ALU_7166 AC019221.4 5.56 3.22E-07 4.23E-02 
6 29892872 ALU_umary_ALU_5054 AF165138.7 5.54 3.52E-07 4.48E-02 
8 21879122 SVA_umary_SVA_369 RMI2 5.53 3.57E-07 4.48E-02 
11 35348849 ALU_umary_ALU_8504 AS3MT 5.53 3.61E-07 4.48E-02 
19 30850007 ALU_umary_ALU_11922 SNHG9 5.53 3.63E-07 4.48E-02 
6 29892872 ALU_umary_ALU_5054 GGTA1P 5.52 3.75E-07 4.53E-02 
22 44324605 L1_umary_LINE1_2991 IGHV3-65 5.52 3.81E-07 4.53E-02 
11 77905200 ALU_umary_ALU_8655 RP11-234B24.2 5.52 3.82E-07 4.53E-02 
11 72381238 ALU_umary_ALU_8635 C9orf57 5.51 3.89E-07 4.53E-02 
20 42310903 ALU_umary_ALU_12175 LAMB1 5.51 3.93E-07 4.53E-02 
3 111271467 ALU_umary_ALU_2617 ROCK1P1 -5.50 4.14E-07 4.72E-02 
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5 8749528 L1_umary_LINE1_1049 CLDN6 5.49 4.21E-07 4.74E-02 
11 7435902 L1_umary_LINE1_2054 C20orf203 5.49 4.35E-07 4.81E-02 
11 7435902 L1_umary_LINE1_2054 FREM2 5.48 4.41E-07 4.81E-02 
6 114078807 ALU_umary_ALU_5489 IGLV2-5 5.48 4.45E-07 4.81E-02 
6 114078807 ALU_umary_ALU_5489 BAMBI 5.48 4.55E-07 4.83E-02 
6 29892872 ALU_umary_ALU_5054 FITM1 5.47 4.58E-07 4.83E-02 
17 55926227 ALU_umary_ALU_11375 TMEM56 5.47 4.68E-07 4.88E-02 
 
Table 11 Genome-wide significant TE-eQTL for European population  
Chr Pos TE Gene t Statistic P-value FDR 
17 43660599 SVA_umary_SVA_704 RP11-259G18.3 11.77 3.32E-27 2.47E-20 
22 19210913 L1_umary_LINE1_2986 CLTCL1 11.05 1.43E-24 5.30E-18 
17 43660599 SVA_umary_SVA_704 KANSL1-AS1 10.44 2.08E-22 5.16E-16 
17 43660599 SVA_umary_SVA_704 RP11-259G18.2 9.89 1.55E-20 2.88E-14 
9 33130564 SVA_umary_SVA_401 B4GALT1 -9.76 4.47E-20 6.64E-14 
6 33030313 SVA_umary_SVA_282 HLA-DPB2 7.74 1.05E-13 1.30E-07 
12 58359071 ALU_umary_ALU_9234 XRCC6BP1 7.50 5.21E-13 5.54E-07 
6 32589834 ALU_umary_ALU_5072 HLA-DRB5 -7.43 8.49E-13 7.89E-07 
17 43660599 SVA_umary_SVA_704 LRRC37A4P -7.01 1.22E-11 1.01E-05 
6 32657952 ALU_umary_ALU_5075 HLA-DQB1-AS1 -6.99 1.36E-11 1.01E-05 
17 43660599 SVA_umary_SVA_704 LRRC37A 6.50 2.71E-10 1.83E-04 
3 154966214 ALU_umary_ALU_2829 LILRA1 6.37 5.94E-10 3.68E-04 
6 32657952 ALU_umary_ALU_5075 HLA-DQB1 -6.33 7.45E-10 4.26E-04 
13 32328983 SVA_umary_SVA_565 CCDC58 6.29 9.26E-10 4.92E-04 
8 5506286 ALU_umary_ALU_6548 CDH23 6.10 2.82E-09 1.40E-03 
6 33030313 SVA_umary_SVA_282 HLA-DPA1 -6.02 4.40E-09 2.04E-03 
2 65163783 ALU_umary_ALU_1256 SLC1A4 -5.85 1.11E-08 4.87E-03 
8 5506286 ALU_umary_ALU_6548 TMEM132B 5.82 1.33E-08 5.50E-03 
8 5506286 ALU_umary_ALU_6548 RP11-492E3.2 5.80 1.46E-08 5.71E-03 
8 5506286 ALU_umary_ALU_6548 APOC2 5.77 1.76E-08 6.53E-03 
7 123194557 ALU_umary_ALU_6352 VARS 5.74 2.03E-08 7.17E-03 
11 86195336 ALU_umary_ALU_8700 IGLV7-46 5.72 2.21E-08 7.48E-03 
8 5506286 ALU_umary_ALU_6548 CD2 5.70 2.56E-08 8.27E-03 
2 227473038 ALU_umary_ALU_2029 IGLV3-27 5.68 2.81E-08 8.69E-03 
2 114106446 ALU_umary_ALU_1441 ACY1 5.66 3.07E-08 9.14E-03 
14 106756949 ALU_umary_ALU_10537 NPR3 5.57 5.08E-08 1.42E-02 
20 9477936 L1_umary_LINE1_2901 FAM110C 5.54 5.78E-08 1.42E-02 
14 106756949 ALU_umary_ALU_10537 AC026703.1 5.54 5.79E-08 1.42E-02 
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14 106756949 ALU_umary_ALU_10537 PRODH 5.54 5.90E-08 1.42E-02 
4 106636862 ALU_umary_ALU_3576 PIK3CA 5.54 5.96E-08 1.42E-02 
6 32589834 ALU_umary_ALU_5072 HLA-DRB6 -5.54 5.98E-08 1.42E-02 
8 5506286 ALU_umary_ALU_6548 FBXO27 5.53 6.12E-08 1.42E-02 
6 32657952 ALU_umary_ALU_5075 HLA-DRB1 -5.53 6.38E-08 1.44E-02 
10 105817214 ALU_umary_ALU_8203 RP1-37N7.3 -5.49 7.59E-08 1.66E-02 
11 100781393 ALU_umary_ALU_8788 HMGN2P19 5.48 8.25E-08 1.75E-02 
14 106756949 ALU_umary_ALU_10537 CLSTN2 5.40 1.21E-07 2.50E-02 
10 17712792 SVA_umary_SVA_438 TMEM236 5.39 1.30E-07 2.62E-02 
1 65346960 ALU_umary_ALU_212 VANGL2 5.38 1.39E-07 2.72E-02 
1 97717644 ALU_umary_ALU_379 IGLV1-50 5.36 1.53E-07 2.91E-02 
9 112908065 ALU_umary_ALU_7651 AC020571.3 5.33 1.74E-07 3.23E-02 
14 106756949 ALU_umary_ALU_10537 CDH2 5.27 2.32E-07 4.21E-02 
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